

(19) 日本国特許庁(JP)

(12) 公表特許公報(A)

(11) 特許出願公表番号

特表2005-508202
(P2005-508202A)

(43) 公表日 平成17年3月31日(2005.3.31)

(51) Int. Cl. ⁷	F I	テーマコード (参考)
A 6 1 M 5/178	A 6 1 M 5/18	4 C O 6 6
A 6 1 J 1/06	A 6 1 J 1/06	E
A 6 1 J 1/20	A 6 1 J 1/06	F
A 6 1 M 5/28	A 6 1 J 1/06	G
	A 6 1 M 5/28	
	審査請求 未請求 予備審査請求 有 (全 162 頁) 最終頁に続く	

(21) 出願番号 特願2002-571129 (P2002-571129)
 (86) (22) 出願日 平成14年3月13日 (2002.3.13)
 (85) 翻訳文提出日 平成15年9月16日 (2003.9.16)
 (86) 国際出願番号 PCT/US2002/007712
 (87) 国際公開番号 W02002/072171
 (87) 国際公開日 平成14年9月19日 (2002.9.19)
 (31) 優先権主張番号 60/275,568
 (32) 優先日 平成13年3月13日 (2001.3.13)
 (33) 優先権主張国 米国 (US)


(71) 出願人 398021744
 エム ディー シー インベストメント
 ホールディングス インコーポレイテッド
 アメリカ合衆国, デラウェア州 1980
 1, ウイルミントン, マーケット ストリ
 ート 900, デラウェア トラスト ビ
 ルディング スイート 200
 (74) 代理人 100104411
 弁理士 矢口 太郎
 (74) 代理人 100104215
 弁理士 大森 純一
 (74) 代理人 100099656
 弁理士 山口 康明

最終頁に続く

(54) 【発明の名称】 予充填式セーフティー希釈剤注入器

(57) 【要約】

安全な有針装置(10、110、210、310)であり、薬剤を混合して2個のチャンバを有するカートリッジ(50、150、250、350)から注入するものが提供される。この装置は、外筒(30、130、230、330)の前端を介して突出する針部材(12、112、212、312)を含むものである。2個のチャンバを有するカートリッジ(50、150、250、350)は、外筒(30、130、230、330)に取り付けられ、チャンバに別々に格納される薬剤成分を含むものである。カートリッジの後端のプランジャ(40、140、240)は、カートリッジに向けて進められ、別々の成分を混合して薬剤を準備するものである。カートリッジ(50、150、250、350)が外筒(30、130、230、330)内で前方に進められると、薬剤が針部材(12、112、212、312)を介して患者に注入される。注入工程の完了時、カートリッジ(50、150、250、350)は針リテーナに係合し、針部材の引き込みを作動させる。その後、この針部材は収納されて汚染された針部材を保護する。



【特許請求の範囲】

【請求項 1】

医療用装置であって、前記医療用装置は、：

開口する手前側の端部及び先端側の端部を有する外筒と、；

第 1 の先端を有し、前記第 1 の先端が前記外筒から前方に突出する突出位置と、前記第 1 の先端が封入されて前記第 1 の先端との不慮の接触が防止される封入位置との間で移動可能な針部材と、；

前記針部材と液連通されるカートリッジであって、前記カートリッジは、：

第 1 の物質を含む第 1 のチャンバ、；

第 2 の物質を含む第 2 のチャンバ、；

前記第 1 のチャンバと第 2 のチャンバとの間の液体流通調整部、；及び

前記カートリッジ内でスライド可能に配置されたプランジャ、；

を有する前記カートリッジと、；

前記針部材を前記外筒に対して移動させる駆動力を提供し、前記第 1 の先端を封入するための付勢要素と、；

前記針部材を前記突出位置でリリース可能に保持する針リテイナと、；

を有する前記医療用装置において、；

前記プランジャが前記第 1 のチャンバ内で軸方向に進められると、前記第 1 の物質が前記液体流通調整部を介して前記第 2 のチャンバに進められ、前記第 1 の物質は前記第 2 の物質と混合されて薬剤混合物が形成され、前記混合物が前記カートリッジから放出された後、前記プランジャ及び前記カートリッジの前記外筒に対する継続的な前進が前記針リテイナを作動させて前記針部材がリリースされ、これにより前記付勢要素が前記針部材を前記外筒に対して移動させて前記第 1 の先端が封入される、

ことを特徴とする前記医療用装置。

【請求項 2】

請求項 1 記載の前記医療用装置において、前記医療用装置は前記針部材に固定されたニードルキャリアを更に有するものである。

【請求項 3】

請求項 1 記載の前記医療用装置において、前記針部材は第 2 の先端を後端部に有するものである。

【請求項 4】

請求項 1 記載の前記医療用装置において、前記針部材は前記プランジャにかけられる圧力が開放されると引き込まれるものである。

【請求項 5】

請求項 1 記載の前記医療用装置において、前記医療用装置は、前記針部材が前記保護位置に移動するに従い、前記第 1 の尖針端が前記外筒の前記手前側を通過して継続的に後方に移動することを防止する 1 以上の止め部を更に有するものである。

【請求項 6】

請求項 1 記載の前記医療用装置において、前記プランジャはエラストマー系のシールに結合されたプラスチック成形のプランジャロッドからなるものである。

【請求項 7】

請求項 1 記載の前記医療用装置において、前記第 1 の物質が前記第 1 のチャンバから放出される間、前記プランジャは前記カートリッジに対して移動させることができるが、前記混合物が前記第 2 のチャンバから放出される間、前記プランジャは前記カートリッジに対して静止されているものである。

【請求項 8】

請求項 1 記載の前記医療用装置において、前記第 2 の物質はパウダー材料である。

【請求項 9】

請求項 1 記載の前記医療用装置において、前記第 2 の物質は液体材料である。

【請求項 10】

10

20

30

40

50

請求項 1 記載の前記医療用装置において、前記第 2 のチャンバの容量は、前記第 1 の物質と前記第 2 の物質を混合させた容量よりも大きいものである。

【請求項 1 1】

請求項 1 記載の前記医療用装置において、前記液体流通調整部は、；
開口を有する前記第 1 及び第 2 のチャンバの間の壁部と、；
前記開口を介して配置され、前記第 1 のチャンバに突出する先端を有する中空突刺構成要素と、；
前記突刺構成要素を介する液体流通路と、；
を有する前記液体流通調整部において、；
前記カートリッジが前記外筒に向けて軸方向に移動させられると、前記プランジヤは前記
プランジヤが前記突刺構成要素により破られるまで移動し、前記突刺構成要素の液体流通
10 流路と同軸上にある前記プランジヤを通過する流路が形成され、第 1 の物質を前記プランジヤを介して前記第 2 のチャンバに流通させるものである。

【請求項 1 2】

請求項 1 記載の前記医療用装置において、前記液体流通調整部は、；
開口を有する前記第 1 及び第 2 のチャンバの間のバリアと、；
前記開口を介して配置され、前記第 1 のチャンバに突出する先端を有する中空突刺構成要素と、；
前記突刺構成要素を介する液体流通路と、；
前記第 1 のチャンバ内で軸方向に配置可能であり、前記突刺構成要素で突刺されることにより、前記第 1 及び第 2 のチャンバ間に液連通を提供する前記突刺可能な中間シールと、
20 ；
を有する前記液体流通調整部において、；
前記プランジヤが前記外筒に向けて軸方向に移動させられると、前記突刺可能な中間シールは前記中間シールが前記突刺構成要素により破られるまで移動し、前記突刺構成要素の液体流通路と同軸上にある前記中間シールを通過する流路が形成され、第 1 の物質を前記中間シールを介して前記第 2 のチャンバに流通させるものである。

【請求項 1 3】

請求項 1 記載の前記医療用装置において、前記液体流通調整部は、；
前記カートリッジ内で軸方向に移動可能な前記第 1 及び第 2 のチャンバ間にある中間シールと、；
30 ；
前記カートリッジの前記側壁に設けられた細長の液体流路と、；
を有する前記液体流通調整部において、；
前記プランジヤが前記外筒に向けて軸方向に移動させられると、前記中間シールは前記液体流路と直線的に位置決めされ、前記中間シールと前記液体流路の前記内壁との間に流路が形成され、前記第 1 の物質を前記中間シール周辺から前記第 2 チャンバに流通させるものである。

【請求項 1 4】

請求項 1 記載の前記医療用装置において、前記カートリッジは略永久的に前記外筒に取り付けられるものである。
40

【請求項 1 5】

請求項 1 記載の前記医療用装置において、前記カートリッジは、前記カートリッジの前記先端側にピース状の環状リムを有し、前記外筒は前記外筒の手前側の端部で前記外筒の内側貫通孔から径方向内側に突出するリップを含み、前記リップは前記カートリッジの前記ピース状のリムに係合させるようにされており、針部材収納後、前記カートリッジが前記外筒の後方から取り外されることを防止するものである。

【請求項 1 6】

請求項 2 記載の前記医療用装置において、前記付勢要素は、前記外筒の前記先端側の端部と前記針キャリアとの間に配置された圧縮バネを含むものである。

【請求項 1 7】

請求項 2 記載の前記医療用装置において、前記針リテイナは、前記針キャリアから径方向外側に突出し、前記外筒の壁面にある一对のウインドウにリリース可能に係合するよう構成された一对の前方歯 (forward tines) を有するものである。

【請求項 18】

請求項 2 記載の前記医療用装置において、円筒形のスリーブは、前記注入工程の終わりにおける前記カートリッジの軸方向への前進が前記スリーブを前記外筒の前記先端側の端部に向けて移動させ前記針リテイナを作動させるように、通常前記カートリッジと軸方向に位置決めされている針キャリアの外周近傍で配置される前記カートリッジと略同様の外径を有するものである。

【請求項 19】

請求項 3 記載の前記医療用装置において、前記カートリッジは前記カートリッジの先端側の端部にフロントシールを更に有し、前記第 2 の先端により突刺されて前記針部材と第 2 のチャンバとを液連通させるように構成されているものである。

【請求項 20】

請求項 19 記載の前記医療用装置において、前記フロントシールに穴を開けるために必要な前記プランジャにかかる最小限の軸方向への駆動力は、前記後方チャンバで前記プランジャを軸方向に移動させるために必要な最小限の軸方向への駆動力よりも小さい又は等しいものである。

【請求項 21】

請求項 19 記載の前記医療用装置において、前記フロントシールの前記先端側の端部は外側スレッドを含み、前記針キャリアの前記手前側の端部は前記フロントシールの前記ねじ込み形 (threaded end) を受け入れるようにされたキャビティを含むものである。

【請求項 22】

医療用装置であって、前記医療用装置は、：
開口する手前側の端部、先端側の端部、及び外筒の長手軸方向に対して垂直方向に位置する前記外筒の壁部を貫く開口を有する外筒と、；

第 1 の先端を有し、前記第 1 の先端が前記外筒から前方に突出する突出位置と、前記第 1 の先端が保護され前記第 1 の先端との不慮の接触が防止される保護位置との間で移動可能な針部材と、；

前記針部材と液連通するカートリッジであって、前記カートリッジは、：

第 1 の物質を含む第 1 のチャンバ、；

第 2 の物質を含む第 2 のチャンバ、；

前記第 1 のチャンバと前記第 2 のチャンバとを結合させる液体流通調整部、；及び

前記カートリッジ内でスライド可能に配置されたプランジャ；

を有する前記カートリッジと、；

前記針部材を前記外筒に対して移動させることができ、前記第 1 の先端を封入するための動力を提供する付勢要素と、；

前記外筒に着脱可能に結合された係止用クリップと、；

を有する前記医療用装置において、；

前記プランジャが前記第 1 のチャンバ内で軸方向に進められると、前記第 1 の物質は前記第 1 の物質が前記第 2 の物質と混合され薬剤混合物が形成される前記第 2 のチャンバに前記液体流通調整部を介して進められ、前記係止用クリップが前記外筒から外されると、前記プランジャと前記カートリッジは前記外筒に対して更に進められて前記第 2 のチャンバから前記混合物が放出され、その後、前記カートリッジが軸方向に進められると前記針リテイナは係合から外され、前記付勢要素が前記針部材を前記外筒に対して移動させて前記第 1 の先端が封入されるものである。

【請求項 23】

請求項 22 記載の前記医療用装置において、前記医療用装置は前記針部材に固定された針キャリアを更に有するものである。

10

20

30

40

50

【請求項 24】

請求項 22 記載の前記医療用装置において、前記針部材は第 2 の先端を前記針部材の後端に有するものである。

【請求項 25】

請求項 22 記載の前記医療用装置において、前記針部材は前記プランジャにかけられる圧力が開放されると引き込まれるものである。

【請求項 26】

請求項 22 記載の前記医療用装置において、前記カートリッジは前記カートリッジの前記先端側の端部にビーズ状の環状リムを有し、前記外筒は前記外筒の手前側の端部で前記外筒の内側貫通孔から径方向内側に突出するリップを含み、前記リップは前記カートリッジの前記ビーズ状のリムに係合させるようにされ、針部材収納後、前記カートリッジが前記外筒の後方から取り外されることを防止するものである。

10

【請求項 27】

請求項 22 記載の前記医療用装置において、前記医療用装置は、前記針部材が前記保護位置まで移動するに従い、前記第 1 の先端が前記外筒の前記開口する手前側の端部を超えて継続的に後方移動することを防止する 1 以上の止め部を更に有するものである。

【請求項 28】

請求項 22 記載の前記医療用装置において、前記プランジャは、エラストマー系シールに結合されたプラスチック成形のプランジャロッドからなるものである。

【請求項 29】

請求項 22 記載の前記医療用装置において、前記第 1 の物質が前記第 1 のチャンバから放出されている間、前記プランジャは前記カートリッジに対して移動可能であり、前記混合物が前記第 2 のチャンバから放出される際、前記プランジャは前記カートリッジに対して静止するものである。

20

【請求項 30】

請求項 22 記載の前記医療用装置において、前記係止用クリップは、前記内側エッジに沿う複数の歯を有する平坦なリ形状のディスクを有し、前記クリップは前記外筒の前記スリットを介して前記外筒の長手軸に対して垂直方向に、前記カートリッジと前記針リテイナとの間でスライドし、これにより前記カートリッジと前記針リテイナが接触することを防止するものである。

30

【請求項 31】

請求項 22 記載の前記医療用装置において、前記第 2 の物質はパウダー材料である。

【請求項 32】

請求項 22 記載の前記医療用装置において、前記第 2 の物質は液体材料である。

【請求項 33】

請求項 22 記載の前記医療用装置において、前記第 2 のチャンバの容量は、前記第 1 の物質と前記第 2 の物質が結合された容量よりも大きいものである。

【請求項 34】

請求項 22 記載の前記医療用装置において、前記液体流通調整部は、
開口を有する前記第 1 及び第 2 のチャンバの間のバリアと、
前記開口を介して配置され、前記第 1 のチャンバに突出する先端を有する中空突刺構成要素と、
前記突刺構成要素を介する液体流通路と、
前記第 1 のチャンバ内で軸方向に配置可能であり、前記突刺構成要素で突刺されることにより前記第 1 及び第 2 のチャンバ間に液連通を提供する前記穴開け可能な中間シールと、
;

40

を有する前記液体流通調整部において、;

前記プランジャが前記外筒に向けて最初に軸方向に移動させられると、前記突刺可能な中間シールが移動して前記突刺構成要素と接触し、前記中間シールに穴が開けられ、前記突刺構成要素内の液体流通路の直線上にある中間シールを貫通する流路が形成され、前記第

50

1の物質を前記中間シールを介して前記第2のチャンバに流通させるものである。

【請求項35】

請求項22記載の医療用装置において、前記液体流通調整部は、；

前記カートリッジ内で軸方向に移動可能な前記第1及び第2のチャンバ間にある中間シールと、；

前記中間シールと前記カートリッジの先端側の端部との間にある前記カートリッジの前記側壁に設けられた細長の液体流路と、；

を有する前記液体流通調整部において、；

前記プランジャが前記外筒に向けて軸方向に移動させられると、前記中間シールは前記液体流路と直線的に位置決めされ、前記中間シールと前記液体流路の前記内壁との間に流路が形成され、前記第1の物質を前記中間シール周辺から前記第2チャンバに流通させるものである。

10

【請求項36】

請求項23記載の前記医療用装置において、前記付勢要素は前記外筒の前記先端側の端部と前記針キャリアとの間に配置された圧縮バネを含むものである。

【請求項37】

請求項23記載の前記医療用装置において、前記針リテイナは、前記外筒の壁面に設けられた一对のウインドウと、前記針キャリアから径方向外側に突出して前記外筒の壁面に設けられた一对のウインドウにリリース可能に係合するよう構成された一对の前方歯 (forward tines) とを有するものである。

20

【請求項38】

請求項24記載の前記医療用装置において、前記カートリッジは、前記カートリッジの先端側の端部にフロントシールを更に有し、前記第2の先端により突刺されて前記針部材と第2のチャンバとが液連通されるように構成されている。

【請求項39】

請求項38記載の前記医療用装置において、前記フロントシールに穴を開けるために必要な前記プランジャにかけられる最小限の軸方向への駆動力は、前記後方チャンバで前記プランジャを軸方向に移動させるために必要な最小限の軸方向への駆動力よりも小さい又は等しいものである。

30

【請求項40】

医療用装置であって、前記医療用装置は、；

開口する手前側の端部及び先端側の端部を有する外筒と、；

第1の先端を有し、前記第1の先端が前記外筒から前方に突出する突出位置と、前記第1の先端が保護され前記第1の先端との不慮の接触が防止される保護位置との間で移動可能な針部材と、；

前記針部材と液連通するカートリッジであって、前記カートリッジは：

第1の物質を含む第1のチャンバ、；

第2の物質を含む第2のチャンバ、；

前記第1のチャンバと前記第2のチャンバとの間の液体流通調整部、；及び、

前記針部材を前記外筒に対して移動させることができ前記第1の先端を保護する動力を提供する付勢要素と、；

40

を有する前記カートリッジと、；

前記針部材を前記突出位置でリリース可能に保持する針リテイナと、；

を有する前記医療用装置において、；

前記液体流通調整部は、使用前、前記第1及び第2の物質は隔離され続けるようにされており、注入前、前記第1及び第2の物質は混合されるようにされており、使用后、前記針部材は前記保護位置に移動させられるものである。

【請求項41】

薬剤を注入する方法であって、前記注入工程は、；

第1の薬剤成分を含む第1のチャンバ、第2の薬剤成分を含む第2のチャンバ、及び針部

50

材を有する注入装置を提供する工程と；

前記第2の薬剤成分を前記第1のチャンバから前記第2のチャンバに送る工程と；

前記第1及び第2の成分を混合して薬剤混合物を形成する工程と；

前記薬剤混合物を前記チャンバから放出させる工程と；

前記薬剤液が放出された後、前記針部材を収納して前記針部材を接触から保護する工程と；

を有する前記薬剤を注入する方法。

【発明の詳細な説明】

【技術分野】

【0001】

本出願は、2001年3月13日付けで出願された米国特許仮出願第60/275,568号の優先権を主張するものであり、この引用により本願明細書に組み込まれたものとする。

【0002】

本発明は医療用装置に関し、より具体的には、2個のチャンバに別々の薬剤成分を格納し、これらの成分を混合して最終的に患者へ投与するカートリッジを有する医療用装置に関する。

【背景技術】

【0003】

予充填式のシリンジは、別々の薬剤成分を格納して混合するものである。これらシリンジの多くは、「混合用シリンジ」と称され、第1の成分を1つ目のコンパートメントに、希釈剤又は第2の成分を2つ目のコンパートメントに格納する。これらのシリンジは、シリンジが使用される直前まで2つの成分を別々に格納することができ、シリンジ使用時において成分をシリンジ内で混合して直接患者に投与することができる。

【0004】

予充填式の混合用シリンジは、多様な薬剤にとって利点を有する。抗生物質、ビタミン及びホルモンのようないくつかの薬剤は、保管寿命を向上させるため成分毎にパッケージして保管しなければならない。これらの薬剤は、パウダー要素及び希釈剤、又は別々の一組の溶液として保管する必要がある。予充填式の混合用シリンジは、薬剤が投与される直前まで薬剤を成分毎に分けて格納することができる。加えて、予充填式の混合用シリンジは、薬剤成分の測量や希釈剤を別の容器から混合させる負担を取り除くものである。

【0005】

これらの利点があるにも関わらず、従来混合用シリンジは、注入に付随する不慮の針刺しからシリンジの使用者を保護するための、確実な安全機能を提供するものではなかった。具体的には、従来シリンジアセンブリは、注入の完了に際し、自動的に保護することができる注入用針部材と一体的に機能する混合用シリンジを提供するものではなかった。

【発明の開示】

【課題を解決するための手段】

【0006】

上記事情に鑑み、本発明は別々の成分を混合して薬剤を患者に注入するための予充填式の医療用装置を提供するものである。この装置は2個のチャンバを有する容器を含むものであって、使用後に自動的に引き込む針部材と結合したカートリッジ等である。収納後、汚染された針先は装置内に封入されて不慮の針刺しが防止される。

【0007】

この装置は、針部材を囲み、ソケットを形成する通常開口している後端を有する中空の外筒を含む。薬剤成分を保持する2チャンバ式カートリッジは、ソケットに係合するようになっている。使用前、成分は別々に2個のカートリッジチャンバに格納される。使用中、カートリッジの後端に配置されたプランジャはカートリッジ内へと進められ、2つの成分が1つに混合される。そして、プランジャにかけられる圧力により、薬剤混合物は針部材を介して患者に投入される。

10

20

30

40

50

【0008】

この注入用針部材は、突出位置と収納位置との間で移動可能である。突出位置において、針部材の先端は外筒から前方に突出する。収納位置において、先端は外筒内に封入される。針部材が突出位置にある場合、付勢要素は、この針部材を収納位置に向けて付勢する。針リテイナは、付勢要素の力に抗してこの針部材を突出位置でリリース可能に保持する。注入動作中、カートリッジが針リテイナとの係合から外れると、付勢要素は針部材を外筒に向けて後方に駆動する。

【発明を実施するための最良の形態】

【0009】

図面全体、特に図1～11を参照すると、注入装置10は、患者に挿入される先尖端16を有する針部材12と共に示されている。図4に示されるように、注入装置10は、第1のチャンバ52及び第2のチャンバ56を有する一体式のカートリッジ50を有している。2個のチャンバ52、56には、注入前に混合されるべき薬剤成分が予め充填されている。カートリッジ50はまた、カートリッジ内でスライド可能なプランジャ40を含む。最初、プランジャ40がカートリッジ50内で前進させられると、薬剤成分が第1のチャンバ52から第2のチャンバ56に放出され、2種類の薬剤成分が混合される。成分が混合された後、更にプランジャが前進させられると、カートリッジが前方に駆動され薬剤が患者に注入される。注入工程が完了すると、医療専門家はプランジャから圧力を開放し、針部材12を装置10内に自動的に収納して汚染された針部材12を不慮の接触から保護する。

10

20

【0010】

注入装置10は、両頭の針部材12、略円筒形の外筒30、圧縮バネ26及び針部材をバネの付勢力に抗してリリース可能に保持する針リテイナ20を含むものである。図4及び5に示されるように、針部材12は手前側の先端14及び先端側の先端16を有する。バネ26は針部材12を囲み、外筒30の先端側の内面に対して圧縮されている。バネ26の後端は、針リテイナ20の内部で支持され、針部材12及び針リテイナ20に後方に向けて付勢する。

【0011】

針部材12は、突出位置と収納位置の2個所の間で移動可能である。突出位置において、針部材12は外筒30の前端から前方に突出している。収納位置において、針部材12は外筒30内に引き込まれ、これにより針部材12の先端16は外筒内に封入されて先端との不慮の接触が防止される。針部材が突出位置にある場合、バネ26は、針部材12を収納位置に向けて後方に付勢する。針リテイナ20は、バネ26の付勢力に抗して針部材12を突出位置でリリース可能に保持する。注入工程の間、図10に示されるように、カートリッジ50は針リテイナ20と協働して針部材を外筒30に収納させることができる。

30

【0012】

図5～7を参照すると、カートリッジ50は、第1の薬剤成分54を保持する第1のチャンバ52と、第2の薬剤成分58を保持する第2のチャンバ56を含むものである。チャンバ52、56は、オリフィス62を含む中間壁60により隔てられている。後方シール70は、第1のチャンバ52を密封し、成分同士が使用前に混合されることを防止する。後方シール70が突刺されてプランジャ40がカートリッジ50内へと進められると、図6～7に示されるように、第1の成分54が第2のチャンバ56にオリフィス62を介して流れ込み、第2の成分58と混合されて薬剤59が形成される。プランジャ40とカートリッジ50にかけられる更なる圧力が針部材12を介して薬剤59を患者に投入する。

40

【0013】

図4～6を参照して、注入装置10の構成要素をより詳細に説明する。外筒30は略円筒形であり、外筒の先端側はテーパがかけられたノーズ32を有する。このノーズ32は、針部材12が延伸される開口を有しており、これにより針部材の先端16を患者に挿入することができる。外筒30の後端は開口しており、カートリッジ50を受け入れるようにされた円筒形のソケット34を形成する。2つの側方に延びるフランジ36は、外筒の長

50

手軸を横断して外筒 30 から外側方向に突設され、一对のフィンガーグリップが装置 10 の操作に形成されている。外筒 30 は、一对の保持開口 38 と一对のロックアウトウィンドウ 39 とを更に有し、下記のように針リテイナ 20 と協働する。

【0014】

図 5 に示されるように、ハブ 21 は針リテイナ 20 の後端から突出している。ハブ 21 は、中央貫通孔 23 を有する略円筒形の構成要素である。針部材 12 は、ハブ 21 の中央貫通孔 23 内に配置され、これにより針部材 12 の後端 14 はハブから後方に突出し、針部材の前端 16 はハブから前方に突出する。針部材 12 は、いくつかの方法でハブ 21 に取り付けることができる。例えば、針部材 12 は、UV 硬化粘着剤などの接着剤でハブ 21 に取り付けることができる。或いは、針部材 12 は、プラスチックから形成されるハブ 21 内に成形することができる。ハブ 21 の後端は、円周に引っかかりが設けられたコネクタ 25 を有しており、更に下記のように、カートリッジ 50 と協働してカートリッジとニードルハブ 21 とを結合させる。

10

【0015】

針リテイナ 20 は外筒 30 内で軸方向に移動可能であり、針部材の収納を容易にさせる。針リテイナ 20 は、ポリカーボネートなどの硬い、高強度の樹脂から成形することができる。引き込み前、薬剤 59 がカートリッジ 50 から放出されている間、針リテイナ 20 は所定の軸方向位置で維持される。注入後、針リテイナ 20 と取り付けられた針部材 12 は圧縮バネ 26 により後方に移動させられる。

【0016】

バネ 26 は圧縮バネであり、ステンレススチール、処理済みのカーボンスチールワイヤ又はその他の適切な腐食性のないバネ金属から形成されてもよい。針リテイナが係合から外れる前のバネの残圧は十分な大きさがあり、針部材の収納を容易に完了させ、装置 10 内で摺動する構成要素間の摩擦抵抗を上回るものである。

20

【0017】

図 6 を参照すると、針リテイナ 20 は、針リテイナ 20 の先端側から径方向外側かつ前方に延びる一对の保持アーム 22 を含むものである。動作中、針リテイナ 20 は係止位置と非係止位置との間で移動可能である。係止位置において、保持アーム 22 は外筒の壁の保持開口 38 に係合し、外筒 30 から前方に突出している針部材 12 の先端 16 と共に、針部材を所定の軸方向位置に固定する。より具体的には、係止位置において、保持アーム 22 は外筒 30 に係合し、バネ 26 の後方への付勢力に抗してニードルハブ 21 と針部材 12 とを保持する。非係止位置において、保持アーム 22 は、ニードルハブ 21 と針部材 12 とを後方に収納できるように位置決めされる。より具体的には、非係止位置において、保持アーム 22 は保持開口 38 との係合から外され、バネ 26 がニードルハブ 21 と針部材 12 とを後方に駆動することができるようにする。

30

【0018】

上記のように、針リテイナ 20 の保持アーム 22 は、前方外側に向けて突出し、外筒 30 の壁の保持開口 38 と係合する。各アームの終端は保持用タブ 24 を形成し、保持開口 38 で突出するように構成されている。より具体的には、保持用タブ 24 は、外筒 30 の壁の各保持開口 38 により形成されたリップに係合する。このようにして、保持用タブ 24 は一对のラッチとして動作し、バネの後方への付勢力に抗してニードルハブ 21 と針部材 12 とを保持する。

40

【0019】

再度図 4 及び図 5 を参照すると、カートリッジ 50 は、ホウケイ酸塩などの薬品の品質を有するガラス、又はポリオレフィン若しくはポリエステルなどの硬い不活性プラスチックから成形されてもよい略円筒形の容器である。第 1 及び第 2 のチャンバを隔てる中間壁 60 は、ポリオレフィン又はポリエステルなどの硬い不活性プラスチックから形成されてもよい。バリア又は中間壁 60 は、カートリッジ 50 の一部として成形することができる。若しくはカートリッジの内壁に接着させることができる。各チャンバは、装置 10 の製造中、所定量の薬剤で満たされる。

50

【0020】

前方チャンバ56の前端は、ポリイソブレンなどのセルフシールの生体適合性エラストマーで成形することができるエラストマー系フロントシール80により密封されている。フロントシール80は略円筒形であり、複数の軸方向に離間した環状リブ81を有する。リブ81は、図2でより明確に示されているが、容器の内側で摩擦及び密閉係合して液体密封シールを提供し、これにより液体がカートリッジ50から漏れることを防止する。また、フロントシール80は前端を有し、針部材12の後尖端14により突刺可能である。突刺後、フロントシール80の前端は針部材12の周りを再び密閉し、液体がカートリッジ50から漏れることを防止する。

【0021】

図5及び6を参照すると、フロントシール80は、ニードルハブ21にある、引っかかりが設けられたコネクタ25と協働するように構成されたソケット82を有する。ソケット82は、2つの径方向にリリース(released)された凹部82a及び82bを含み、引っかかりが設けられたコネクタ25と結合する。具体的には、引っかかりが設けられたコネクタ25は、フロントシール80に第1の位置及び第2の位置で係合する。

【0022】

第1の位置において、引っかかりが設けられたコネクタ25は、図5に示される第1の凹部82aに係合する。この位置で、カートリッジはハブに取り付けられるが、針部材の後端はフロントシール80を突刺しない。プランジャ40に圧力がかけられると、カートリッジはハブに対して前方に移動し、これによりバンプが第2の位置に移動する。第2の位置において、引っかかりが設けられたコネクタ25は、図6に示されるように第2の凹部82bに係合する。この位置で、針部材12の後端はフロントシール80を突刺する。

【0023】

フロントシール80は、その後端に中空のキャビティ84を含むものである。このようにして、突刺可能な壁86は、キャビティ84と第2の凹部82bとの間のフロントシール80で形成される。図5に示されるように、使用前、カートリッジ50は第1の位置に取り付けられ、これにより引っかかりが設けられたコネクタ25は第1の凹部82aに係合する。この位置において、針部材12は突刺可能な壁86を貫通しない。図6に示されるように、ハブ21が第1の位置から第2の位置に移動するに従い、針部材12の後端14は壁86を突刺してキャビティ84へと延びる。キャビティ84は、カートリッジ50の第2チャンバ56内で開いており、これにより針部材12が中空部分84に突出する場合、針部材はカートリッジの内側と液連通する。針部材12が突刺可能な壁86を貫通した後、この壁は針部材の周囲を再び密閉して液体密封シールを形成し、カートリッジ内の薬剤が針部材の周囲に漏れることを防止する。

【0024】

注入装置10を使用に向けて準備するため、医療専門家は、カートリッジ50を針リテイナ20に対して前方に移動させ、引っかかりが設けられたコネクタが第2の凹部82bに係合するように、前方シール80は引っかかりが設けられたコネクタ25を覆って駆動される。同時に、針部材12の手前側の尖端14は、突刺可能な壁86に穴を開け、図6に示されるように、これにより針部材は第2のチャンバと液連通される。

【0025】

フロントシール80とニードルハブ21の結合は、一方向の係合であることが好ましい。すなわち、フロントシール80が引っかかりが設けられたコネクタ25に取り付けられている場合、カートリッジ50を引っかかりが設けられたコネクタに対して前方に移動させることができるが、カートリッジを引っかかりが設けられたコネクタに対して後方に移動させることができない。このようにして、カートリッジ50は外筒30のニードルハブ21から容易に取り外すことはできず、カートリッジは略永久的にニードルハブと外筒に取り付けられることになる。

【0026】

一方向の結合は、引っかかりが設けられたコネクタ25の後面テーパショルダ及び引っか

10

20

30

40

50

かりが設けられたコネクタの方形前面ショルダにより容易になされる。具体的には、引っかかりが設けられたコネクタ25の後面ショルダは、第1と第2の半径方向の凹部82a及び82b内のテーパ面と協働し、第1の凹部から第2の凹部までプラグが相対移動することを可能にさせる。第2の凹部82bから第1の凹部82aに戻る逆移動は、逆移動を防止する引っかかりが設けられたコネクタ25の方形前面ショルダによって阻止される。

【0027】

図4を参照すると、引っかかりが設けられたコネクタ25が、第1の半径方向の凹部82aに係合する第1の位置から、引っかかりが設けられたコネクタ25が第2の半径方向の凹部82bに係合する第2の位置まで移動する場合、フロントシール80が液体の噴出を防止するように構成されている。具体的には、フロントシール80はフレアヘッド88 (flared head) 又は環状フランジをフロントシールの前端に含むものである。カートリッジ50の開口末端はビーズ状のリム51で終端処理され、フレアヘッド88の後方エッジに対して合わさる。フレアヘッド88の外径は、カートリッジ50の開口末端の内径よりも大きく、これにより力が最初にプランジャ40にかけられる時、フロントシール80がカートリッジに後方移動することが防止される。加えて、フロントシール80の外面とカートリッジ50の内面との摩擦接触を克服するために要する力は、プラグ25を第1の凹部82aから第2の凹部82bまで移動させるのに要する力よりも大きい。従って、力が最初にプランジャ40にかけられる時、フロントシール80はカートリッジ50に対して定位置にとどまるが、引っかかりが設けられたコネクタ25は第2の位置に移動させられる。針部材12が壁86を突刺するとき、フロントシール80のこの制約は、カートリッジ50から液体がリリースされることを制限する。

10

20

【0028】

注入装置10の保管中、図5に示されるように、薬剤は2種類の別々の成分に分けられてカートリッジ50に格納される。具体的には、薬剤の第1の成分54は後方チャンバ52に格納され、薬剤の第2の成分58は前方チャンバ56に格納される。2個のチャンバはオリフィス62及びこのオリフィスに取り付けられた中空突刺部材64を含む中間壁60により隔てられている。オリフィス62は、中間壁60に軸方向に配置されている。加えて、小さな通気孔63は中間壁60の中心から外れたところに配置され、中間壁と中間シール70との間のデッドスペースエリアから空気を通風する。突刺部材64は、ステンレススチール又は処理済みのカーボンスチールワイヤなどの適切な非腐食性材料からなるものであるのが好ましい。プランジャ40がカートリッジ50内で軸方向に移動すると、後方チャンバ52の第1の成分54は、突刺部材64を介して前方チャンバ56に進められ、第2の成分58と混合される。

30

【0029】

注入装置10の使用前、第1及び第2のチャンバ間の液連通は、エラストマー系の中間シール70によって防止される。なお、この中間シール70は、ポリイソブレンなどのセルフシールの生体適合性エラストマーで成形されてもよい。図4~5に示されているように、まず、中間シール70は、突刺部材64と第1の成分54の間で第1のチャンバ52内に摺動可能に配置される。図2でより明確に示されているように、中間シール70は略円筒形であり、複数の軸方向に離間した環状リブ71を有する。リブ71はカートリッジ50の内壁に擦って入り込むように係合し、液体密封シールを提供する。この液体密封シールは、第1のチャンバの液体が突刺部材64に流入することを防止する。また、中間シール70は中間シールの前端に形成された中空部分72を含むものであり、中間シールの後端で第1のチャンバ52に対して開いている。中間シール70の前端は、膜78により閉じられており、突刺部材64により突刺可能である。膜78が突刺されると、第1及び第2のチャンバ間で液連通が確立され、薬剤の第1及び第2の成分を混合させることができる。

40

【0030】

フロントシール80や中間シール70のように、プランジャ40は略円筒形であり、好ましくは複数の軸方向に離間した環状リブ41を有するものである。プランジャ40は、ポ

50

リイソブレンなどのセルフシールの生体適合性エラストマーで成形されてもよい。或いは、プランジャ40は、2つの部分から組み立てることができ、円筒形のエラストマー系シールを硬性プラスチックのプランジャロッドに取り付けることができる。リブ41は、図2でより明確に示されているが、カートリッジ50の内側に擦って入り込むように係合して液体密封シールを提供し、これにより液体がカートリッジの手前側から漏れることが防止される。

【0031】

プランジャ40は、親指パッド42にかかる圧力に応じ、第1のチャンバ52内で摺動可能である。プランジャ40がカートリッジ50に向けて軸方向に駆動されると、第1の成分54は、第1チャンバ52内の中間シール70の後端に向けて押される。中間シール70にかかるバックプレッシャが中間シールとカートリッジ50の間の摩擦抵抗を上回ると、図6に示されているように、膜78に穴が開くまで中間シールは突刺部材64方向に駆動される。中間シールが進むに従い、中間シールと中間壁とのスペースの空気は中間壁の通気孔63を介して通風される。その場合、突刺部材64は、中空部分72を介して貫通し、第1のチャンバ52と第2のチャンバ56を液連通する。

10

【0032】

中間シール70が突刺された後、プランジャ40にかけられる圧力は、第1の成分54を、第1及び第2の成分が最終的に混合され薬剤59が形成される第2のチャンバ56に突刺部材64を介して移動させる。プランジャ40は、図7に示されるように、親指パッド42のフランジ部分がカートリッジ50の手前側に接触するまで、第1のチャンバ52に対して前方に移動させられる。親指パッド42の外径は、カートリッジ50の内径よりも大きく、これにより一旦親指パッドがカートリッジ50の手前側に接触すると、プランジャ40の更なる移動が防止される。プランジャ40の前端と中間シール70の後端との距離は、親指パッド42のフランジ部分とカートリッジ50の手前側との距離と等しいものであるのが好ましい。一旦親指パッド42がカートリッジ50の手前側に接触すると、プランジャはカートリッジ50に対して固定される。この時点で、より詳しく後述されるように、外筒30に対してカートリッジ50が軸方向に移動することは抑制される。

20

【0033】

注入装置10は、2種類の成分を混合させる前、第2のチャンバの内容物の不慮の放出を防止する係止機能を含むものであるのが好ましい。図7に示される本実施形態において、外筒30は係止用クリップ100を外筒の壁面に保持し、薬剤成分の不慮の放出を防止する。外筒30の壁面は、平面で形成され外筒の長手軸を横断する一対の径方向スロット104を含む。係止用クリップ100がスロット104に挿通されると、クリップは、カートリッジ50がフロントシール80に対して不慮に前方に移動することを防ぎ、これにより薬剤成分が針部材12を介して不慮に押されることは防止される。係止用クリップ100は、アセチル又はポリカーボネートなどの弾力性があり高強度かつ高モジュラスな樹脂から形成され、外筒30のスロット104にリリース可能に係合されるように構成されるものであるのが好ましい。

30

【0034】

図1～3を参照すると、係止用クリップ100は、弾力性を有し、たわませることができ、U形状を共に形成する一対のレッグ101を有する平面部材であるのが好ましい。係止用クリップ100の開端はテーパがかけられたエッジ102を有しており、係止用クリップ100が外筒30の側壁に挿入されるに従い、レッグ101が外側に曲がる。加えて、係止用クリップ100は、レッグ101の内側エッジに複数の歯103を有しており、径方向スロット104のエッジと係合するようにされている。

40

【0035】

係止用クリップが外筒30の側壁に挿入されるに従い、レッグ101は外側に曲がり、径方向スロット104のエッジを歯103にクリアにさせる。外側に曲げられている場合、レッグ101の弾力性は、レッグを元の位置に向けて径方向内側へ付勢する。一旦歯103がスロット104内に配置されると、レッグ101は元の位置に向けて径方向内側に曲

50

がり、外筒30の針リテナ20の外側エッジにリリース可能に係合する。挿入位置において、係止用クリップ100の閉端は、図1及び4に示されるように、外筒30の外側にとどまる。

【0036】

薬剤成分がカートリッジ内で混合された後、図8に示されるように、係止用クリップ100が取り外されて薬剤59の注入が可能になる。係止用クリップ100は、外筒の長手軸を横断する方向にクリップの閉端を引くことによって外筒30から取り外される。この方向は、図1において「A」で示されている。このようにクリップを引くことで、レグ101はスロット104から外側に曲がり、スロット104のエッジを歯103にクリアにさせる。

10

【0037】

係止用クリップ100が外筒30から取り外された後、カートリッジを外筒に向けて前方に移動させることにより、薬剤59が患者に注入される。親指パッド42にかけられる圧力は、プランジャ40とカートリッジ50を外筒30に対して前方に移動させる。フロントシール80の第2の凹部82bに取り付けられた引っかかりが設けられたコネクタ25により、フロントシールは静止するが、図9に示されるように、カートリッジ50は前方に移動する。フロントシール80とフレアヘッド88は、カートリッジ50の内側と滑りばめを形成するように構成されており、カートリッジはフロントシールを覆って摺動する。カートリッジ50が進められると、中間シール70と中間壁60はフロントシール80に向けて移動する。これが第2のチャンバ56内の薬量を減少させて薬剤が針部材に移動し注入を容易にさせる。注入完了後、図9に示されるように、中間壁60はフロントシール80の後端を支持する。

20

【0038】

図9～10を参照して、針部材12の自動収納を説明する。カートリッジ50は、薬剤59が第2のチャンバ56から完全に放出されるまで外筒30の手前側に向けて軸方向に進められる。カートリッジ50が進められるに従い、カートリッジのビーズ状の環状リム51が針リテナ20の保持アーム22と係合するように移動する。カートリッジが第2の位置で引っかかりが設けられたコネクタ25に取り付けられる際、カートリッジ50は、フロントシール80の後端と中間壁60との長さ距離が、カートリッジの環状リム51と保持アーム22との長さ距離に対応するように構成されるのが好ましい。このようにして、略全ての薬剤59が装置10から放出されると、カートリッジ50のリム51は保持アーム22に係合する。

30

【0039】

カートリッジ50のリム51が保持アーム22に係合した後、図9に示されるように、カートリッジの継続的な軸方向への駆動は保持アームを径方向内側に曲げ、保持タブ24が内側に移動させられる。内側位置において、保持タブ24は外筒30の保持開口38との係合から外される。このようにして、カートリッジ50は作動装置として動作し、カートリッジの軸方向への移動が針リテナ20を非係止位置に移動させる。非係止位置において、針リテナ20はもはや、バネ26の力に抗した位置に係止されない。針リテナ20が非係止位置にあり、使用者がプランジャ40にかかる圧力を放した後、針部材の手前側の先端16が外筒30内に封入されるまでバネ26は針部材12を後方に押す。

40

【0040】

図10に示されるように、針部材12が引き込まれる際、針部材、針リテナ20及びカートリッジ50は後方に共に移動する。引き込み中、保持アーム22は径方向外側に付勢されており、保持タブ24は外筒の内壁に沿って駆動する。バネ26の力は、ガイドアーム28と外筒30との間で生成される摩擦抵抗を上回るには十分に強いものである。

【0041】

注入装置10は、引き込み要素が後方に移動することを制限する機能を含むものであるのが好ましい。図2、4及び10を参照すると、針リテナ20は、外筒30の内壁に形成された一対のアラインメントチャンネル又は溝31と協働する一対のガイドアーム28を含

50

む。ガイドアーム 28 は、ポリカーボネートなどの硬性、弾力性がある高強度な樹脂から成形されてもよい。ガイドアーム 28 は、針リテナ 20 から前方に延び、径方向外側に突出してアラインメント溝 31 に係合する。

【0042】

各ガイドアーム 28 は、好ましくは外筒 30 の長手軸と略平行で直線的な細長の後部を含む。各ガイドアーム 28 の前部は、外筒 30 の長手軸を横断するように外側に曲がり、アラインメント溝 31 の 1 つに達する。針リテナ 20 が外筒内に配置される際、ガイドアーム 28 は自然な状態から径方向内側に曲がる。この位置において、ガイドアームの弾力特性により、ガイドアーム 28 は外筒 30 の内壁に対して径方向外側に付勢される。

【0043】

ガイドアーム 28 の前端は、好ましくはアラインメント溝 31 に含まれ、針部材の引き込み中、針部材と針リテナ 20 の回転を実質的に制限するものである。この係合は、ガイドアームがロックアウトウインドウ 39 で位置決めされ、これによりガイドアームが引き込みの最後でロックアウトウインドウに留まることを確実にさせる。このようにして、針リテナ 20 は、針部材引き込み中、軸方向に移動することを制限される。引き込み中、ガイドアーム 28 の前端と外筒 30 の内壁との摩擦抵抗は、パネ 26 の膨張力によって克服される。

【0044】

図 4 に示されるように、各ガイドアーム 28 の直線的な細長の後部は、外筒 30 の内壁から径方向内側に離間しており、ガイドアームの直線部分と外筒との間に空間距離が作り出される。空間距離の最低限の径方向の厚さは、カートリッジ 50 又はカートリッジリム 51 の壁の厚さよりも大きいものであるのが好ましい。このようにして、カートリッジ 50 が前方に進められ保持アーム 22 が係合から外される時、カートリッジの前進はガイドアーム 28 により妨げられることがない。

【0045】

各アラインメント溝 31 は、外筒 30 の長手軸と略平行である。図 4 には、外筒の後端まで延びている溝 31 が示されている。しかし、この溝は外筒の後端の手前で終端することが望ましい場合もある。各アラインメント溝 31 の後部は、外筒 30 の壁に形成されたロックアウトウインドウ 39 に交差する。ロックアウトウインドウ 39 は、図 10 に示されるように、ガイドアーム 28 の前端を受け入れるようにされている。具体的には、針部材の引き込み中、各ガイドアーム 28 の前端が対応するロックアウトウインドウ 39 で位置決めされると、ガイドアームの径方向外側への付勢力がアームを外側に移動させ、これにより前端はロックアウトウインドウで突出する。ガイドアーム 28 とロックアウトウインドウ 39 の係合は、リテナ 22 が更に軸方向に移動することを防止する。結果として、引き込み要素が前方又は後方に更に移動することが制限される。

【0046】

注入装置 10 は、変更又は外筒ソケット 34 からカートリッジ 50 を取り外すことを制限する機能を含むものであるのが好ましい。図 11 を参照すると、本実施形態は、外筒 30 のソケット 34 の内壁から径方向内側に突出している環状リップ 35 を含む。リップ 35 は、カートリッジ 50 のピース状のリム 51 に対して係合をさせるようにされており、カートリッジが外筒 30 から容易に引き抜くことができないようにされている。結果として、引き込み要素、特に汚染された針部材へのアクセスが制限される。

【0047】

図 4 ~ 10 を参照して、注入装置 10 の操作を説明する。使用前、針部材 12 は突出位置に配置され、これにより針部材の先端側 16 は、図 4 に示されるように、外筒 30 から前方に突出する。装置 10 は、すでに外筒 30 と一体化されているカートリッジ 50 と共に出荷され、引っかけが設けられたコネクタ 25 が第 1 の凹部 82 a に係合しているものが好ましい。或いは、カートリッジ 50 が外筒 30 と別個に出荷され、カートリッジは使用前に外筒に取り付けられるものであってもよい。

【0048】

10

20

30

40

50

カートリッジ 50 と外筒 30 が組み立てられた状態で装置 10 は垂直に保持され、これにより針部材 12 の先端側 16 は上を向く。使用者は、プランジャ 40 の親指パッド 42 を下向きにして使用者の親指を支持位置に置き、装置 10 を保持する。加えて、使用者は指を各フィンガーグリップ 36 に置き、装置 10 の動作をコントロールする。フィンガーグリップ 36 に固定された使用者の指で、通常のシリンジと同様に、使用者は親指パッド 42 を少し押圧する。押圧は、カートリッジ 50 を外筒に対して前方に移動させ、これにより針リテイナ 20 の引っかかりが設けられたコネクタ 25 がフロントシール 80 の第 2 の凹部 82 b に係合し、針部材 12 が壁 86 を突刺する。フロントシール 80 が突刺されると、前方チャンバ 56 内に閉じ込められた空気が針部材 12 を介して通風される。

【0049】

プランジャ 40 の継続的な前進は、突刺構成要素 64 が中間シールを突刺するまで、シール 70 を突刺構成要素 64 に向けて移動させ、前方と後方のチャンバ 52、56 との間に液連通を提供する。このとき、第 1 の成分 54 が前方チャンバ 56 に向けて移動させられてもよい。第 1 の成分 54 が後方チャンバ 52 から前方チャンバ 56 に完全に放出され、プランジャの前端が中間シール 70 の後端に接触するまで、圧力が親指パッド 42 にかける。その後、使用者は、注入装置 10 を振り、前方チャンバ 56 内の第 1 及び第 2 の成分 54、58 を混合させる。

【0050】

混合中、係止用クリップ 100 は、カートリッジ 50 が針リテイナ 20 に向かって前方に移動することを防止する。カートリッジ 50 にかかるこの制限は、針部材 12 から薬剤 59 が不慮に放出される可能性及び針部材の予定外の引き込みを制限する。一旦薬剤 59 が十分に混合されると、使用者は係止用クリップ 100 を外筒 30 から取り外し、これによりカートリッジ 50 を外筒内で前方に移動させることができる。このとき、親指パッド 42 にかけられた最初の圧力がカートリッジを押し進め、余分な空気を第 2 のチャンバ 56 から通風させる。

【0051】

その後、針部材は患者に挿入され、プランジャ 40 が押されて外筒 30 に対してカートリッジ 50 が軸方向に進められ、薬剤 59 はカートリッジから患者に注入される。注入工程の終わりに、カートリッジ 50 のピース状のリム 51 は保持アーム 22 に係合し、保持タブ 24 が径方向内側に移動して係合が外され、針リテイナ 20 が非係止位置に移動する。針リテイナ 22 は非係止位置にあるが、針部材 12 は使用者が親指パッド 42 から圧力を開放するまで収納されない。このようにして、針部材が患者から抜かれるまで、使用者は親指パッド 42 への圧力を維持することができる。その後、使用者は圧力を親指パッド 42 から開放し、針部材はバネ 26 により後方に移動させられる。或いは、使用者は圧力を親指パッド 42 から開放するが、針部材 12 は患者に挿入したままにすることができる。一旦親指パッド 42 がリリースされると、バネ 26 が針部材 12 を後方に移動させ、針部材の汚染された先端側 16 は外筒 30 内に封入される。

【0052】

図 12 ~ 16 全体を参照し、具体的には図 12 ~ 13 を参照すると、安全な希釈剤が予め充填された注入器の第 2 の実施形態が示されている。注入装置 110 は、図 1 ~ 11 で示された第 1 の実施形態 10 に関連して上述された構成要素と略同様の構成要素を含むものである。これらの構成要素は、両頭の針部材 112、略円筒形の外筒 130、圧縮バネ 126、バネの付勢力に抗して針部材をリリース可能に保持する針リテイナ 120、係止用クリップ 200 を含むものである。針部材 112、は手前側の先端 114 及び先端側の先端 116 を有する。バネ 126 は針部材 112 を囲み、外筒の前端で外筒 130 の内面を押す。バネ 126 の後端は、針リテイナ 120 の内側を支持して針部材 112 及び針リテイナを後方に付勢する。

【0053】

上記実施形態とは対照的に、第 2 の実施形態は、第 1 の実施形態における上記のような中間壁や突刺可能なシールではなく、2 種類の薬剤成分を隔てるための選択的に密閉可能な

10

20

30

40

50

バイパス液体流路 160 を有するカートリッジ 150 を利用するものである。使用前、カートリッジ 150 内の中間シール 170 は 2 種類の薬剤成分 154、158 を隔てる。使用前、中間シール 170 は、液体流路を提供するバイパス流路 160 に近接して前方に移動され、2 種類の薬剤成分 154、158 を混合することができるようにされる。その後、混合された成分は患者に注入される。

【0054】

図 12、13 を参照して、カートリッジ 150 の細部をより詳細に説明する。カートリッジは略円筒形の容器である。カートリッジの前端は突刺可能な前方シール 180 により密閉されている。カートリッジの後端は、ピストン 143 により密閉されており、カートリッジの内壁と液体密封シールを形成する。前方シール 180 とピストン 143 との中間で、中間シール 170 はカートリッジの内壁と液体密封シールを形成し、カートリッジを第 1 の成分 158 を受け入れる前方チャンバ 156 と第 2 の成分 154 を受け入れる後方チャンバ 152 の 2 個のチャンバに隔てる。

10

【0055】

カートリッジ 150 は、カートリッジの側面から外側に突出した泡のような液体流路 160 を含む。液体流路 160 には、カートリッジの直径が中間シールの直径よりも大きい箇所が形成されている。液体流路 160 は軸方向に細長のチャネルであり、中間シール 170 の軸方向の長さよりも長く、好ましくは中間シールとピストン 143 が結合した長さよりも短いものである。

【0056】

液体流路 160 は泡のような突出物として示されているが、この液体流路はその他の構成で形成されてもよい。例えば、液体流路は、カートリッジ 150 の内壁に形成された凹部又は軸方向の溝であってもよく、この場合液体流路はカートリッジの外側表面から突出することはない。同様に、液体流路はカートリッジの内壁に形成された環状の凹部であってもよい。

20

【0057】

図 12 を参照すると、装置 110 は「格納」位置で示されている。この位置では、中間シール 170 は 2 種類の薬剤成分が混合されることを防止する。従って、密閉されたカートリッジ 150 は、所望の場合、薬剤成分の有効性を損なうことなく長期間保存することができる。保存位置において、中間シール 170 は液体流路 160 の後方に配置され、中間シールとカートリッジの内壁との間で中間シールの全周にわたり液体密封シールが形成される。

30

【0058】

注入装置 110 の保存中、図 12 ~ 13 に示されるように、薬剤はカートリッジ 150 に格納された 2 種類の別々の成分に分けられる。具体的には、薬剤の第 1 の成分 154 は第 1 のチャンバ 152 に格納され、薬剤の第 2 の成分 158 は第 2 のチャンバ 156 に格納される。更に下記に示されるように、カートリッジが製造中に充填される場合、多少の空気が第 2 のチャンバ 156 内に残ることが好ましい。

【0059】

プランジャ 140 はカートリッジ 150 の後端に摺動可能に配置される。プランジャ 140 は、プラスチック成形されたプランジャロッド 141 とエラストマ - 系ピストン 143 からなる。ピストン 143 は、液体密封シールをカートリッジの内壁と共に形成し、カートリッジ内で摺動させることができる。プランジャロッド 141 は、プランジャシール 143 に様々な方法で結合させることができる。本実施形態において、プランジャロッド 141 は外部ねじスレッド (external screw thread) を有し、プランジャシール 143 内の内側スレッドと係合させるように構成されており、プランジャロッドとシールはねじ締めすることができる。

40

【0060】

図 14 を参照して、第 1 の薬剤要素 154 の第 2 チャンバ 156 への移動について説明する。中間シール 170 は、液体流路 160 に合わさるまで軸方向に前進される。その

50

後、液体流路160はバイパス流路を提供し、これにより後方チャンバの成分を前方チャンバに注入することができる。前方チャンバは、好ましくは多少の空気（又は他の圧縮性の液体）を含んでいるので、前方チャンバの材料は圧縮されて中間シールが液体流路160に合わさるように前進させることができる。或いは、液体が後方チャンバから前方チャンバに移動した場合、前方チャンバは空気を前方チャンバから通風させる通気孔を含むものであってもよい。通気孔が含まれる場合、通気孔は密閉可能であり、混合された成分が注入中に漏れることを防ぐものであるのが好ましい。

【0061】

具体的には、カートリッジ内で2つの成分を混合させるためにプランジャ140はカートリッジ150に向かって軸方向に進められ、第1の成分154は中間シール170の後端に対して第1のチャンバ内152で押される。中間シール170にかけられるバックプレッシャは、中間シールとカートリッジ150の摩擦抵抗を上回るものであり、中間シールはカートリッジ内で前方に移動させられる。一旦中間シール170が移動して液体流路160に係合すると、図14に示されるように、流路が中間シールと液体流路の内壁との間に作られる。

10

【0062】

液体流路160は十分に大きく、第1の物質154は中間シール周辺を流れ、第2の物質158と混合される第2のチャンバ156に流入することができる。一旦第1の成分が第2のチャンバ156に完全に移動すると、図15に示されるように、プランジャシール143は中間シール170に隣接するまで進められる。中間シール170とピストン143が結合した軸方向の長さは、液体流路160の長さよりもわずかに長い。従って、中間シールとピストンは、液体流路を全長にわたり密閉する。これが第2のチャンバ156内の成分が混合中に逆流することを防止する。

20

【0063】

成分の混合が完了した後、係止用クリップ200は取り外されて薬剤が患者に注入できるようにされる。圧力がカートリッジ150に加えられ、薬剤が第2のチャンバ156から放出される。注入工程が完了すると、カートリッジ150は針リテイナ120を動作させる。その後、図16に示されるように、カートリッジ150にかけられる圧力は開放されて針部材を収納することができる。

【0064】

図17~23全体を参照し、具体的には図17を参照すると、希釈剤が予め充填された安全な注入器の別の実施形態が一般に210で示されている。注入装置210は、両頭の針部材212、針部材を収納する略円筒形の外筒230及び略円筒形のカートリッジ250を含む。外筒230は更に、圧縮バネ226及び針部材212をバネの付勢力に抗してリリース可能に保持する針リテイナ220を含む。針部材212は後尖端214及び先尖端216を有する。バネ226は、針部材212を囲み、外筒の前端で外筒230の内面に対して圧縮される。バネ226の後端は、針リテイナ220の内部で支持され、針部材212と針リテイナとを後方に付勢する。

30

【0065】

この実施形態において、薬剤成分の移動及び混合は、カートリッジがニードルハブ221に取り付けられる前、カートリッジ250内で行われる。カートリッジ250は、混合中、針アセンブリに結合されていないため、成分の混合中、針部材が不慮に引き込まれるリスクがない。結果として、外筒は他の実施形態のように係止用クリップを含まない。

40

【0066】

図18~19を参照すると、カートリッジ250と外筒230はパッケージで供給され、2つは分解される。カートリッジ250は略円筒形の容器であり、ホウケイ酸塩などの薬品の品質を有するガラス又はポリオレフィン若しくはポリエステルなどの硬質の不活性プラスチックから成形されてもよい。カートリッジキャップ253はカートリッジ250の先端側に配置される。カートリッジ250は、図12~16で示されたカートリッジ150と同様の構成を有し、カートリッジの側方から外側に突出した泡のような液体流路2

50

60を含む。中間シール270は、カートリッジ250内で摺動可能に配置され、カートリッジを第1のチャンバ252と第2のチャンバ256とに隔てる。カートリッジ250の各チャンバには、装置210の製造中、所定量の薬剤成分が充填される。具体的には、第1のチャンバ252には薬剤の第1の成分254が予め充填され、第2のチャンバ256には第2の成分258が予め充填される。

【0067】

図20を参照すると、プランジャ240は、カートリッジ250の手前側に摺動可能に配置されている。プランジャ240は、プラスチック成形されたプランジャロッド241及びエラストマー系プランジャシール243からなる。プランジャ240がカートリッジ250に向けて軸方向に進められる場合、第1の成分254は第1のチャンバ252で中間シール270の後端に対して押される。中間シール270にかかるバックプレッシャが中間シールとカートリッジ250の摩擦抵抗を上回るに従って、中間シールがカートリッジ内で前方に移動される。一旦中間シール270が液体流路260と直線的に配置されると、流路が中間シールと液体流路内壁との間に形成され、第1の物質254は中間シールの近傍を通り第2の物質と混合される第2のチャンバ256に流れることができる。

10

【0068】

液体流路260は、第1の物質254が中間シールの近傍を通り第2の物質258と混合される第2のチャンバ256に流れるように十分な長さのものである。一旦第1の成分が第2のチャンバ256に完全に移動すると、図21に示されるように、プランジャシール243が中間シール270に近接するまで進められる。中間シール270とプランジャシール243が結合された軸方向の長さは、液体流路260の最長よりもわずかに長いものであり、これにより中間シールとプランジャシールは液体流路を全長にわたり閉鎖させる。これは、薬剤の混合中、第2のチャンバ256の中身が逆流することを防止する。

20

【0069】

再度図18を参照すると、カートリッジ250は、エラストマー系フロントシール280をカートリッジの先端側で含む。フロントシール280は、ポリイソブレンなどのセルフシールの生体適合性エラストマーで成形されてもよい。フロントシール280は略円筒形であり、カートリッジ内に配置された幅広の円筒形後端282と、カートリッジの前端から前方に突出して直径が縮小された前端284とを有する。後端282は、カートリッジ250の内径と同様の外径を有する。加えて、後端282は、複数の軸方向に離間した環状リブ286を有し、摩擦摺動でカートリッジの内部に係合し、液体密封シールを提供してカートリッジから液体が漏れることを防止する。

30

【0070】

フロントシール280の前端284は、外部スレッド288を外周に含む。また、先端側284は、浅い正面キャビティ290を含む。第2のチャンバ256と液連通している狭い穴292は、フロントシール280の手前側から延び、直径が縮小された先端側284内で終端する。正面キャビティ290と穴292の液連通は、突刺部材294で塞がれている。

【0071】

図19を参照すると、外筒230は略円筒形であり、先端側にテーパがかけられたノーズ232を有する。ノーズ232は、針部材212が挿通される開口を有している。加えて、ノーズ232は、針部材212が突出位置にある場合、ノーズにフィットして不慮の針刺しを防止する針カバー211を受け入れるように構成されている。外筒230の手前側は開いており、カートリッジ250を受け入れるようにされた円筒形ソケット234を形成する。カートリッジ250に取り付けられる前、外筒230の開口後端は円筒形の外筒キャップ233によって閉じられる。外筒は更に、針部材をリリース可能に保持するための針リテイナ220と協働する一対の保持開口238と、収納位置で針部材をロックするための係止用タブと協働する一対のロックアウトウインドウとを含む。

40

【0072】

針リテイナ220は、略円筒形の本体221と、本体221から径方向前方に延びる一対

50

の保持アーム 222 とを含む。略円筒形の開口 296 は、針リテナ本体 221 の手前側に配置される。開口 296 の内壁は、内側ねじスレッド 298 を含み、カートリッジ 250 内のフロントシール 280 の外側ねじスレッド 288 を受け入れるようにされている。

【0073】

カートリッジキャップ 253 と外筒キャップ 233 は、カートリッジ 250 と外筒 230 から夫々取り外され、カートリッジと外筒を組み立てる準備が整う。カートリッジ 250 は、フロントシールの前端を外筒 230 の開口端を介して挿入し、カートリッジを時計回りに開口 296 にねじ込むことにより外筒 230 に結合される。図 17 に示されるように、カートリッジ 250 が外筒 230 に取り付けられることで針部材の手前側の先端 214 はキャビティ 290 を通って部材 294 を突刺し、これによりカートリッジの第 2 のチャンバが針部材 212 と液連通されるように、フロントシール 280 の正面キャビティ 290 は針部材 212 と同軸上にあることが好ましい。

【0074】

図 17 を参照すると、カートリッジ 250 は外筒 230 に結合され、カートリッジが外筒に向かって前方に進められることにより薬剤が患者に注入される。フロントシール 280 の手前側は、カートリッジ 250 の内側と滑りばめを形成するように構成されており、カートリッジが進む間、カートリッジはフロントシールを覆って摺動する。カートリッジ 250 が進められると、フロントシール 280 の後端は針リテナ 220 を支持し、これによりカートリッジが進められる間、フロントシールの固定状態が維持される。同時に、第 2 のチャンバ 256 の後方で中間シール 270 はフロントシール 280 の方向に配置される。これが第 2 のチャンバ 256 内の薬剤量を減少させ、薬剤は針部材に移動し注入が容易にされる。注入の完了すると、図 22 に示されるように、中間シール 270 はフロントシール 280 の後端で支持される。

【0075】

上記実施形態のように、針部材 212 は、針リテナ 220 を作動させることにより収納される。具体的には、針部材 212 は、保持アーム 222 が外筒壁の保持開口 238 との係合から外され、バネ 226 が針部材 212 を後方に押すことにより引き込まれる。針リテナ 220 を作動させるために、圧力がカートリッジ 250 に向けられ、図 22 に示されるように、カートリッジは針リテナ本体 221 に進められる。進められている間、カートリッジ 250 の先端側は、針リテナ本体 221 の先端側近傍に配置された円筒形のスリーブ 300 に係合する。リリーススリーブ 300 の内径及び外径は、好ましくはカートリッジ 250 の内径及び外径と等しいものであり、これによりカートリッジの先端側はスリーブの手前側と合わさる。カートリッジ 250 に係合する前、針リテナに沿うリリーススリーブ 300 の軸方向への移動は、針リテナ本体 221 上の環状液体流路 223 内でスライドする内側フランジ 302 により制限される。カートリッジ 250 がスリーブ 300 に係合した後、カートリッジの継続的な前進は、スリーブを軸方向前方に駆動させ保持アーム 222 に係合させる。図 23 に示されるように、リリーススリーブ 300 は、保持アームを径方向内側に曲げて保持開口 238 との係合を外させ、バネ 226 が針部材 212 を後方に押させることを可能にする。

【0076】

上記のように、第 3 の実施形態は、最初の 2 つの実施形態で示されたような引っかかりによる結合ではなく、フロントシール 280 と針リテナ 220 のスレッド結合を含むものである。スレッド結合の使用は針リテナ 220 の全長を増大させることができる。すなわち、カートリッジ 250 の先端側と保持アーム 222 との距離を増大させることができるものである。この増大した長さを調節する 1 つの方法は、外筒 230 の長さを増大することである。しかし、リリーススリーブ 300 と協働させて外筒 230 の長さを実質的に増大させる必要はない。リリーススリーブ 300 がカートリッジ 250 の延長として作用することにより、増大した距離を補填する。これは、装置 210 の全長を増大させる必要性を取り除く。リリーススリーブ 300 の長さは、フロントシール 280 と針リテナ 220 のスレッド係合の長さよりもわずかに長いものであるのが好ましい。

【0077】

図24～29全体を参照し、具体的には図24～25を参照すると、希釈剤が予め充填された安全な注入器の第4の実施形態が示されている。注入装置310は、両頭の針部材312、針部材を収納する略円筒形の外筒330及び外筒の手前側内に取り付けられた略円筒形のカートリッジアセンブリ350を含むものである。上記実施形態のように、外筒は更に、圧縮パネ326と、パネの付勢に抗して針部材312をリリース可能に保持する針リテイナ320とを含むものである。装置310はまた、U形状の係止用クリップ400を外筒壁に含み、薬剤が装置310から不慮に放出されることを防止する。

【0078】

カートリッジアセンブリ350は、費用効率の良いプラスチックをアセンブリに使用する利点を提供する2つの設計を有するものである。カートリッジアセンブリ350は、開口手前側を有するフロントシリンダ351と、フロントシリンダの手前側に伸縮自在に取り付けられた先端側開口を有する後方シリンダ353とを含むものである。フロントシリンダ351は、カートリッジアセンブリ350を第1のチャンバ352と第2のチャンバ356に隔てる内壁360を含む。第1のチャンバ352は薬剤の第1の成分354を所定量保持するものであり、第2のチャンバ356は薬剤の第2の成分358を所定量保持するものである。フロントシリンダ351の手前側は、突刺可能なエラストマー系フロントシール380により閉じられている。

10

【0079】

多くの用途において、第2の成分358は、乾燥パウダー状の成分である。乾燥成分はガラス製の容器を必要とせず、成分の長期安定性を悪化させることなくプラスチック製の容器に格納することができる。ガラスよりもプラスチックから複雑な部分を成形した方がより費用効率が良いため、カートリッジアセンブリ350の複雑なガラス部分を最小限にすることが好ましい。この目的を達成するため、フロント及び後方シリンダ351、353を構成し、第1の成分354は後方シリンダ内に完全に格納され、第2の成分356はフロントシリンダ内に完全に格納される。この割り当てにより、フロントシリンダ351はより複雑な構造を含み、後方シリンダを単純なカップ形状の容器にすることが可能になる。従って、より複雑な前方シリンダは、乾燥した第2の成分358を第2のチャンバ356に格納するこれらの装置用に、費用効率の良いプラスチックから成形することができる。ガラスは、例え使用されるとしても、後方シリンダ353を成形するためにのみ使用されるのが好ましい。

20

30

【0080】

上記のように、後方シリンダ353はフロントシリンダ351の手前側に伸縮自在に取り付けられる。後方シールの後方部分の外径は後方シリンダ353の内径と略等しく、後方シリンダの内側に摩擦係合して液体密封シールを提供するものである。後方シリンダ353は、後方シリンダの手前側にかかる圧力に応じて後方シール340を覆って軸方向に摺動するようにされている。

【0081】

外筒330は後方シリンダ353の外径を調節するために十分な大きさの内径を有する。結果として、図25に示されるように、フロントシリンダ351の外壁は空隙によって外筒330の内壁から隔てられている。フロントシリンダ351は、フロントシリンダの外壁にある一对の対向する長手軸リブ355によって、より大きい外筒330と同心関係で維持されている。長手軸リブは図24に示されている。

40

【0082】

エラストマー系の後方シール340はフロントシリンダ351と後方シリンダ353の間に配置されている。後方シール340はフロントシリンダ351の開口手前側に一部に配置された小径端部342を含む。また、後方シール340は後方シリンダ353内に配置されたフランジ形344を含む。小径端部342とフランジ形344は、それぞれフロントシリンダ352及び後方シリンダ354の内側と摩擦摺動して係合する。この係合は液体密封シールを両シリンダの内側で提供する一方、後方シール340をどちらかのシリン

50

ダに対して移動させるものである。フロントシリンダ351に対する後方シール340の前進は、フロントシリンダの手前側で制限され、後方シールのフランジ部分に合わさって係合するように構成される。

【0083】

上記のように、フロントシリンダ351は内壁360を含む。内壁360は、カートリッジの後方開口端に近接し、後方シール340を受け入れるソケットを形成する。内壁360は壁360の中央に設けられたオリフィス362を含む。中空の突刺部材364はオリフィスに取り付けられ、後方シール340に向けて後方に延びる。加えて、通気口(vent opening)が内壁360に提供され、後方シリンダが進み後方シールが突刺される際、後方シール340と内壁の間で空気が通風されることが望ましい。

10

【0084】

後方シール340の先端側は、突刺部材364により突刺されるように構成された膜348で密閉されている。後方シール340は、後方シールの手前側を介して第1のチャンバ352と液連通で結合された中空の中間部分346を含む。一旦膜348が突刺されると、第1及び第2のチャンバ352、356が液連通で結合されるように、液体流路が突刺部材364と後方シール340を介して形成される。後方シール340は、ポリイソブレンなどの高伸長のセルフシール式生体適合性エラストマーで成形されてもよい。

【0085】

次に装置310の動作を説明する。わずかな絞り圧力が後方シリンダ353の手前側にかけられ、後方シリンダはフロントシリンダ351に向かって軸方向に進められる。これにより第1の成分354は、後方シール340と後方シリンダ353の密閉された手前側との間で押される。後方シリンダ353への継続的な圧力は、後方シール340にバックプレッシャをかけ、後方シールを突刺部材364に向けて前方に軸方向移動させる。このとき、膜348は突刺され、液体流路が第1及び第2のチャンバ352、356の間に形成される。

20

【0086】

後方シリンダ353はフロントシリンダ351に対して前方に進められ、第1の成分354を第1のチャンバ352から第2のチャンバ356に放出させる。図26に示されるように、一旦第1の成分354が完全に第1のチャンバ352から放出されると、後方シリンダの密閉された手前側が後方シールの手前側340に近接するまで、後方シリンダへの更なる圧力はフロントシリンダ350に対して後方シリンダを前方に進める。このとき、装置310を振ると、成分は第2のチャンバ356内で混合される。混合処理の間、カートリッジアセンブリ350の移動は係止用クリップ400により防止され、薬剤が不慮に放出される恐れは最小限にされる。

30

【0087】

要素が混合された後、係止用クリップ400は取り外される。その後、カートリッジアセンブリは前方に移動させられ、針部材312の後端が前方シール380を突刺する。そして、空気が前方チャンバから通風される。更なる圧力がカートリッジアセンブリにかけられ、薬剤が第2のチャンバ356から針部材312を介して放出される。図27に示されるように、注入工程の完了時、カートリッジアセンブリ350の手前側が針リテイナ320を作動させる。図28及び29に示されるように、その後、カートリッジアセンブリ350への圧力が開放されることにより、針部材312を収納することができる。

40

【0088】

ある場合には、カートリッジは成分単位で格納されることが望ましい。すなわち、後方シリンダ353は前方シリンダ351から取り外されるものであってもよい。使用前、後方シリンダ353は前方シリンダ351に取り付けられ、一体化したアセンブリは上記のように利用される。この場合、個々の後方コンテナ353は、前端を覆う個々のキャップを含むものであってもよい。同様に、前方シリンダ351は、後端を覆うキャップを含むものであってもよい。取り外し可能な後方シリンダ353は、予め処理された様々な薬剤成分を格納し、使用前、様々なコンビネーションで容易に組み合わせられるものであっても

50

よい。

【0089】

本明細書で使用する用語および表現は、記述目的のものであり、制限目的のものではない。ここに示し説明している機能と同等のいかなる機能を排他する用語および表現も、使用する意図はない。ただし、本発明の要旨を変更しない範囲で種々の変形が可能であることが当業者により認識される。例えば、上記の実施形態は、使用後、針部材を収納するために自動的にリリースさせる一対の径方向に移動可能なアームを有する針リテナを含むものである。しかし、この装置は、使用後、針部材を自動的に収納しても、しなくてもよい異なる針リテナを利用するものに変形されてもよい。従って、本発明は本明細書に記載した特定の実施態様に制限されるものではないが、本発明の要旨を変更しない範囲での変形や修正を含むものである。

10

【図面の簡単な説明】

【0090】

発明の解決しようとする課題及び発明を実施するための最良の形態は、図面との関連で最もよく理解されるものである。

【図1】図1は、薬剤成分部分を格納する2個のチャンバ容器を有する予充填式のカートリッジ型注入器の斜視図である。

【図2】図2は、図1に示されたカートリッジ型注入器の分解斜視図である。

【図3】図3は、図2に示されたカートリッジ型注入器の係止用クリップの拡大図である。

20

【図4】図4は、図1に示されたカートリッジ型注入器であり線4-4に沿う断面図である。

【図5】図5は、図4に示されたカートリッジ型注入器であり線5-5に沿う断面図である。

【図6】図6は、図1に示されたカートリッジ型注入器の断面図であり、薬剤成分部分を混合する前の装置である。

【図7】図7は、図1に示されたカートリッジ型注入器の断面図であり、混合後に注入を防止するためにロックされたカートリッジを有する装置である。

【図8】図8は、図1に示されたカートリッジ型注入器の断面図であり、混合後に注入するためロックが解かれたカートリッジを有する装置である。

30

【図9】図9は、図1に示されたカートリッジ型注入器の断面図であり、注入後であり、針部材が引き込む直前の装置である。

【図10】図10は、図1に示されたカートリッジ型注入器の断面図であり、針部材引き込み後の装置である。

【図11】図11は、図1に示されたカートリッジ型注入器の拡大断片の断面図であり、針部材が引き込まれた後、カートリッジと外筒の開封防止の結合である。

【図12】図12は、引込可能な針部材を有し、2個のチャンバを有する予充填式のカートリッジ型注入器の第2の実施形態の断面図である。

【図13】図13は、図12に示された装置であり線13-13に沿う断面図である。

【図14】図14は、図12に示された装置の断面図であり、カートリッジ内で薬剤成分を混合し、チャンバ間で薬剤成分を移動させている最中の装置である。

40

【図15】図15は、図12に示された装置の断面図であり、薬剤成分が混合された後の装置を示す。

【図16】図16は、図12に示された装置の断面図であり、針部材収納後の装置を示す。

【図17】図17は、収納可能な針部材を有し、2個のチャンバを有する予充填式のカートリッジ型注入器の第3の実施形態の断面図である。

【図18】図18は、図17に示された装置のカートリッジ部分の断面図である。

【図19】図19は、図17に示された装置の断面図であり、カートリッジなしで使用前である。

50

【図20】図20は、図18に示されたカートリッジの断面図であり、薬剤成分を混合している最中の装置である。

【図21】図21は、図18に示された装置の断面図であり、薬剤成分を混合した後の装置である。

【図22】図22は、図17に示された装置の断面図であり、注入完了時の装置である。

【図23】図23は、図17に示された装置の断面図であり、針部材収納後の装置である。

【図24】図24は、収納可能な針部材を有し、2個のチャンバを有する予充填式のカートリッジ型注入器の第4の実施形態の拡大斜視図である。

【図25】図25は、図24に示された装置の断面図である。

【図26】図26は、図24に示された装置の断面図であり、薬剤成分を混合した後の装置である。

【図27】図27は、図24に示された装置の断面図であり、注入完了時の装置である。

【図28】図28は、図24に示された装置の断面図であり、針部材収納後の装置である。

【図29】図29は、図24に示された装置の断面図であり、針部材収納後の装置である。

【図1】




Figure 1

【図2】






Figure 2


【 図 3 】




【 図 4 】



【 図 5 】



【 図 6 】



【 図 7 】




Figure 7

【 図 8 】




Figure 8

【 図 9 】




Figure 9

【 図 10 】





Figure 10


【 図 1 1 】

Figure 11




【 図 1 2 】

Figure 12




【 図 1 3 】

Figure 13



【 図 1 4 】

Figure 14



【 図 1 5 】




Figure 15

【 図 1 6 】




Figure 16

【 図 1 7 】




Figure 17

【 図 1 8 】




Figure 18

【 図 19 】




Figure 19

【 図 20 】




Figure 20

【 図 21 】




Figure 21

【 図 22 】




Figure 22

【 図 2 3 】




Figure 23

【 図 2 4 】




Figure 24

【 図 2 5 】




Figure 25

【 図 2 6 】




Figure 26

【 図 2 7 】




Figure 27

【 図 2 8 】




Figure 28

【 図 2 9 】




Figure 29

【国際公開パンフレット】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)


PCT

(10) International Publication Number
WO 02/072171 A2

- (51) International Patent Classification: **A61M**
- (21) International Application Number: PCT/US02/07712
- (22) International Filing Date: 13 March 2002 (13.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/275,568 13 March 2001 (13.03.2001) US
- (71) Applicant (for all designated States except US): **MDC INVESTMENT HOLDINGS INC.**, [US/US]; Suite 200, 900 Market Street, Wilmington, DE 19801 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BARKER, John** [US/US]; 155 Sunset View Court, Ventura, CA 93003 (US); **HALSETH, Thor** [US/US]; 159 Stonebrook Street, Simi Valley, CA 93065 (US); **CHALLIOL, Bernardo** [US/US]; 3031 Luna Drive, Ventura, CA 93003 (US).
- (74) Agent: **ELAND, Stephen**; Dann, Dorfman, Herrell & Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KI, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI, CG, CL, CM, GA, GN, GQ, GW, ML, MR, NI, SN, TD, TG).

[Continued on next page]

(54) Title: PRE-FILLED SAFETY DILUENT INJECTOR



(57) Abstract: A safety needle-bearing device (10, 110, 210, 310) for mixing and injecting medication from a two-chambered cartridge (50, 150, 250, 350) is provided. The device includes a needle (12, 112, 212, 312) that extends through the forward end of a barrel (30, 130, 230, 330). The two-chambered cartridge (50, 150, 250, 350) is attached to the barrel (30, 130, 230, 330) and contains components of a medication stored separately in the chambers. A plunger (40, 140, 240) in the rearward end of the cartridge can be advanced into the cartridge to combine the separate components and prepare the medication. As the cartridge (50, 150, 250, 350) is advanced forwardly into the barrel (30, 130, 230, 330), the medication is injected through the needle (12, 112, 212, 312) and into a patient. At the completion of the injection stroke, the cartridge (50, 150, 250, 350) engages a needle retainer to actuate needle retraction. The needle is subsequently retracted to shield the contaminated needle.

WO 02/072171 A2

WO 02/072171 A2 

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PRE-FILLED SAFETY DILUENT INJECTOR**PRIORITY CLAIM**

This application claims priority to U.S. Provisional Application No. 60/275,568, filed March 13, 2001, which is hereby incorporated herein by reference.

5

FIELD OF THE INVENTION

The present invention relates to medical devices and more particularly to medical devices having a cartridge with two chambers that store separate components of a medication and allow the components to be mixed and subsequently injected into a patient.

10

BACKGROUND

15

Pre-filled syringes store and allow for mixing of separate medicinal components. Many of these syringes, sometimes called "mixing syringes," store a first component in one compartment and a diluent or a second component in a second compartment. These syringes allow the two components to be stored separately until just before the syringe is used, at which time the components can be mixed within the syringe and immediately injected into a patient.

20

Pre-filled mixing syringes are advantageous for many types of pharmaceuticals. Some medications, like antibiotics, vitamins and hormones, must be packaged and stored in component parts to enhance shelf life. These medications may need to be stored as a powdered component and a diluent, or as a separate pair of solutions. Pre-filled mixing syringes allow medications to be stored in component parts right up until the medication is

25

injected. In addition, pre-filled mixing syringes eliminate the burden of measuring medicinal components and mixing diluents from separate containers.

5 Despite these advantages, prior mixing syringes have not offered reliable safety features to protect the syringe user from accidental needle sticks following injection. In particular, prior syringe assemblies have not provided a mixing syringe that operates integrally with an injection needle that can be automatically shielded upon completion of the injection.

10 **SUMMARY OF THE INVENTION**

With the foregoing in mind, the present invention provides a pre-filled medical device for mixing separate components of a medication and injecting the medication into a patient. The device includes a two-chambered
15 container, such as a cartridge, connected to a needle that retracts automatically after use. After retraction, the contaminated needle tip is enclosed within the device to prevent inadvertent needle sticks.

The device includes a hollow barrel surrounding the needle and
20 having a generally open rearward end that forms a socket. A two-chambered cartridge containing component parts of a medication is adapted to engage the socket. Prior to use, the components are stored separately in the two cartridge chambers. During use, a plunger disposed in the rearward end of the cartridge is advanced into the cartridge to combine the two components in
25 one chamber for mixing. Subsequent pressure on the plunger advances the medicinal mixture through the needle into a patient.

The injection needle is operable between an extended position and a retracted position. In the extended position, the forward tip of the
30 needle projects forwardly from the barrel. In the retracted position, the forward tip is enclosed within the barrel. When the needle is in the extended

position, a biasing element biases the needle toward the retracted position. A
needle retainer releasably retains the needle in the extended position against
the force of the biasing element. During the injection stroke, the cartridge
disengages the needle retainer to allow the biasing element to propel the
5 needle rearwardly into the barrel.

DESCRIPTION OF THE DRAWINGS

The foregoing summary as well as the following detailed
10 description of the preferred embodiments will be best understood when read
in conjunction with the following drawings, in which:

Fig. 1 is perspective view of a pre-filled cartridge injector having a two-
15 chambered container that stores component parts of a medication;

Fig. 2 is an exploded perspective view of the cartridge injector shown in
Fig. 1;

Fig. 3 is an enlarged view of a locking clip of the cartridge injector shown in
20 Fig. 2;

Fig. 4 is a sectional view of the cartridge injector shown in Fig. 1 taken along
the line 4-4;

25 Fig. 5 is a sectional view of the cartridge injector shown in Fig. 4 taken along
the line 5-5;

Fig. 6 is a sectional view of the cartridge injector shown in Fig. 1, illustrating
30 the device prior to mixing the component parts of the medication;

Fig. 7 is a sectional view of the cartridge injector shown in Fig. 1, illustrating

WO 02/072171

PCT/US02/07712

4

the device after mixing with the cartridge locked to impede injection;

Fig. 8 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device after mixing the cartridge unlocked to allow injection;

5

Fig. 9 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device, after injection, just prior to needle retraction;

Fig. 10 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device after needle retraction.

10

Fig. 11 is an enlarged fragmentary sectional view of the cartridge injector shown in Fig. 1, illustrating the tamper resistant connection between the cartridge and barrel after the needle is retracted.

15

Fig. 12 is a sectional view of a second embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

Fig. 13 is a sectional view of the device shown in Fig. 12 taken along the line 13-13.

20

Fig. 14 is a sectional view of the device shown in Fig. 12 illustrating the device during mixture of the medicinal components in the cartridge transfer of one component of medicine between chambers.

25

Fig. 15 is a sectional view of the device shown in Fig. 12 illustrating the device after mixture of the medicinal components.

Fig. 16 is a sectional view of the device shown in Fig. 12 illustrating the device after needle retraction.

30

WO 02/072171

5

PCT/US02/07712

Fig. 17 is a sectional view of a third embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

5 Fig. 18 is a sectional view of the cartridge portion of the device illustrated in Fig. 17.

Fig. 19 is a sectional view of the device shown in Fig. 17 illustrated without the cartridge, illustrated prior to use.

10 Fig. 20 is a sectional view of the cartridge in Fig. 18 illustrating the device during mixture of the medical components.

Fig. 21 is a sectional view of the device shown in Fig. 18 illustrating the device after mixture of the medical components.

15 Fig. 22 is a sectional view of the device shown in Fig. 17 illustrating the device at the completion of an injection.

20 Fig. 23 is a sectional view of the device shown in Fig. 17 illustrating the device after needle retraction.

Fig. 24 is an exploded perspective view of a fourth embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

25 Fig. 25 is a sectional view of the device illustrated in Fig. 24.

Fig. 26 is a sectional view of the device in Fig. 24 illustrating the device after mixture of the medical components.

30 Fig. 27 is a sectional view of the device shown in Fig. 24 illustrating the device at the completion of an injection.

WO 02/072171

6

PCT/US02/07712

Fig. 28 is a sectional view of the device shown in Fig. 24 illustrating the device after needle retraction.

5 Fig. 29 is a sectional view of the device shown in Fig. 24 illustrating the device after needle retraction.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring now to the figures in general, and to Figs. 1-11 specifically, an injector device **10** is shown with a needle **12** having a sharpened distal tip **16** for insertion into a patient. As shown in Fig. 4, the injector device **10** has an attached cartridge **50** having a first chamber **52** and a second chamber **56**. The two chambers **52**, **56** are pre-filled with component parts of a medication that are to be mixed prior to injection. The cartridge **50** also includes a plunger **40** that is slidable within the cartridge. Initially, advancing the plunger **40** in the cartridge **50** expels the medicinal component from the first chamber **52** into the second chamber **56** to mix the two medicinal components. After mixing the components, advancing the plunger drives the cartridge forwardly to inject the medicine into a patient. Upon completion of the injection stroke, the medical professional releases pressure from the plunger to allow automatic retraction of the needle **12** into the device **10** to protect the contaminated needle **12** from inadvertent contact.

The injector device **10** includes a double-ended needle **12**, a generally cylindrical barrel **30**, a compression spring **26** and a needle retainer **20** releasably retaining the needle against the bias of the spring. As shown in Figs. 4 and 5, the needle **12** has a sharpened proximal tip **14** and a sharpened distal tip **16**. The spring **26** circumscribes the needle **12** and is compressed against the interior of the barrel **30** at the barrel's distal end. The rearward end of the spring **26** bears against the interior of the needle retainer **20** to bias the needle **12** and needle retainer in the rearward direction.

The needle 12 is operable between two positions, an extended position and a retracted position. In the extended position, the needle 12 projects forwardly from the forward end of the barrel 30. In the retracted position, the needle 12 is retracted into the barrel 30 so that the sharpened tip 16 of needle 12 is enclosed within the barrel to prevent inadvertent contact with the sharpened tip. When the needle is in the extended position, the spring 26 biases the needle 12 rearwardly toward the retracted position. The needle retainer 20 releasably retains the needle 12 in the extended position, against the bias of the spring 26. During the injection stroke, the cartridge 50 cooperates with the needle retainer 20 to allow the needle to retract into the barrel 30, as shown in Fig. 10.

Referring now to Figs. 5-7, the cartridge 50 includes a first chamber 52 containing a first medicinal component 54 and a second chamber 56 containing a second medicinal component 58. The chambers 52, 56 are separated by a mid wall 60 containing an orifice 62. A rear seal 70 seals the first chamber 52 to prevent the components from being mixed prior to use. When the rear seal 70 is pierced and the plunger 40 is advanced into the cartridge 50, the first component 54 flows into the second chamber 56 through the orifice 62, where it combines with the second component 58 to form the medication 59, as shown in Figs. 6-7. Subsequent pressure on the plunger 40 and cartridge 50 forces the medication 59 through the needle 12 and into the patient.

Referring now to Figs. 4-6, the elements of the injector device 10 will be described in greater detail. The barrel 30 is generally cylindrical and the distal end of the barrel has a tapered nose 32. The nose 32 has an opening through which the needle 12 extends so that the sharpened tip 16 of the needle can be inserted into a patient. The rearward end of the barrel 30 is open, forming a cylindrical socket 34 adapted to receive the cartridge 50. Two laterally extending flanges 36 project outwardly from the barrel 30,

transverse the longitudinal axis of the barrel, forming a pair of finger grips for operating the device 10. The barrel 30 further includes a pair of retaining apertures 38 and a pair of lockout windows 39 that cooperate with the needle retainer 20 as described further below.

5

As shown in Fig. 5, a hub 21 projects from the rearward end of the needle retainer 20. The hub 21 is a generally cylindrical element having a central bore 23. The needle 12 is disposed within the central bore 23 of the hub 21 so that the rearward end 14 of the needle 12 projects rearwardly from the hub and the forward end 16 of the needle projects forwardly from the hub. The needle 12 can be attached to the hub 21 in one of several ways. For example, the needle 12 can be attached to the hub 21 by an adhesive such as a UV curable adhesive. Alternatively, the needle 12 can be molded into the hub 21, which is formed of plastic. The rearward end of the hub 21 includes a circumferentially barbed connector 25 configured to cooperate with the cartridge 50 to connect the cartridge to the needle hub 21 as discussed further below.

10

15

The needle retainer 20 is axially displaceable within barrel 30 to facilitate needle retraction. The needle retainer 20 can be molded out of a rigid, high strength resin, such as polycarbonate. Prior to retraction, the needle retainer 20 is maintained in a fixed axial position while the medication 59 is expelled from the cartridge 50. After the injection, the needle retainer 20 and the attached needle 12 are displaced rearwardly by the compression spring 26.

20

25

The spring 26 is a compression spring and may be formed of stainless steel, treated carbon steel wire or other suitable non-corrosive spring metal. The residual compression of the spring prior to disengagement of the needle retainer is of sufficient magnitude to facilitate complete needle retraction and overcome the frictional resistance between sliding components within the device 10.

30

Referring now to Fig. 6, the needle retainer **20** includes a pair of retaining arms **22** that extend radially outwardly and forwardly from the distal end of the needle retainer **20**. During operation, the needle retainer **20** is operable between a locked position and an unlocked position. In the locked position, the retaining arms **22** engage the retaining apertures **38** in the barrel wall to maintain the needle in a fixed axial position with the forward tip **16** of needle **12** projecting forwardly from the barrel **30**. More specifically, in the locked position, the retaining arms **22** engage the barrel **30** to hold the needle hub **21** and needle **12** against the rearward bias of the spring **26**. In the unlocked position, the retaining arms **22** are positioned so as to allow the needle hub **21** and needle **12** to be retracted rearwardly. More specifically, in the unlocked position, the retaining arms **22** are disengaged from the retaining apertures **38**, allowing the spring **26** to propel the needle hub **21** and needle **12** rearwardly.

As discussed above, the retaining arms **22** on the needle retainer **20** project forwardly and outwardly into engagement with the retaining apertures **38** in the wall of the barrel **30**. The terminal end of each arm forms a retaining tab **24** that is configured to project into a retaining aperture **38**. More specifically, the retaining tabs **24** engage the lip formed by each retaining aperture **38** in the wall of the barrel **30**. In this way, the retaining tabs **24** operate as a pair of latches to retain the needle hub **21** and needle **12** against the rearward bias of the spring.

Referring again to Figs. 4 and 5, the cartridge **50** is a generally cylindrical vessel that may be molded out of pharmaceutical quality glass such as borosilicate, or a rigid inert plastic such as polyolefin or polyester. The midwall **60** that separates the first and second chambers may be formed of a rigid inert plastic such as polyolefin or polyester. The barrier or midwall **60** can be molded as part of the cartridge **50** or bonded to the inside wall of the cartridge. Each chamber is filled with a predetermined amount of a

medication during manufacturing of the device 10.

The front end of the forward chamber 56 is sealed by an elastomeric front seal 80, which may be molded in a self-sealing
5 biocompatible elastomer such as polyisoprene. The front seal 80 is generally cylindrical, having a plurality of axially-spaced circumferential ribs 81. The ribs 81, which are more clearly shown in Fig. 2, frictionally and sealingly engage the interior of the container to provide a fluid tight seal, thereby preventing fluid from leaking from the cartridge 50. The front seal 80 also has
10 a front end that is pierceable by the rearward sharpened tip 14 of needle 12. After being pierced, the front end of the front seal 80 reseals around the needle 12 to prevent fluid from leaking from the cartridge 50.

Referring now to Figs. 5 and 6, the front seal 80 has a socket 82
15 configured to cooperate with the barbed connector 25 on the needle hub 21. The socket 82 includes two radially relieved recesses, 82a and 82b, that mate with the barbed connector 25. Specifically, the barbed connector 25 matingly engages the front seal 80 in a first position and a second position.

In the first position, the barbed connector 25 engages the first
20 recess 82a, as shown in Fig. 5. In this position, the cartridge is attached to the hub, but the rearward end of the needle does not pierce the front seal 80. Applying pressure to the plunger 40 displaces the cartridge forwardly relative to the hub, thereby displacing the barb into to the second position. In the
25 second position, the barbed connector 25 engages the second recess 82b, as shown in Fig. 6. In this position, the rearward end of the needle 12 pierces the front seal 80.

The front seal 80 includes a hollowed cavity 84 at its rearward
30 end. In this way, a pierceable wall 86 is formed in the front seal 80 between the cavity 84 and the second recess 82b. As shown in Fig. 5 prior to use, the

cartridge 50 is mounted in the first position so that the barbed connector 25 engages the first recess 82a. In this position, the needle 12 does not penetrate the pierceable wall 86. As the hub 21 is displaced from the first position to the second position, the rearward end 14 of the needle 12 pierces the wall 86 and extends into the cavity 84 as shown in Fig. 6. The cavity 84 opens into the interior of the second chamber 56 of cartridge 50 so that when the needle 12 projects into the hollowed section 84, the needle is in fluid communication with the interior of the cartridge. After the needle 12 penetrates the pierceable wall 86, the wall reseals around the needle to form a fluid-tight seal and prevent medication in the cartridge 50 from leaking around the needle.

To prepare the injection device 10 for use, the medical professional displaces the cartridge 50 forwardly relative to the needle retainer 20, so that the forward seal 80 is driven over the barbed connector 25, such that the barbed connector engages the second recess 82b. At the same time, the proximal tip 14 of needle 12 pierces the pierceable wall 86, so that the needle is in fluid communication with the second chamber, as shown in Fig. 6.

The connection between the front seal 80 and the needle hub 21 is preferably a one-way engagement. In other words, when the front seal 80 is mounted on the barbed connector 25, the cartridge 50 can be displaced forwardly relative to the barbed connector, but the cartridge cannot be displaced rearwardly relative to the barbed connector. In this way, the cartridge 50 cannot be readily removed from the needle hub 21 in barrel 30, such that the cartridge is substantially permanently attached to the needle hub and barrel.

The one-way connection is facilitated by the rearward-facing tapered shoulder of the barbed connector 25 and the square shaped forward-

WO 02/072171

12

PCT/US02/07712

facing shoulder of the barbed connector. In particular, the rearward-facing shoulder of the barbed connector **25** cooperates with tapered sides in the first and second radial recesses **82a** and **82b** to permit relative displacement of the plug from the first recess to the second recess. Reverse displacement from the second recess **82b** back to the first recess **82a** is resisted by the square shaped forward-facing shoulders on barbed connector **25**, which act to impede reverse displacement.

Referring now to Fig. 4, the front seal **80** is configured to prevent ejection of fluid when the barbed connector **25** is displaced from the first position, in which the barbed connector **25** engages the first radial recess **82a**, to the second position, in which the barbed connector engages the second radial recess **82b**. Specifically, the front seal **80** includes a flared head **88** or circumferential flange at the forward end of the front seal. The open distal end of the cartridge **50** terminates with a beaded rim **51** that seats against the rearward edge of the flared head **88**. The outside diameter of the flared head **88** is greater than the inside diameter of the open distal end of the cartridge **50**, thereby impeding rearward displacement of the front seal **80** into the cartridge when force is initially applied to the plunger **40**. In addition, the force required to overcome the frictional engagement between the outer circumference of the front seal **80** and the inner wall of the cartridge **50** is greater than the force required to displace the plug **25** from the first recess **82a** to the second recess **82b**. Accordingly, when force is initially applied to the plunger **40**, the front seal **80** remains in a fixed position relative to the cartridge **50**, while the barbed connector **25** is displaced into the second position. This restriction on the front seal **80** limits the release of fluid from the cartridge **50** when the needle **12** pierces the wall **86**.

During storage of the injection device **10**, the medication is divided into two separate components stored in the cartridge **50**, as shown in Fig. 5. Specifically, a first component **54** of the medicine is stored in the rear

chamber 52 and a second component 58 of the medicine is stored in the forward chamber 56. The two chambers are separated by the mid-wall 60 containing an orifice 62 and a hollow piercing member 64 mounted in the orifice. The orifice 62 is located axially at the center of the midwall 60. In addition, a small vent hole 63 is located just off center in the midwall 60 to vent the air from the dead space area between the mid wall and the mid seal 70. Preferably, the piercing member 64 is fabricated out of suitable non-corrosive material such as stainless steel or treated carbon steel wire. When the plunger 40 is axially advanced in the cartridge 50, the first component 54 in the rear chamber 52 advances through the piercing member 64 and into the forward chamber 56 to combine with the second component 58.

Prior to use of the injection device 10, fluid communication between the first and second chambers is prevented by an elastomeric mid seal 70, which may be molded in a self-sealing biocompatible elastomer such as polyisoprene. The mid seal 70 is initially slidably disposed in the first chamber 52 between the piercing member 64 and the first component 54, as shown in Figs. 4-5. The mid seal 70 is generally cylindrical, having a plurality of axially-spaced circumferential ribs 71, as shown more clearly in Fig. 2. The ribs 71 frictionally and sealingly engage the inner wall of the cartridge 50 to provide a fluid-tight seal. This fluid-tight seal prevents fluid in the first chamber from entering the piercing member 64. The mid seal 70 also includes a hollowed section 72 formed in the forward end of the mid seal that opens to the first chamber 52 at the rearward end of the mid seal. The forward end of the mid seal 70 is closed by a membrane 78 that is pierceable by the piercing member 64. Upon piercing the membrane 78, fluid communication is established between the first and second chambers to allow the first and second components of the medication to be mixed.

Like the front seal 80 and mid seal 70, the plunger 40 is generally cylindrical, preferably having a plurality of axially-spaced

circumferential ribs 41. The plunger 40 may be molded in a self-sealing biocompatible elastomer such as polyisoprene. Alternatively, the plunger 40 could be a two-part assembly in which a cylindrical elastomeric seal is mounted to a rigid plastic plunger rod. The ribs 41, which are more clearly shown in Fig. 2, frictionally and sealingly engage the interior of the cartridge 50 to provide a fluid tight seal, thereby preventing fluid from leaking from the proximal end of the cartridge.

The plunger 40 is slidable within the first chamber 52 in response to pressure applied to the thumb pad 42. When the plunger 40 is axially advanced into the cartridge 50, the first component 54 is compressed against the rearward end of the mid seal 70 in the first chamber 52. As back pressure on the mid seal 70 overcomes the frictional resistance between the mid seal and the cartridge 50, the mid seal is displaced into the piercing member 64 until the membrane 78 is pierced, as shown in Fig. 6. As the mid seal advances, air from the space between the mid seal and mid wall vents through the vent hole 63 in the mid wall. At such time, the piercing member 64 penetrates through the hollowed section 72 to connect the first chamber 52 and second chamber 56 in fluid communication.

After the mid seal 70 is pierced, pressure applied to the plunger 40 advances the first component 54 through the piercing member 64 and into the second chamber 56 where the first and second components are subsequently mixed to form the medication 59. The plunger 40 is displaced forwardly relative to the first chamber 52 until the flanged portion of the thumb pad 42 contacts the proximal end of the cartridge 50, as shown in Fig. 7. The outside diameter of the thumb pad 42 is larger than the inside diameter of the cartridge 50, thereby preventing further displacement of the plunger 40 once the thumb pad contacts the proximal end of the cartridge 50. Preferably, the distance between the forward end of the plunger 40 and the rearward end of the mid seal 70 is equal to the distance between the flanged portion of the

thumb pad **42** and the proximal end of the cartridge **50**. Once the thumb pad **42** contacts the proximal end of the cartridge **50**, the plunger is fixed relative to the cartridge **50**. At this point, axial advancement of the cartridge **50** relative to the barrel **30** is restricted, as described in more detail below.

5

Preferably, the injection device **10** includes a locking mechanism for preventing accidental release of the contents in the second chamber prior to mixing the two components. In the present embodiment shown in Fig. 7, the barrel **30** includes a locking clip **100** in the barrel wall to prevent accidental discharge of the medicinal components. The wall of the barrel **30** includes a pair of radial slots **104** formed in a plane that is transverse the longitudinal axis of the barrel. When the locking clip **100** is inserted through the slots **104**, the clip prevents inadvertent forward displacement of the cartridge **50** relative to the front seal **80**, thereby preventing accidental advancement of the medicinal components through the needle **12**. The locking clip **100** is preferably formed of a resilient high strength and high modulus resin, such as acetyl or polycarbonate, and is configured to releasably engage the slots **104** in the barrel **30**.

10

15

20

Referring to Figs. 1-3, the locking clip **100** is preferably a flat member having a pair of resiliently deflectable legs **101** that join to form a U-shape. The open end of the locking clip **100** has tapered edges **102** that allow the legs **101** to deflect outwardly as the locking clip **100** is inserted into the sidewall of the barrel **30**. In addition, the locking clip **100** has a plurality of teeth **103** on the inside edge of the legs **101** that are adapted to engage the edges of radial slots **104**.

25

As the locking clip is inserted into the sidewall of the barrel **30**, the legs **101** deflect outwardly to allow the teeth **103** to clear the edges of radial slots **104**. Upon being deflected outwardly, the resilience of legs **101** bias the legs radially inwardly toward their original position. Once the teeth

30

103 are disposed within the slots 104, the legs 101 deflect radially inwardly toward their original position and releasably engage the outer edges of the needle retainer 20 in barrel 30. In the inserted position, the closed end of the locking clip 100 remains outside the barrel 30, as shown in Figs. 1 and 4.

5

After the medicinal components are mixed within the cartridge, the locking clip 100 is removed to permit injection of the medicine 59, as shown in Fig. 8. The locking clip 100 is removed from the barrel 30 by pulling the closed end of the clip in a direction transverse to the longitudinal axis of the barrel. This direction is marked "A" in Fig. 1. By pulling the clip in this manner, the legs 101 are deflected outwardly from the slots 104 to allow the teeth 103 to clear the edges of slots 104.

10

After the locking clip 100 is removed from the barrel 30, the medication 59 is injected into the patient by advancing the cartridge forwardly into the barrel. Pressure applied to the thumb pad 42 causes the plunger 40 and cartridge 50 to move forwardly relative to the barrel 30. With the barbed connector 25 mounted in the second recess 82b in the front seal 80, the front seal remains stationary while the cartridge 50 is advanced forwardly, as shown in Fig. 9. The front seal 80 and flared head 88 are configured to form a sliding fit with the interior of the cartridge 50 so that the cartridge can slide over the front seal. As the cartridge 50 is advanced, the mid seal 70 and the mid wall 60 are displaced toward the front seal 80. This causes a reduction of volume in the second chamber 56, whereby the medication is displaced into the needle to facilitate the injection. At the completion of the injection, the mid wall 60 bears against the rearward end of the front seal 80, as shown in Fig. 9.

15

20

25

30

Referring now to Figs. 9-10, the automatic retraction of the needle 12 shall be described. The cartridge 50 is axially advanced to the

proximal end of the barrel 30 until the medication 59 is completely expelled from the second chamber 56. As the cartridge 50 is advanced, the beaded circumferential rim 51 of the cartridge is displaced into engagement with the retaining arms 22 of needle retainer 20. Preferably, the cartridge 50 is
5 configured so that the longitudinal distance between the rearward end of the front seal 80 and the mid wall 60 corresponds to the longitudinal distance between the circumferential rim 51 of the cartridge and the retaining arms 22 when the cartridge is mounted on the barbed connector 25 in the second
10 position. In this way, the rim 51 of the cartridge 50 engages the retaining arms 22 when substantially all of the medication 59 is expelled from the device 10.

After the rim 51 of cartridge 50 engages the retaining arms 22, continued axial advancement of the cartridge deflects the retaining arms
15 radially inwardly so that the retaining tabs 24 are displaced inwardly, as shown in Fig. 9. In the inward position, the retaining tabs 24 are disengaged from the retaining apertures 38 of the barrel 30. In this way, the cartridge 50 operates as an actuator, such that axial advancement of the cartridge
20 displaces the needle retainer 20 into an unlocked position. In the unlocked position, the needle retainer 20 is no longer locked in place against the force of the spring 26. After the needle retainer 20 is in the unlocked position and the user releases pressure on the plunger 40, the spring 26 propels the
25 needle 12 rearwardly until the sharpened distal tip 16 of the needle is enclosed within the barrel 30.

As shown in Fig. 10, when the needle 12 is retracted, the needle, needle retainer 20 and cartridge 50 are displaced rearwardly together. During retraction, the retaining arms 22 are biased radially
30 outwardly so that the retaining tabs 24 ride along the inside wall of the barrel. The force of the spring 26 is sufficiently strong to overcome the frictional resistance generated between the guide arms 28 and the barrel 30.

Preferably, the injection device 10 includes a mechanism for limiting rearward displacement of the retracted elements. Referring now to Figs. 2, 4 and 10, the needle retainer 20 includes a pair of guide arms 28 that cooperate with a pair of alignment channels or grooves 31 formed in the interior wall of the barrel 30. The guide arms 28 may be molded out of a rigid, resilient high strength resin, such as polycarbonate. The guide arms 28 extend forwardly from the needle retainer 20 and project radially outwardly into engagement with the alignment grooves 31.

Each guide arm 28 includes a linear elongated rear portion which preferably is generally parallel to the longitudinal axis of barrel 30. The forward portion of each guide arm 28 bends outwardly transverse to the longitudinal axis of the barrel 30 and extends into one of the alignment grooves 31. When the needle retainer 20 is disposed within the barrel, the guide arms 28 are deflected radially inwardly from their natural state. In this position, the guide arms 28 are biased radially outwardly against the inner wall of the barrel 30 due to the resilient properties of the guide arms.

The forward ends of guide arms 28 are preferably contained within the alignment grooves 31 to substantially limit rotation of the needle and needle retainer 20 during needle retraction. This engagement ensures that the guide arms are aligned with the lockout windows 39 so that the guide arms snap into the lockout windows at the end of retraction. In this way, the needle retainer 20 is limited to axial displacement during needle retraction. During retraction, the frictional resistance between the forward ends of the guide arms 28 and the inside wall of the barrel 30 is overcome by the expansion force of the spring 26.

As shown in Fig. 4, the linear elongated rear portion of each guide arm 28 is spaced radially inwardly from the inner wall of the barrel 30 to create a clearance space between the linear portion of the guide arms and

the barrel. Preferably, the minimum radial thickness of the clearance space is greater than the thickness of the wall of the cartridge 50 or the cartridge rim 51. In this way, when the cartridge 50 is advanced forwardly to disengage the retaining arms 22, advancement of the cartridge will not be impeded by the guide arms 28.

Each alignment groove 31 is substantially parallel to the longitudinal axis of the barrel 30. In Fig. 4, the groove 31 is shown extending to rearward end of the barrel. However, it may be desirable to terminate the groove forward of the rearward end of the barrel. The rearward portion of each alignment groove 31 intersects a lockout window 39 formed in the wall of the barrel 30. The lockout windows 39 are adapted to receive the forward ends of the guide arms 28, as shown in Fig. 10. In particular, as the front end of each guide arm 28 aligns with the corresponding lockout window 39 during needle retraction, the radially outward bias of the guide arm displaces the arm outwardly so that the forward end projects into the lockout window. The engagement between the guide arms 28 and lockout windows 39 prevent further axial movement of the retainer 22. As a result, the retracted elements are limited from further displacement in the forward or rearward direction.

Preferably, the injection device 10 includes a mechanism to limit tampering or removal of the cartridge 50 from the barrel socket 34. Referring now to Fig. 11, the present embodiment includes an annular lip 35 that projects radially inwardly from the inside wall of the socket 34 in barrel 30. The lip 35 is adapted to seat against the beaded rim 51 on the cartridge 50 so that the cartridge can not be easily pulled out of the rear of the barrel 30. As a result, access to the retracted elements, and the contaminated needle in particular, is limited.

Referring now to Figs. 4-10, the operation of the injection device

10 will be described. Prior to use, the needle 12 is disposed in an extended position so that the distal end 16 of the needle projects forwardly from the barrel 30, as shown in Fig. 4. Preferably, the device 10 is shipped with the cartridge 50 already mounted in barrel 30 so that the barbed connector 25 is engaged in the first recess 82a. Alternatively, the cartridge 50 may be shipped separately from the barrel 30, so that the cartridge must be attached to the barrel prior to use.

With the cartridge 50 and barrel 30 assembled, the device 10 is held vertically so that the distal end 16 of needle 12 points upwardwardly. The user holds the device 10 by placing the user's thumb in a supporting position beneath the thumb pad 42 of plunger 40. In addition, the user places a finger over each finger grip 36 to control the operation of the device 10. With the user's fingers anchored over the finger grips 36, the user applies a slight squeezing pressure on the thumb pad 42, much like a conventional syringe. The squeezing pressure displaces the cartridge 50 forwardly relative to the barrel so that the barbed connector 25 on the needle retainer 20 engages the second recess 82b in front seal 80 and the needle 12 pierces the wall 86. As the front seal 80 is pierced, entrapped air in the forward chamber 56 is vented through needle 12.

Continued advancement of the plunger 40 drives the seal 70 toward the piercing element 64 until the piercing element pierces the mid seal, thereby providing fluid communication between the forward and rearward chambers 52, 56. At this point, the first component 54 may be advanced into the forward chamber 56. Pressure is applied on the thumb pad 42 until the first component 54 is completely expelled from the rearward chamber 52 into the forward chamber 56 and the forward end of the plunger meets the rearward end of the mid seal 70. The user then shakes the injector device 10 to mix the first and second components 54, 58 inside the forward chamber 56.

During mixing, the locking clip 100 prevents the cartridge 50 from being advanced forwardly into the needle retainer 20. This constraint on the cartridge 50 limits the potential for inadvertent discharge of the medication 59 from the needle 12 and premature needle retraction. Once the medication 59 is adequately mixed, the user removes the locking clip 100 from the barrel 30 so that the cartridge 50 can be advanced forwardly within the barrel. At this point, initial pressure applied to the thumb pad 42 advances the cartridge and vents excess air out of the second chamber 56.

The needle is then inserted into a patient and the plunger 40 is depressed to axially advance the cartridge 50 relative to the barrel 30, thereby injecting the medication 59 from the cartridge into the patient. At the end of the injection stroke, the beaded rim 51 on the cartridge 50 engages the retaining arms 22, thereby displacing the retaining tabs 24 radially inwardly to disengage the needle retainer 20 into the unlocked position. Although the needle retainer 22 is in the unlocked position, the needle 12 does not retract until the user releases pressure from the thumb pad 42. In this way, the user can retain pressure on the thumb pad 42 until after the needle is withdrawn from the patient. The user can then release pressure from the thumb pad 42 so that the needle is propelled rearwardly by the spring 26. Alternatively, the user can release pressure from the thumb pad 42 while the needle 12 is still inserted in the patient. Once the thumb pad 42 is released, the spring 26 propels the needle 12 rearwardly so that the contaminated distal tip 16 of the needle is enclosed within the barrel 30.

Referring now to Figs. 12-16 in general, and to Figs. 12-13 specifically, a second embodiment of a pre-filled safety diluent injector is shown. The injector device 110 includes elements that are substantially similar to the elements described above in connection with the first embodiment 10, illustrated in Figs. 1-11. These elements include: a double-ended needle 112, a generally cylindrical barrel 130, a compression spring

126, a needle retainer 120 releasably retaining the needle against the bias of the spring, a locking clip 200. The needle 112 has a sharpened proximal tip 114 and a sharpened distal tip 116. The spring 126 circumscribes the needle 112 and is compressed against the interior of the barrel 130 at the barrel's forward end. The rearward end of the spring 126 bears against the interior of the needle retainer 120 to bias the needle 112 and needle retainer in the rearward direction.

In contrast to the previous embodiment, the second embodiment utilizes a cartridge 150 having a selectively sealable by-pass fluid passage 160 to separate the two medicinal components, rather than a mid wall and a pierceable seal as described above with the first embodiment. Prior to use, a mid seal 170 within the cartridge 150 separates the two medicinal components 154, 158. Prior to use, the mid seal 170 is displaced forwardly adjacent the by-pass passage 160, which provides a fluid passage, allowing the two medicinal components 154, 158 to be mixed. The mixed components can then be injected into the patient.

Referring to Figs. 12, 13, the detail of the Cartridge 150 will be described in greater detail. The cartridge is a generally cylindrical container. The forward end of the cartridge is sealed by the pierceable forward seal 180. The rearward end of the cartridge is sealed by a piston 143 that forms a fluid-tight seal with the interior wall of the cartridge. Intermediate the forward seal 180 and the piston 143, a mid seal 170 forms a fluid-tight seal with the interior wall of the cartridge, separating the cartridge into two chambers, a forward chamber 156 for receiving a first component 158, and a rearward chamber 152 for receiving a second component 154.

The cartridge 150 includes a bubble-like fluid passage 160 that protrudes outwardly from the side of the cartridge. The fluid passage 160 forms an area in which the diameter of the cartridge is greater than the

diameter of the mid seal. The fluid passage **160** is an axially elongated channel having a length that is greater than the axial length of the mid seal **170**, and preferably, is shorter than the combined length of the mid seal and the piston **143**.

5

Although the fluid passage **160** is illustrated as a bubble-like protrusion, the fluid passage may be formed in other configurations. For instance, the fluid passage may be a recess or axial groove formed in the interior wall of the cartridge **150**, so that the fluid passage does not protrude from the exterior surface of the cartridge. Similarly, the fluid passage may be an annular recess formed in the interior wall of the cartridge.

10

Referring to Fig. 12, the device **110** is illustrated in a "storage" position. In this position, the mid seal **170** prevents the two medicinal components from mixing. Therefore, the sealed cartridge **150** can be stored for an extended period, if desired, without compromising the efficacy of the medicinal components. In the stored position, the mid seal **170** is disposed rearwardly of the fluid passage **160** so a fluid-tight seal is formed between the mid seal and the interior wall of the cartridge, around the entire circumference of the mid seal.

15

20

During storage of the injection device **110**, the medication is divided into two separate components stored in the cartridge **150**, as shown in Figs. 12-13. Specifically, the first component **154** of the medicine is stored in the first chamber **152** and the second component **158** of the medicine is stored in the second chamber **156**. As discussed further below, preferably, when the cartridge is being filled during manufacture, a quantity of air remains within the second chamber **156**.

25

A plunger **140** is slidably disposed in the rearward end of the cartridge **150**. The plunger **140** is comprised of a plastic molded plunger rod

30

141 and an elastomeric piston 143. The piston 143 forms a fluid-tight seal with the inner wall of the cartridge, and is slidably displaceable within the cartridge. The plunger rod 141 can be connected to the plunger seal 143 in a number of ways. In the present embodiment, the plunger rod 141 includes
5 external screw threads that are configured to engage internal threads inside the plunger seal 143, whereby the plunger rod and seal can be screwed together.

Referring now to Fig. 14, the transfer of the first medicine
10 component 154 into the second chamber 156 shall be described. The mid seal 170 is advanced axially until it registers with the fluid passage 160. The fluid passage 160 then provides a by-pass passage so that the component in the rearward chamber can be injected into the forward chamber. Since the forward chamber preferably includes a quantity of air (or other compressible
15 fluid), the material in the forward chamber can be compressed to allow the mid seal to be advanced into registry with the fluid passage 160. Alternatively, the forward chamber may include a vent for venting the air from the forward chamber when the fluid is transferred from the rearward chamber into the forward chamber. If a vent is included, preferably the vent is sealable
20 to prevent leakage of the mixed components during injection.

Specifically, to mix the two components in the cartridge, the plunger 140 is axially advanced into the cartridge 150, to compress the first component 154 against the rearward end of the mid seal 170 in the first chamber 152. As back pressure on the mid seal 170 overcomes the frictional
25 resistance between the mid seal and the cartridge 150, the mid seal is displaced forwardly in the cartridge. Once the mid seal 170 is displaced into alignment with the fluid passage 160, a passage is created between the mid seal and the inside wall of the fluid passage, as shown in Fig. 14.

30 The fluid passage 160 is sufficiently large to allow the first

substance **154** to flow around the mid seal and into the second chamber **156** where it is mixed with the second substance **158**. Once the first component is completely transferred to the second chamber **156**, the plunger seal **143** is advanced until it abuts the mid seal **170**, as shown in Fig. 15. The combined
5 axial length of the mid seal **170** and piston **143** is slightly longer than the length of the fluid passage **160**. Therefore, the mid seal and piston seal off the entire length of the fluid passage. This prevents the contents of the second chamber **156** from backflowing during mixing of the components.

10 After mixing of the components is completed, the locking clip **200** is removed to allow injection of the medication into the patient. Pressure is applied to the cartridge **150** to discharge the medication from the second chamber **156**. At the completion of the injection stroke, the cartridge **150** actuates the needle retainer **120**. Pressure on the cartridge **150** is then
15 released so that the needle can be retracted, as shown in Fig. 16.

Referring now to Figs. 17-23 in general, and to Fig. 17 specifically, another embodiment of a pre-filled safety diluent injector is designated generally **210**. The injector device **210** includes a double-ended
20 needle **212**, a generally cylindrical barrel **230** that houses the needle and a generally cylindrical cartridge **250**. The barrel **230** further includes a compression spring **226** and a needle retainer **220** releasably retaining the needle **212** against the bias of the spring. The needle **212** has a sharpened rearward tip **214** and a sharpened forward tip **216**. The spring **226**
25 circumscribes the needle **212** and is compressed against the interior of the barrel **230** at the barrel's forward end. The rearward end of the spring **226** bears against the interior of the needle retainer **220** to bias the needle **212** and needle retainer in the rearward direction.

30 In this embodiment, the transferring and mixing of the medication components is done in the cartridge **250** prior to attaching the

cartridge to the needle hub 221. Since the cartridge 250 is not connected to the needle assembly during mixing, there is no risk of inadvertently retracting the needle during the mixture of the components. As a result, the barrel does not include a locking clip, as in the other embodiments.

5

Referring now to Figs. 18-19, the cartridge 250 and barrel 230 are packaged and distributed so that the two are disassembled. The cartridge 250 is a generally cylindrical vessel that may be molded out of pharmaceutical quality glass such as borosilicate or a rigid inert plastic such as polyolefin or polyester. A cartridge cap 253 is disposed over the distal end of the cartridge 250. The cartridge 250 is configured similar to the cartridge 150 illustrated in Figs. 12 - 16, and includes a bubble-like fluid passage 260 that protrudes outwardly from the side of the cartridge. A mid seal 270 is slidably disposed in the cartridge 250 and divides the cartridge into a first chamber 252 and a second chamber 256. Each chamber of cartridge 250 is filled with a predetermined amount of a component of medication during manufacturing of the device 210. In particular, the first chamber 252 is prefilled with a first component 254 of the medication and the second chamber 256 is prefilled with a second component 258.

10

15

20

Referring now to Fig. 20, a plunger 240 is slidably disposed in the proximal end of the cartridge 250. The plunger 240 is comprised of a plastic molded plunger rod 241 and an elastomeric plunger seal 243. When the plunger 240 is axially advanced into the cartridge 250, the first component 254 is compressed against the rearward end of the mid seal 270 in the first chamber 252. As back pressure on the mid seal 270 overcomes the frictional resistance between the mid seal and the cartridge 250, the mid seal is displaced forwardly in the cartridge. Once the mid seal 270 is displaced into alignment with the fluid passage 260, a passage is created between the mid seal and the inside wall of the fluid passage to allow the first substance 254 to flow around the mid seal and into the second chamber 256 where it is mixed

25

30

with the second substance **258**.

5 The fluid passage **260** is sufficiently long to allow the first substance **254** to flow around the mid seal and into the second chamber **256** where it is mixed with the second substance **258**. Once the first component is completely transferred to the second chamber **256**, the plunger seal **243** is advanced until it abuts the mid seal **270**, as shown in Fig. 21. The combined axial length of the mid seal **270** and plunger seal **243** is slightly longer than the maximum length of the fluid passage **260** so that the mid seal and plunger seal close off the entire length of the fluid passage. This prevents the contents of the second chamber **256** from backflowing during mixing of the components.

15 Referring again to Fig. 18, the cartridge **250** includes an elastomeric front seal **280** in the distal end of the cartridge. The front seal **280** may be molded of a self-sealing biocompatible elastomer such as polyisoprene. The front seal **280** is generally cylindrical with a wide cylindrical rearward end **282** disposed within the cartridge and a reduced diameter forward end **284** projecting forwardly from the forward end of the cartridge. The rearward end **282** has an outside diameter that is similar to the inside diameter of the cartridge **250**. In addition, the rearward end **282** has a plurality of axially-spaced circumferential ribs **286** that frictionally and sealingly engage the interior of the cartridge to provide a fluid tight seal and prevent fluid from leaking from the cartridge.

25 The forward end **284** of front seal **280** includes an external thread **288** about its circumference. The distal end **284** also contains a shallow frontal cavity **290**. A narrow bore **292** in fluid connection with the second chamber **256** extends from the proximal end of the front seal **280** and terminates within the reduced diameter distal end **284**. Fluid communication between the frontal cavity **290** and the bore **292** is obstructed by a pierceable

30

membrane **294**.

Referring now to Fig. 19, the barrel **230** is generally cylindrical and has a tapered nose **232** at its distal end. The nose **232** has an opening through which the needle **212** extends. In addition, the nose **232** is configured to receive a needle cover **211** that fits over the nose to prevent accidental needle sticks when the needle **212** is in an extended position. The proximal end of the barrel **230** is open, forming a cylindrical socket **234** adapted to receive the cartridge **250**. Prior to attachment with the cartridge **250**, the rearward open end of the barrel **230** is closed by a cylindrical barrel cap **233**. The barrel further includes a pair of retaining apertures **238** that cooperate with the needle retainer **220** to releasably retain the needle, and a pair of lockout windows that cooperate with locking tabs to lock the needle in the retracted position.

The needle retainer **220** includes a generally cylindrical body **221** and a pair of retaining arms **222** that extend radially forwardly from the body **221**. A generally cylindrical aperture **296** is disposed within the proximal end of the needle retainer body **221**. The inner wall of the aperture **296** includes internal screw threads **298** that are adapted to receive the external screw thread **288** of the front seal **280** in the cartridge **250**.

The cartridge cap **253** and barrel cap **233** are removed from the cartridge **250** and barrel **230**, respectively, to prepare the cartridge and barrel for assembly. The cartridge **250** is connected to the barrel **230** by inserting the forward end of the front seal through the open end of the barrel **230** and screwing the cartridge clockwise into the aperture **296**. The frontal cavity **290** in the front seal **280** is preferably coaxial with the needle **212**, such that attachment of the cartridge **250** to the barrel **230** causes the proximal needle tip **214** to enter the cavity **290** and pierce the membrane **294**, thereby connecting the second chamber of the cartridge in fluid communication with

the needle **212**, as shown in Fig. 17.

Referring to Fig. 17, the cartridge **250** is connected to the barrel **230**, the medication can be injected into the patient by advancing the cartridge forwardly into the barrel. The proximal end of the front seal **280** is configured to form a sliding fit with the interior of the cartridge **250** so that the cartridge slides over the front seal during advancement of the cartridge. As the cartridge **250** is advanced, the rearward end of the front seal **280** bears against the needle retainer **220**, thereby keeping the front seal stationary during advancement of the cartridge. At the same time, the mid seal **270** at the rear of the second chamber **256** is displaced toward the front seal **280**. This causes a reduction of volume in the second chamber **256**, whereby the medication is displaced into the needle to facilitate the injection. At the completion of the injection, the mid seal **270** bears against the rearward end of the front seal **280**, as shown in Fig. 22.

As in the previous embodiments, the needle **212** is retracted by actuating the needle retainer **220**. In particular, the needle **212** is retracted by disengaging the retaining arms **222** from the retaining apertures **238** in the barrel wall to allow the spring **226** to propel the needle **212** rearwardly. To actuate the needle retainer **220**, pressure is applied to the cartridge **250** to advance the cartridge over the needle retainer body **221**, as shown in Fig. 22. During advancement, the distal end of the cartridge **250** engages a cylindrical sleeve **300** that is disposed around the distal end of the needle retainer body **221**. The inside and outside diameters of the release sleeve **300** are preferably equal to the inside and outside diameters of the cartridge **250** so that the distal end of the cartridge mates with the proximal end of the sleeve. Prior to engagement with the cartridge **250**, axial movement of the release sleeve **300** along the needle retainer is limited by an internal flange **302** that slides within an annular fluid passage **223** on the needle retainer body **221**. After the cartridge **250** engages the sleeve **300** continued advancement of

WO 02/072171

30

PCT/US02/07712

the cartridge drives the sleeve axially forwardly into engagement with the retaining arms 222. The release sleeve 300 deflects the retaining arms radially inwardly and out of engagement with the retaining apertures 238, allowing the spring 226 to propel the needle 212 rearwardly, as shown in Fig. 23.

As described above, the third embodiment includes a threaded engagement between the front seal 280 and the needle retainer 220 rather than a barbed connection as described in the first two embodiments. Using a threaded connection can increase the overall length of the needle retainer 220, which in turn increases the distance between the distal end of the cartridge 250 and the retaining arms 222. One manner for accommodating this increased length is to increase the length of the barrel 230. However, by incorporating the release sleeve 300, the length of the barrel 230 need not be substantially increased. The release sleeve 300 compensates for the increased distance by acting as an extension of the cartridge 250. This eliminates the need to increase the overall length of the device 210. Preferably, the length of the release sleeve 300 is slightly longer than the length of the threaded engagement between the front seal 280 and the needle retainer 220.

Referring now to Figs. 24-29 in general, and to Figs. 24-25 specifically, a fourth embodiment of a pre-filled safety diluent injector is shown. The injector device 310 includes a double-ended needle 312, a generally cylindrical barrel 330 that houses the needle and a generally cylindrical cartridge assembly 350 mounted within the proximal end of the barrel. Like the previous embodiments, the barrel further includes a compression spring 326 and a needle retainer 320 releasably retaining the needle 312 against the bias of the spring. The device 310 also includes a U-shaped locking clip 400 in the barrel wall to prevent accidental discharge of medication from the device 310.

The cartridge assembly **350** has a two-part design that offers the advantage of using cost-efficient plastic in the assembly. The cartridge assembly **350** includes a front cylinder **351** having an open proximal end and a rear cylinder **353** having an open distal end telescopically mounted to the proximal end of the front cylinder. The front cylinder **351** contains an internal wall **360** that divides the cartridge assembly **350** into a first chamber **352** and a second chamber **356**. The first chamber **352** contains a predetermined amount of a first component **354** of medication, and the second chamber **356** contains a predetermined amount of a second component **358** of medication. The proximal end of the front cylinder **351** is closed by a pierceable elastomeric front seal **380**.

In many applications, the second component **358** will be a dry powdered component. Dry components do not require a glass container and can be stored in plastic containers without jeopardizing long term stability of the component. Since it is more cost-efficient to mold complex parts out of plastic than glass, it is preferable to minimize the complexity of the glass portion of the cartridge assembly **350**. To this end, the front and rear cylinders **351**, **353** are configured so that the first component **354** is stored entirely within the rear cylinder and the second component **356** is stored entirely within the front cylinder. In this arrangement, the front cylinder **351** comprises a more complicated structure to allow the rear cylinder to be a simple cup-shaped container. Therefore, the more complex forward cylinder can be molded out of cost-efficient plastic for those devices that store a dry second component **358** in the second chamber **356**. Preferably, glass is only used, if at all, to mold the rear cylinder **353**.

As stated earlier, the rear cylinder **353** is telescopically mounted on the proximal end of the front cylinder **351**. The outside diameter of the rear portion of the rear seal is generally equal to the inside diameter of the rear cylinder **353** so as to frictionally engage the interior of the rear cylinder

and provide a fluid tight seal. The rear cylinder **353** is adapted to slide axially over the rear seal **340** in response to pressure applied to the proximal end of the rear cylinder.

5 The barrel **330** has an inside diameter large enough to accommodate the outside diameter of the rear cylinder **353**. As a result, the outside wall of the front cylinder **351** is separated from the interior wall of barrel **330** by a clearance space, as shown in Fig. 25. The front cylinder **351** is maintained in a concentric relationship with the much larger barrel **330** by a pair of opposing longitudinal ribs **355** on the outside wall of the front cylinder. The longitudinal ribs are illustrated in Fig. 24.

15 An elastomeric rear seal **340** is disposed between the front cylinder **351** and rear cylinder **353**. The rear seal **340** includes a reduced diameter end **342** partially disposed in the open proximal end of the front cylinder **351**. The rear seal **340** also includes a flanged end **344** disposed within the rear cylinder **353**. The reduced diameter end **342** and flanged end **344** frictionally and sealingly engage the interior of the front cylinder **352** and rear cylinder **354**, respectively. This engagement provides a fluid tight seal with the interior of both cylinders, while allowing the rear seal **340** to be displaced relative to either cylinder. Forward advancement of the rear seal **340** relative to the front cylinder **351** is limited by the proximal end of the front cylinder, which is configured to matingly engage the flanged portion of the rear seal.

25 As stated earlier, the front cylinder **351** contains an internal wall **360**. The internal wall **360** is adjacent the rearward open end of the cartridge, forming a socket for receiving the rear seal **340**. The internal wall **360** contains an orifice **362** mounted in the center of the wall **360**. A hollow piercing member **364** is mounted in the orifice and extends rearwardly toward the rear seal **340**. In addition, it may be desirable to provide a vent opening in

30

the internal wall 360 to vent the air between the rear seal 340 and the internal wall when the rear cylinder is advanced to pierce the rear seal.

5 The distal end of the rear seal 340 is closed by a membrane 348 that is configured to be pierced by piercing member 364. The rear seal 340 includes a hollowed mid section 346 that is connected in fluid communication with the first chamber 352 through the proximal end of the rear seal. Once the membrane 348 is pierced, a fluid passage is created through the piercing member 364 and rear seal 340, such that the first and 10 second chambers, 352, 356 are connected in fluid communication. The rear seal 340 may be molded in a high elongation self-sealing biocompatible elastomer, such as polyisoprene.

15 The operation of the device 310 will now be described. A slight squeezing pressure is applied to the proximal end of the rear cylinder 353 to axially advance the rear cylinder over the front cylinder 351. This causes the first component 354 to become compressed between the rear seal 340 and the closed proximal end of the rear cylinder 353. Continued pressure on the rear cylinder 353 creates back pressure on the rear seal 340 which axially 20 displaces the rear seal forwardly into the piercing member 364. At this time, the membrane 348 is pierced to create a fluid passage between the first and second chambers 352, 356.

25 The rear cylinder 353 is advanced forwardly relative to the front cylinder 351 to expel the first component 354 from the first chamber 352 into the second chamber 356. Once the first component 354 is completely expelled from the first chamber 352, additional pressure on the rear cylinder 353 advances the rear cylinder forwardly relative to the front cylinder 351 until the closed proximal end of the rear cylinder abuts the proximal end of the rear 30 seal 340, as shown in Fig. 26. At this point, the device 310 is shaken to mix the components within the second chamber 356. During the mixing process,

displacement of the cartridge assembly 350 is prevented by the locking clip 400, thereby minimizing the potential for accidental discharge of the medication.

5 After the components are mixed, the locking clip 400 is removed. The cartridge assembly is then displaced forwardly so that the rearward end of the needle 312 pierces the forward seal 380. The air is then vented from the forward chamber. Further pressure is applied to the cartridge assembly 350 to discharge the medication from the second chamber 356 and
10 through the needle 312. At the completion of the injection stroke, the proximal end of the cartridge assembly 350 actuates the needle retainer 320, as shown in Fig. 27. Pressure on the cartridge assembly 350 is then released so that the needle 312 can be retracted, as shown in Figs. 28 and 29.

15 In some instances, it may be desirable to store the cartridge in its component parts. In other words, the rear cylinder 353 may be detached from the forward cylinder 351. Prior to use, the rear cylinder 353 would be attached to the forward cylinder 351 and the combined assembly would be utilized as described above. In such instances, the separate rear container
20 353 may include a separate cap to cover its forward end. Similarly, the forward cylinder 351 may include a cap to cover its rearward end. The detachable rearward cylinder 353 may permit a variety of pre-measured medicinal components to be stored and readily combined in various combinations prior to use.

25 The terms and expressions which have been employed are used as terms of description and not of limitation. There is no intention in use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof. It is recognized, however, that
30 various modifications of the embodiments described herein are possible within the scope and spirit of the invention. For instance, the embodiments

WO 02/072171

35

PCT/US02/07712

described above include a needle retainer having a pair of radially
displaceable arms to automatically release the needle for retraction after use.
However, the devices may be modified by utilizing different needle retainers
that may or may not automatically retract the needle after use. Accordingly,
5 the invention incorporates variations that fall within the scope of the following
claims.

CLAIMS

1. A medical device, comprising:
 - a barrel having an open proximal end and a distal end;
 - a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
 - a cartridge in fluid communication with the needle, comprising:
 - a first chamber containing a first substance;
 - a second chamber containing a second substance;
 - a fluid flow controller between the first chamber and the second chamber; and
 - a plunger slidably disposed within the cartridge;
 - a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip; and
 - a needle retainer releasably retaining the needle in the extended position;

wherein axially advancing the plunger within the first chamber advances the first substance through the fluid flow controller and into the second chamber where said first substance combines with the second substance to form a medicinal mixture, and continued advancement of the plunger and cartridge relative to the barrel after the mixture is expelled from the cartridge actuates the needle retainer to release the needle, whereupon the biasing element displaces the needle relative to the barrel to shield the first sharpened tip.
2. The medical device in claim 1 wherein the medical device further comprises a needle carrier fixed to the needle.
3. The medical device in claim 1 wherein the needle has a second sharpened tip at its rearward end.

WO 02/072171

37

PCT/US02/07712

4. The medical device in claim 1 wherein the needle is retracted upon release of pressure on the plunger.
5. The medical device in claim 1 wherein the medical device further comprises one or more stops that impede continued rearward displacement of the first sharpened needle tip beyond the proximal end of the barrel as the needle is moved to the shielded position.
6. The medical device in claim 1 wherein the plunger is comprised of a plastic molded plunger rod connected to an elastomeric seal.
7. The medical device in claim 1 wherein the plunger is displaceable relative to the cartridge while the first substance is expelled from the first chamber, and the plunger is stationary relative to the cartridge when the mixture is expelled from the second chamber.
8. The medical device in claim 1 wherein the second substance is a powdered material.
9. The medical device in claim 1 wherein the second substance is a liquid material.
10. The medical device in claim 1 wherein the volume of the second chamber is greater than the combined volume of the first substance and the second substance.
11. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a wall between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending into the first chamber; and
 - a fluid flow pathway through the piercing element;wherein axially displacing the cartridge toward the barrel displaces the plunger until the plunger is ruptured by the piercing element,

creating a passage through the plunger which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the plunger into the second chamber.

12. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a barrier between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending into the first chamber;
 - a fluid flow pathway through the piercing element; and
 - a pierceable mid seal axially displaceable within the first chamber that provides fluid communication between the first and second chambers upon being pierced by the piercing element;wherein axially displacing the plunger toward the barrel displaces the pierceable mid seal until the mid seal is ruptured by the piercing element, creating a passage through the mid seal which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the mid seal into the second chamber.
13. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a mid seal between the first and second chambers that is axially displaceable within the cartridge; and
 - an elongated fluid passage in the side wall of the cartridge;wherein axially displacing the plunger toward the barrel displaces the mid seal into alignment with the fluid passage, creating a passage between said mid seal and the inside wall of the fluid passage that allows the first substance to flow around the mid seal into the second chamber.
14. The medical device in claim 1 wherein the cartridge is substantially permanently attached to the barrel.

15. The medical device in claim 1 wherein the cartridge comprises a beaded circumferential rim on the distal end of the cartridge, and the barrel contains a lip projecting radially inwardly from the inner bore of the barrel at the barrel's proximal end, said lip adapted to engage the beaded rim of the cartridge to impede removal of the cartridge from the rear of the barrel after needle retraction.
16. The medical device in claim 2 wherein the biasing element comprises a compression spring disposed between the distal end of the barrel and the needle carrier.
17. The medical device in claim 2 wherein the needle retainer comprises a pair of forward tines extending radially outwardly from the needle carrier and configured to releasably engage a pair of windows in the barrel wall.
18. The medical device in claim 2 wherein a cylindrical sleeve having generally the same outside diameter as the cartridge is disposed around the circumference of the needle carrier in general axial alignment with the cartridge, such that axial advancement of the cartridge at the end of the injection stroke displaces the sleeve toward the distal end of the barrel to actuate the needle retainer.
19. The medical device in claim 3 wherein the cartridge further comprises a front seal at the distal end of the cartridge that is configured to be pierced by the second sharpened tip to connect the needle and second chamber in fluid communication.
20. The medical device in claim 19 wherein the minimum axial force on the plunger that is required to pierce the front seal is less than or equal to the minimum axial force required to axially displace the plunger in the rear chamber.
21. The medical device in claim 19 wherein the distal end of the front seal

includes an external thread and the proximal end of the needle carrier includes a cavity adapted to receive the threaded end of the front seal.

22. A medical device, comprising:
- a barrel having an open proximal end, a distal end and an opening through the barrel wall oriented perpendicularly to the longitudinal axis of the barrel;
 - a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
 - a cartridge in fluid communication with the needle, comprising:
 - a first chamber containing a first substance;
 - a second chamber containing a second substance;
 - a fluid flow controller connecting the first chamber and the second chamber; and
 - a plunger slidably disposed within the cartridge;
 - a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip;
 - a needle retainer releasably retaining the needle in the extended position; and
 - a locking clip detachably connected to the barrel;
- wherein axially advancing the plunger within the first chamber advances the first substance through the fluid flow controller and into the second chamber where said first substance combines with the second substance to form a medicinal mixture, and removal of the locking clip from the barrel permits further advancement of the plunger and cartridge relative to the barrel to expel the mixture from the second chamber, whereafter axially advancing the cartridge disengages the needle retainer to allow the biasing element to displace the needle relative to the barrel to shield the first sharpened tip.

WO 02/072171

41

PCT/US02/07712

23. The medical device in claim 22 wherein the medical device further comprises a needle carrier fixed to the needle.
24. The medical device in claim 22 wherein the needle has a second sharpened tip at its rearward end.
25. The medical device in claim 22 wherein the needle is retracted upon release of pressure on the plunger.
26. The medical device in claim 22 wherein the cartridge comprises a beaded circumferential rim on the distal end of the cartridge, and the barrel contains a lip projecting radially inwardly from the inner bore of the barrel at the barrel's proximal end, said lip adapted to engage the beaded rim of the cartridge to impede removal of the cartridge from the rear of the barrel after needle retraction.
27. The medical device in claim 22 wherein the medical device further comprises one or more stops that impede continued rearward displacement of the first sharpened tip beyond the open proximal end of the barrel as the needle is moved to the shielded position.
28. The medical device in claim 22 wherein the plunger is comprised of a plastic molded plunger rod connected to an elastomeric seal.
29. The medical device in claim 22 wherein the plunger is displaceable relative to the cartridge while the first substance is expelled from the first chamber, and the plunger is stationary relative to the cartridge when the mixture is expelled from the second chamber.
30. The medical device in claim 22 wherein the locking clip comprises a flat U-shaped disk having a plurality of teeth along the inner edge, said clip being configured to slide through the slits in the barrel in a direction perpendicular to the longitudinal axis of the barrel and at a location between the cartridge and the needle retainer, thereby impeding

contact between the cartridge and the needle retainer.

31. The medical device in claim 22 wherein the second substance is a powdered material.
32. The medical device in claim 22 wherein the second substance is a liquid material.
33. The medical device in claim 22 wherein the volume of the second chamber is greater than the combined volume of the first substance and the second substance.
34. The medical device in claim 22 wherein the fluid flow controller comprises:
 - a barrier between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending within the first chamber;
 - a fluid flow pathway through the piercing element; and
 - a pierceable mid seal axially displaceable within the first chamber that provides fluid communication between the first and second chambers upon being pierced by the piercing element;wherein initial axial displacement of the plunger toward the barrel displaces the pierceable mid seal into contact with the piercing element, piercing the mid seal and creating a passage through the mid seal which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the mid seal into the second chamber.
35. The medical device in claim 22 wherein the fluid flow controller comprises:
 - a mid seal between the first and second chambers that is axially displaceable within the cartridge; and
 - an elongated fluid passage in the side wall of the cartridge between the

WO 02/072171

43

PCT/US02/07712

mid seal and the distal end of the cartridge;

wherein axially displacing the plunger toward the barrel displaces the mid seal into alignment with the fluid passage, creating a passage between said mid seal and the inside wall of the fluid passage that allows the first substance to flow around the mid seal into the second chamber.

36. The medical device in claim 23 wherein the biasing element comprises a compression spring disposed between the distal end of the barrel and the needle carrier.
37. The medical device in claim 23 wherein the needle retainer comprises a pair of forward windows in the barrel wall and a pair of forward tines extending radially outwardly from the needle carrier and configured to releasably engage the forward windows.
38. The medical device in claim 24 wherein the cartridge further comprises a front seal at the distal end of the cartridge that is configured to be pierced by the second sharpened tip to connect the needle and second chamber in fluid communication.
39. The medical device in claim 38 wherein the minimum axial force on the plunger that is required to pierce the front seal is less than or equal to the minimum axial force required to axially displace the plunger in the rear chamber.
40. A medical device, comprising:
 - a barrel having an open proximal end and a distal end;
 - a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
 - a cartridge in fluid communication with the needle, comprising:

WO 02/072171

44

PCT/US02/07712

a first chamber containing a first substance;
a second chamber containing a second substance;
a fluid flow controller between the first chamber and the second chamber; and

a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip; and
a needle retainer releasably retaining the needle in the extended position;

wherein the fluid flow controller is adapted to keep the first and second substances separate prior to use, and also adapted to allow mixing of the first and second substances prior to an injection, wherein after use the needle is disposed in the shielded position.

41. A method for injecting medicine, comprising the steps of:
providing an injection device having a first chamber containing a first medicinal component, a second chamber containing a second medicinal component, and a needle;
transferring the first medicinal component from the first chamber to the second chamber;
mixing the first and second components to form a medicinal mixture;
expelling the medicinal mixture from the chamber; and
retracting the needle after expelling the medicinal fluid to shield the needle against contact.




Figure 1

WO 02/072171

2/19

PCT/US02/07712




Figure 2




Figure 3






Figure 4

Figure 5

WO 02/072171

4/19



PCT/US02/07712



WO 02/072171

5/19

PCT/US02/07712






Figure 10






Figure 11

WO 02/072171

8/19

PCT/US02/07712



WO 02/072171

9/19

PCT/US02/07712

Figure 14





Figure 15






Figure 16






Figure 17

WO 02/072171

12/19

PCT/US02/07712







Figure 22





Figure 23



WO 02/072171

15/19

PCT/US02/07712




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28

Figure 29

【 国際公開パンフレット (コレクション) 】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072171 A2


- (51) International Patent Classification: **A61M** Simi Valley, CA 93065 (US). **CHALLIOL, Bernardo** [US/US]; 3031 Luna Drive, Ventura, CA 93003 (US).
- (21) International Application Number: PCT/US02/07712 **MCWETHY, Robert** [US/US]; 1543 Daffodil Avenue, Ventura, CA 93004 (US). **KOVALSKI, Joseph** [US/US]; 1296 Martha's Vineyard Court, Ventura, CA 93001 (US).
- (22) International Filing Date: 13 March 2002 (13.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/275,568 13 March 2001 (13.03.2001) US
- (71) Applicant (for all designated States except US): **MDC INVESTMENT HOLDINGS INC.** [US/US]; Suite 200, 900 Market Street, Wilmington, DE 19801 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BARKER, John** [US/US]; 155 Sunset View Court, Ventura, CA 93003 (US). **HALSETH, Thor** [US/US]; 159 Stonebrook Street,
- (74) Agent: **ELAND, Stephen**; Dann, Dorfman, Herrell & Skilman, Suite 720, 1601 Market Street, Philadelphia, PA 19105 (US).
- (81) Designated States (national): AU, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW).

[Continued on next page]

(54) Title: PRE-FILLED SAFETY DILUENT INJECTOR



WO 02/072171 A2



(57) Abstract: A safety needle-bearing device (10, 110, 210, 310) for mixing and injecting medication from a two-chambered cartridge (50, 150, 250, 350) is provided. The device includes a needle (12, 112, 212, 312) that extends through the forward end of a barrel (30, 130, 230, 330). The two-chambered cartridge (50, 150, 250, 350) is attached to the barrel (30, 130, 230, 330) and contains components of a medication stored separately in the chambers. A plunger (40, 140, 240) in the rearward end of the cartridge can be advanced into the cartridge to combine the separate components and prepare the medication. As the cartridge (50, 150, 250, 350) is advanced forwardly into the barrel (30, 130, 230, 330), the medication is injected through the needle (12, 112, 212, 312) and into a patient. At the completion of the injection stroke, the cartridge (50, 150, 250, 350) engages a needle retainer to actuate needle retraction. The needle is subsequently retracted to shield the contaminated needle.

WO 02/072171 A2 

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SI, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(48) Date of publication of this corrected version:
31 October 2002

(15) Information about Correction:
see PCT Gazette No. 44/2002 of 31 October 2002, Sec-
tion II

Published:
without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 02/072171

PCT/US02/07712

-1-

PRE-FILLED SAFETY DILUENT INJECTOR**PRIORITY CLAIM**

This application claims priority to U.S. Provisional Application No. 60/275,568, filed March 13, 2001, which is hereby incorporated herein by reference.

5

FIELD OF THE INVENTION

The present invention relates to medical devices and more particularly to medical devices having a cartridge with two chambers that store separate components of a medication and allow the components to be mixed and subsequently injected into a patient.

10

BACKGROUND

Pre-filled syringes store and allow for mixing of separate medicinal components. Many of these syringes, sometimes called "mixing syringes," store a first component in one compartment and a diluent or a second component in a second compartment. These syringes allow the two components to be stored separately until just before the syringe is used, at which time the components can be mixed within the syringe and immediately injected into a patient.

15

20

Pre-filled mixing syringes are advantageous for many types of pharmaceuticals. Some medications, like antibiotics, vitamins and hormones, must be packaged and stored in component parts to enhance shelf life. These medications may need to be stored as a powdered component and a diluent, or as a separate pair of solutions. Pre-filled mixing syringes allow medications to be stored in component parts right up until the medication is

25

WO 02/072171

PCT/US02/07712

-2-

injected. In addition, pre-filled mixing syringes eliminate the burden of measuring medicinal components and mixing diluents from separate containers.

5 Despite these advantages, prior mixing syringes have not offered reliable safety features to protect the syringe user from accidental needle sticks following injection. In particular, prior syringe assemblies have not provided a mixing syringe that operates integrally with an injection needle that can be automatically shielded upon completion of the injection.

10 **SUMMARY OF THE INVENTION**

15 With the foregoing in mind, the present invention provides a pre-filled medical device for mixing separate components of a medication and injecting the medication into a patient. The device includes a two-chambered container, such as a cartridge, connected to a needle that retracts automatically after use. After retraction, the contaminated needle tip is enclosed within the device to prevent inadvertent needle sticks.

20 The device includes a hollow barrel surrounding the needle and having a generally open rearward end that forms a socket. A two-chambered cartridge containing component parts of a medication is adapted to engage the socket. Prior to use, the components are stored separately in the two cartridge chambers. During use, a plunger disposed in the rearward end of the cartridge is advanced into the cartridge to combine the two components in
25 one chamber for mixing. Subsequent pressure on the plunger advances the medicinal mixture through the needle into a patient.

30 The injection needle is operable between an extended position and a retracted position. In the extended position, the forward tip of the needle projects forwardly from the barrel. In the retracted position, the forward tip is enclosed within the barrel. When the needle is in the extended

WO 02/072171

PCT/US02/07712

-3-

position, a biasing element biases the needle toward the retracted position. A
needle retainer releasably retains the needle in the extended position against
the force of the biasing element. During the injection stroke, the cartridge
disengages the needle retainer to allow the biasing element to propel the
5 needle rearwardly into the barrel.

DESCRIPTION OF THE DRAWINGS

The foregoing summary as well as the following detailed
10 description of the preferred embodiments will be best understood when read
in conjunction with the following drawings, in which:

Fig. 1 is perspective view of a pre-filled cartridge injector having a two-
15 chambered container that stores component parts of a medication;

Fig. 2 is an exploded perspective view of the cartridge injector shown in
Fig. 1;

Fig. 3 is an enlarged view of a locking clip of the cartridge injector shown in
20 Fig. 2;

Fig. 4 is a sectional view of the cartridge injector shown in Fig. 1 taken along
the line 4-4;

25 Fig. 5 is a sectional view of the cartridge injector shown in Fig. 4 taken along
the line 5-5;

Fig. 6 is a sectional view of the cartridge injector shown in Fig. 1, illustrating
the device prior to mixing the component parts of the medication;

30 Fig. 7 is a sectional view of the cartridge injector shown in Fig. 1, illustrating

WO 02/072171

PCT/US02/07712

-4-

the device after mixing with the cartridge locked to impede injection;

Fig. 8 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device after mixing the cartridge unlocked to allow injection;

5

Fig. 9 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device, after injection, just prior to needle retraction;

10

Fig. 10 is a sectional view of the cartridge injector shown in Fig. 1, illustrating the device after needle retraction.

Fig. 11 is an enlarged fragmentary sectional view of the cartridge injector shown in Fig. 1, illustrating the tamper resistant connection between the cartridge and barrel after the needle is retracted.

15

Fig. 12 is a sectional view of a second embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

20

Fig. 13 is a sectional view of the device shown in Fig. 12 taken along the line 13-13.

Fig. 14 is a sectional view of the device shown in Fig. 12 illustrating the device during mixture of the medicinal components in the cartridge transfer of one component of medicine between chambers.

25

Fig. 15 is a sectional view of the device shown in Fig. 12 illustrating the device after mixture of the medicinal components.

30

Fig. 16 is a sectional view of the device shown in Fig. 12 illustrating the device after needle retraction.

WO 02/072171

PCT/US02/07712

-5-

Fig. 17 is a sectional view of a third embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

5 Fig. 18 is a sectional view of the cartridge portion of the device illustrated in Fig. 17.

Fig. 19 is a sectional view of the device shown in Fig. 17 illustrated without the cartridge, illustrated prior to use.

10 Fig. 20 is a sectional view of the cartridge in Fig. 18 illustrating the device during mixture of the medical components.

Fig. 21 is a sectional view of the device shown in Fig. 18 illustrating the device after mixture of the medical components.

15 Fig. 22 is a sectional view of the device shown in Fig. 17 illustrating the device at the completion of an injection.

20 Fig. 23 is a sectional view of the device shown in Fig. 17 illustrating the device after needle retraction.

Fig. 24 is an exploded perspective view of a fourth embodiment of a two-chambered pre-filled cartridge injector having a retractable needle.

25 Fig. 25 is a sectional view of the device illustrated in Fig. 24.

Fig. 26 is a sectional view of the device in Fig. 24 illustrating the device after mixture of the medical components.

30 Fig. 27 is a sectional view of the device shown in Fig. 24 illustrating the device at the completion of an injection.

WO 02/072171

PCT/US02/07712

-6-

Fig. 28 is a sectional view of the device shown in Fig. 24 illustrating the device after needle retraction.

5 Fig. 29 is a sectional view of the device shown in Fig. 24 illustrating the device after needle retraction.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring now to the figures in general, and to Figs. 1-11 specifically, an injector device **10** is shown with a needle **12** having a sharpened distal tip **16** for insertion into a patient. As shown in Fig. 4, the injector device **10** has an attached cartridge **50** having a first chamber **52** and a second chamber **56**. The two chambers **52**, **56** are pre-filled with component parts of a medication that are to be mixed prior to injection. The cartridge **50** also includes a plunger **40** that is slidable within the cartridge. 10
Initially, advancing the plunger **40** in the cartridge **50** expels the medicinal component from the first chamber **52** into the second chamber **56** to mix the two medicinal components. After mixing the components, advancing the plunger drives the cartridge forwardly to inject the medicine into a patient. 15
Upon completion of the injection stroke, the medical professional releases pressure from the plunger to allow automatic retraction of the needle **12** into the device **10** to protect the contaminated needle **12** from inadvertent contact. 20

The injector device **10** includes a double-ended needle **12**, a generally cylindrical barrel **30**, a compression spring **26** and a needle retainer **20** releasably retaining the needle against the bias of the spring. As shown in 25
Figs. 4 and 5, the needle **12** has a sharpened proximal tip **14** and a sharpened distal tip **16**. The spring **26** circumscribes the needle **12** and is compressed against the interior of the barrel **30** at the barrel's distal end. The rearward end of the spring **26** bears against the interior of the needle retainer **20** to bias the needle **12** and needle retainer in the rearward direction. 30

WO 02/072171

PCT/US02/07712

-7-

The needle 12 is operable between two positions, an extended position and a retracted position. In the extended position, the needle 12 projects forwardly from the forward end of the barrel 30. In the retracted position, the needle 12 is retracted into the barrel 30 so that the sharpened tip 16 of needle 12 is enclosed within the barrel to prevent inadvertent contact with the sharpened tip. When the needle is in the extended position, the spring 26 biases the needle 12 rearwardly toward the retracted position. The needle retainer 20 releasably retains the needle 12 in the extended position, against the bias of the spring 26. During the injection stroke, the cartridge 50 cooperates with the needle retainer 20 to allow the needle to retract into the barrel 30, as shown in Fig. 10.

Referring now to Figs. 5-7, the cartridge 50 includes a first chamber 52 containing a first medicinal component 54 and a second chamber 56 containing a second medicinal component 58. The chambers 52, 56 are separated by a mid wall 60 containing an orifice 62. A rear seal 70 seals the first chamber 52 to prevent the components from being mixed prior to use. When the rear seal 70 is pierced and the plunger 40 is advanced into the cartridge 50, the first component 54 flows into the second chamber 56 through the orifice 62, where it combines with the second component 58 to form the medication 59, as shown in Figs. 6-7. Subsequent pressure on the plunger 40 and cartridge 50 forces the medication 59 through the needle 12 and into the patient.

Referring now to Figs. 4-6, the elements of the injector device 10 will be described in greater detail. The barrel 30 is generally cylindrical and the distal end of the barrel has a tapered nose 32. The nose 32 has an opening through which the needle 12 extends so that the sharpened tip 16 of the needle can be inserted into a patient. The rearward end of the barrel 30 is open, forming a cylindrical socket 34 adapted to receive the cartridge 50. Two laterally extending flanges 36 project outwardly from the barrel 30,

WO 02/072171

PCT/US02/07712

-8-

transverse the longitudinal axis of the barrel, forming a pair of finger grips for operating the device 10. The barrel 30 further includes a pair of retaining apertures 38 and a pair of lockout windows 39 that cooperate with the needle retainer 20 as described further below.

5

As shown in Fig. 5, a hub 21 projects from the rearward end of the needle retainer 20. The hub 21 is a generally cylindrical element having a central bore 23. The needle 12 is disposed within the central bore 23 of the hub 21 so that the rearward end 14 of the needle 12 projects rearwardly from the hub and the forward end 16 of the needle projects forwardly from the hub. The needle 12 can be attached to the hub 21 in one of several ways. For example, the needle 12 can be attached to the hub 21 by an adhesive such as a UV curable adhesive. Alternatively, the needle 12 can be molded into the hub 21, which is formed of plastic. The rearward end of the hub 21 includes a circumferentially barbed connector 25 configured to cooperate with the cartridge 50 to connect the cartridge to the needle hub 21 as discussed further below.

10

15

The needle retainer 20 is axially displaceable within barrel 30 to facilitate needle retraction. The needle retainer 20 can be molded out of a rigid, high strength resin, such as polycarbonate. Prior to retraction, the needle retainer 20 is maintained in a fixed axial position while the medication 59 is expelled from the cartridge 50. After the injection, the needle retainer 20 and the attached needle 12 are displaced rearwardly by the compression spring 26.

20

25

The spring 26 is a compression spring and may be formed of stainless steel, treated carbon steel wire or other suitable non-corrosive spring metal. The residual compression of the spring prior to disengagement of the needle retainer is of sufficient magnitude to facilitate complete needle retraction and overcome the frictional resistance between sliding components within the device 10.

30

WO 02/072171

PCT/US02/07712

-9-

Referring now to Fig. 6, the needle retainer 20 includes a pair of retaining arms 22 that extend radially outwardly and forwardly from the distal end of the needle retainer 20. During operation, the needle retainer 20 is operable between a locked position and an unlocked position. In the locked position, the retaining arms 22 engage the retaining apertures 38 in the barrel wall to maintain the needle in a fixed axial position with the forward tip 16 of needle 12 projecting forwardly from the barrel 30. More specifically, in the locked position, the retaining arms 22 engage the barrel 30 to hold the needle hub 21 and needle 12 against the rearward bias of the spring 26. In the unlocked position, the retaining arms 22 are positioned so as to allow the needle hub 21 and needle 12 to be retracted rearwardly. More specifically, in the unlocked position, the retaining arms 22 are disengaged from the retaining apertures 38, allowing the spring 26 to propel the needle hub 21 and needle 12 rearwardly.

As discussed above, the retaining arms 22 on the needle retainer 20 project forwardly and outwardly into engagement with the retaining apertures 38 in the wall of the barrel 30. The terminal end of each arm forms a retaining tab 24 that is configured to project into a retaining aperture 38. More specifically, the retaining tabs 24 engage the lip formed by each retaining aperture 38 in the wall of the barrel 30. In this way, the retaining tabs 24 operate as a pair of latches to retain the needle hub 21 and needle 12 against the rearward bias of the spring.

Referring again to Figs. 4 and 5, the cartridge 50 is a generally cylindrical vessel that may be molded out of pharmaceutical quality glass such as borosilicate, or a rigid inert plastic such as polyolefin or polyester. The midwall 60 that separates the first and second chambers may be formed of a rigid inert plastic such as polyolefin or polyester. The barrier or midwall 60 can be molded as part of the cartridge 50 or bonded to the inside wall of the cartridge. Each chamber is filled with a predetermined amount of a

WO 02/072171

PCT/US02/07712

-10-

medication during manufacturing of the device **10**.

The front end of the forward chamber **56** is sealed by an elastomeric front seal **80**, which may be molded in a self-sealing
5 biocompatible elastomer such as polyisoprene. The front seal **80** is generally cylindrical, having a plurality of axially-spaced circumferential ribs **81**. The ribs **81**, which are more clearly shown in Fig. 2, frictionally and sealingly engage the interior of the container to provide a fluid tight seal, thereby preventing fluid from leaking from the cartridge **50**. The front seal **80** also has
10 a front end that is pierceable by the rearward sharpened tip **14** of needle **12**. After being pierced, the front end of the front seal **80** reseals around the needle **12** to prevent fluid from leaking from the cartridge **50**.

Referring now to Figs. 5 and 6, the front seal **80** has a socket **82**
15 configured to cooperate with the barbed connector **25** on the needle hub **21**. The socket **82** includes two radially relieved recesses, **82a** and **82b**, that mate with the barbed connector **25**. Specifically, the barbed connector **25** matingly engages the front seal **80** in a first position and a second position.

20 In the first position, the barbed connector **25** engages the first recess **82a**, as shown in Fig. 5. In this position, the cartridge is attached to the hub, but the rearward end of the needle does not pierce the front seal **80**. Applying pressure to the plunger **40** displaces the cartridge forwardly relative to the hub, thereby displacing the barb into to the second position. In the
25 second position, the barbed connector **25** engages the second recess **82b**, as shown in Fig. 6. In this position, the rearward end of the needle **12** pierces the front seal **80**.

The front seal **80** includes a hollowed cavity **84** at its rearward
30 end. In this way, a pierceable wall **86** is formed in the front seal **80** between the cavity **84** and the second recess **82b**. As shown in Fig. 5 prior to use, the

WO 02/072171

PCT/US02/07712

-11-

cartridge 50 is mounted in the first position so that the barbed connector 25 engages the first recess 82a. In this position, the needle 12 does not penetrate the pierceable wall 86. As the hub 21 is displaced from the first position to the second position, the rearward end 14 of the needle 12 pierces the wall 86 and extends into the cavity 84 as shown in Fig. 6. The cavity 84 opens into the interior of the second chamber 56 of cartridge 50 so that when the needle 12 projects into the hollowed section 84, the needle is in fluid communication with the interior of the cartridge. After the needle 12 penetrates the pierceable wall 86, the wall reseals around the needle to form a fluid-tight seal and prevent medication in the cartridge 50 from leaking around the needle.

To prepare the injection device 10 for use, the medical professional displaces the cartridge 50 forwardly relative to the needle retainer 20, so that the forward seal 80 is driven over the barbed connector 25, such that the barbed connector engages the second recess 82b. At the same time, the proximal tip 14 of needle 12 pierces the pierceable wall 86, so that the needle is in fluid communication with the second chamber, as shown in Fig. 6.

The connection between the front seal 80 and the needle hub 21 is preferably a one-way engagement. In other words, when the front seal 80 is mounted on the barbed connector 25, the cartridge 50 can be displaced forwardly relative to the barbed connector, but the cartridge cannot be displaced rearwardly relative to the barbed connector. In this way, the cartridge 50 cannot be readily removed from the needle hub 21 in barrel 30, such that the cartridge is substantially permanently attached to the needle hub and barrel.

The one-way connection is facilitated by the rearward-facing tapered shoulder of the barbed connector 25 and the square shaped forward-

WO 02/072171

PCT/US02/07712

-12-

facing shoulder of the barbed connector. In particular, the rearward-facing shoulder of the barbed connector **25** cooperates with tapered sides in the first and second radial recesses **82a** and **82b** to permit relative displacement of the plug from the first recess to the second recess. Reverse displacement from the second recess **82b** back to the first recess **82a** is resisted by the square shaped forward-facing shoulders on barbed connector **25**, which act to impede reverse displacement.

Referring now to Fig. 4, the front seal **80** is configured to prevent ejection of fluid when the barbed connector **25** is displaced from the first position, in which the barbed connector **25** engages the first radial recess **82a**, to the second position, in which the barbed connector engages the second radial recess **82b**. Specifically, the front seal **80** includes a flared head **88** or circumferential flange at the forward end of the front seal. The open distal end of the cartridge **50** terminates with a beaded rim **51** that seats against the rearward edge of the flared head **88**. The outside diameter of the flared head **88** is greater than the inside diameter of the open distal end of the cartridge **50**, thereby impeding rearward displacement of the front seal **80** into the cartridge when force is initially applied to the plunger **40**. In addition, the force required to overcome the frictional engagement between the outer circumference of the front seal **80** and the inner wall of the cartridge **50** is greater than the force required to displace the plug **25** from the first recess **82a** to the second recess **82b**. Accordingly, when force is initially applied to the plunger **40**, the front seal **80** remains in a fixed position relative to the cartridge **50**, while the barbed connector **25** is displaced into the second position. This restriction on the front seal **80** limits the release of fluid from the cartridge **50** when the needle **12** pierces the wall **86**.

During storage of the injection device **10**, the medication is divided into two separate components stored in the cartridge **50**, as shown in Fig. 5. Specifically, a first component **54** of the medicine is stored in the rear

WO 02/072171

PCT/US02/07712

-13-

chamber 52 and a second component 58 of the medicine is stored in the forward chamber 56. The two chambers are separated by the mid-wall 60 containing an orifice 62 and a hollow piercing member 64 mounted in the orifice. The orifice 62 is located axially at the center of the midwall 60. In addition, a small vent hole 63 is located just off center in the midwall 60 to vent the air from the dead space area between the mid wall and the mid seal 70. Preferably, the piercing member 64 is fabricated out of suitable non-corrosive material such as stainless steel or treated carbon steel wire. When the plunger 40 is axially advanced in the cartridge 50, the first component 54 in the rear chamber 52 advances through the piercing member 64 and into the forward chamber 56 to combine with the second component 58.

Prior to use of the injection device 10, fluid communication between the first and second chambers is prevented by an elastomeric mid seal 70, which may be molded in a self-sealing biocompatible elastomer such as polyisoprene. The mid seal 70 is initially slidably disposed in the first chamber 52 between the piercing member 64 and the first component 54, as shown in Figs. 4-5. The mid seal 70 is generally cylindrical, having a plurality of axially-spaced circumferential ribs 71, as shown more clearly in Fig. 2. The ribs 71 frictionally and sealingly engage the inner wall of the cartridge 50 to provide a fluid-tight seal. This fluid-tight seal prevents fluid in the first chamber from entering the piercing member 64. The mid seal 70 also includes a hollowed section 72 formed in the forward end of the mid seal that opens to the first chamber 52 at the rearward end of the mid seal. The forward end of the mid seal 70 is closed by a membrane 78 that is pierceable by the piercing member 64. Upon piercing the membrane 78, fluid communication is established between the first and second chambers to allow the first and second components of the medication to be mixed.

Like the front seal 80 and mid seal 70, the plunger 40 is generally cylindrical, preferably having a plurality of axially-spaced

WO 02/072171

PCT/US02/07712

-14-

circumferential ribs 41. The plunger 40 may be molded in a self-sealing biocompatible elastomer such as polyisoprene. Alternatively, the plunger 40 could be a two-part assembly in which a cylindrical elastomeric seal is mounted to a rigid plastic plunger rod. The ribs 41, which are more clearly shown in Fig. 2, frictionally and sealingly engage the interior of the cartridge 50 to provide a fluid tight seal, thereby preventing fluid from leaking from the proximal end of the cartridge.

The plunger 40 is slidable within the first chamber 52 in response to pressure applied to the thumb pad 42. When the plunger 40 is axially advanced into the cartridge 50, the first component 54 is compressed against the rearward end of the mid seal 70 in the first chamber 52. As back pressure on the mid seal 70 overcomes the frictional resistance between the mid seal and the cartridge 50, the mid seal is displaced into the piercing member 64 until the membrane 78 is pierced, as shown in Fig. 6. As the mid seal advances, air from the space between the mid seal and mid wall vents through the vent hole 63 in the mid wall. At such time, the piercing member 64 penetrates through the hollowed section 72 to connect the first chamber 52 and second chamber 56 in fluid communication.

After the mid seal 70 is pierced, pressure applied to the plunger 40 advances the first component 54 through the piercing member 64 and into the second chamber 56 where the first and second components are subsequently mixed to form the medication 59. The plunger 40 is displaced forwardly relative to the first chamber 52 until the flanged portion of the thumb pad 42 contacts the proximal end of the cartridge 50, as shown in Fig. 7. The outside diameter of the thumb pad 42 is larger than the inside diameter of the cartridge 50, thereby preventing further displacement of the plunger 40 once the thumb pad contacts the proximal end of the cartridge 50. Preferably, the distance between the forward end of the plunger 40 and the rearward end of the mid seal 70 is equal to the distance between the flanged portion of the

WO 02/072171

PCT/US02/07712

-15-

thumb pad **42** and the proximal end of the cartridge **50**. Once the thumb pad **42** contacts the proximal end of the cartridge **50**, the plunger is fixed relative to the cartridge **50**. At this point, axial advancement of the cartridge **50** relative to the barrel **30** is restricted, as described in more detail below.

5

Preferably, the injection device **10** includes a locking mechanism for preventing accidental release of the contents in the second chamber prior to mixing the two components. In the present embodiment shown in Fig. 7, the barrel **30** includes a locking clip **100** in the barrel wall to prevent accidental discharge of the medicinal components. The wall of the barrel **30** includes a pair of radial slots **104** formed in a plane that is transverse the longitudinal axis of the barrel. When the locking clip **100** is inserted through the slots **104**, the clip prevents inadvertent forward displacement of the cartridge **50** relative to the front seal **80**, thereby preventing accidental advancement of the medicinal components through the needle **12**. The locking clip **100** is preferably formed of a resilient high strength and high modulus resin, such as acetyl or polycarbonate, and is configured to releasably engage the slots **104** in the barrel **30**.

10

15

20

Referring to Figs. 1-3, the locking clip **100** is preferably a flat member having a pair of resiliently deflectable legs **101** that join to form a U-shape. The open end of the locking clip **100** has tapered edges **102** that allow the legs **101** to deflect outwardly as the locking clip **100** is inserted into the sidewall of the barrel **30**. In addition, the locking clip **100** has a plurality of teeth **103** on the inside edge of the legs **101** that are adapted to engage the edges of radial slots **104**.

25

As the locking clip is inserted into the sidewall of the barrel **30**, the legs **101** deflect outwardly to allow the teeth **103** to clear the edges of radial slots **104**. Upon being deflected outwardly, the resilience of legs **101** bias the legs radially inwardly toward their original position. Once the teeth

30

WO 02/072171

PCT/US02/07712

-16-

103 are disposed within the slots 104, the legs 101 deflect radially inwardly toward their original position and releasably engage the outer edges of the needle retainer 20 in barrel 30. In the inserted position, the closed end of the locking clip 100 remains outside the barrel 30, as shown in Figs. 1 and 4.

5

After the medicinal components are mixed within the cartridge, the locking clip 100 is removed to permit injection of the medicine 59, as shown in Fig. 8. The locking clip 100 is removed from the barrel 30 by pulling the closed end of the clip in a direction transverse to the longitudinal axis of the barrel. This direction is marked "A" in Fig. 1. By pulling the clip in this manner, the legs 101 are deflected outwardly from the slots 104 to allow the teeth 103 to clear the edges of slots 104.

10

15

After the locking clip 100 is removed from the barrel 30, the medication 59 is injected into the patient by advancing the cartridge forwardly into the barrel. Pressure applied to the thumb pad 42 causes the plunger 40 and cartridge 50 to move forwardly relative to the barrel 30. With the barbed connector 25 mounted in the second recess 82b in the front seal 80, the front seal remains stationary while the cartridge 50 is advanced forwardly, as shown in Fig. 9. The front seal 80 and flared head 88 are configured to form a sliding fit with the interior of the cartridge 50 so that the cartridge can slide over the front seal. As the cartridge 50 is advanced, the mid seal 70 and the mid wall 60 are displaced toward the front seal 80. This causes a reduction of volume in the second chamber 56, whereby the medication is displaced into the needle to facilitate the injection. At the completion of the injection, the mid wall 60 bears against the rearward end of the front seal 80, as shown in Fig. 9.

20

25

30

Referring now to Figs. 9-10, the automatic retraction of the needle 12 shall be described. The cartridge 50 is axially advanced to the

WO 02/072171

PCT/US02/07712

-17-

proximal end of the barrel 30 until the medication 59 is completely expelled from the second chamber 56. As the cartridge 50 is advanced, the beaded circumferential rim 51 of the cartridge is displaced into engagement with the retaining arms 22 of needle retainer 20. Preferably, the cartridge 50 is
5 configured so that the longitudinal distance between the rearward end of the front seal 80 and the mid wall 60 corresponds to the longitudinal distance between the circumferential rim 51 of the cartridge and the retaining arms 22 when the cartridge is mounted on the barbed connector 25 in the second
10 position. In this way, the rim 51 of the cartridge 50 engages the retaining arms 22 when substantially all of the medication 59 is expelled from the device 10.

After the rim 51 of cartridge 50 engages the retaining arms 22, continued axial advancement of the cartridge deflects the retaining arms
15 radially inwardly so that the retaining tabs 24 are displaced inwardly, as shown in Fig. 9. In the inward position, the retaining tabs 24 are disengaged from the retaining apertures 38 of the barrel 30. In this way, the cartridge 50 operates as an actuator, such that axial advancement of the cartridge displaces the needle retainer 20 into an unlocked position. In the unlocked
20 position, the needle retainer 20 is no longer locked in place against the force of the spring 26. After the needle retainer 20 is in the unlocked position and the user releases pressure on the plunger 40, the spring 26 propels the needle 12 rearwardly until the sharpened distal tip 16 of the needle is enclosed within the barrel 30.

As shown in Fig. 10, when the needle 12 is retracted, the needle, needle retainer 20 and cartridge 50 are displaced rearwardly together. During retraction, the retaining arms 22 are biased radially
25 outwardly so that the retaining tabs 24 ride along the inside wall of the barrel. The force of the spring 26 is sufficiently strong to overcome the frictional
30 resistance generated between the guide arms 28 and the barrel 30.

WO 02/072171

PCT/US02/07712

-18-

Preferably, the injection device **10** includes a mechanism for limiting rearward displacement of the retracted elements. Referring now to Figs. 2, 4 and 10, the needle retainer **20** includes a pair of guide arms **28** that cooperate with a pair of alignment channels or grooves **31** formed in the interior wall of the barrel **30**. The guide arms **28** may be molded out of a rigid, resilient high strength resin, such as polycarbonate. The guide arms **28** extend forwardly from the needle retainer **20** and project radially outwardly into engagement with the alignment grooves **31**.

Each guide arm **28** includes a linear elongated rear portion which preferably is generally parallel to the longitudinal axis of barrel **30**. The forward portion of each guide arm **28** bends outwardly transverse to the longitudinal axis of the barrel **30** and extends into one of the alignment grooves **31**. When the needle retainer **20** is disposed within the barrel, the guide arms **28** are deflected radially inwardly from their natural state. In this position, the guide arms **28** are biased radially outwardly against the inner wall of the barrel **30** due to the resilient properties of the guide arms.

The forward ends of guide arms **28** are preferably contained within the alignment grooves **31** to substantially limit rotation of the needle and needle retainer **20** during needle retraction. This engagement ensures that the guide arms are aligned with the lockout windows **39** so that the guide arms snap into the lockout windows at the end of retraction. In this way, the needle retainer **20** is limited to axial displacement during needle retraction. During retraction, the frictional resistance between the forward ends of the guide arms **28** and the inside wall of the barrel **30** is overcome by the expansion force of the spring **26**.

As shown in Fig. 4, the linear elongated rear portion of each guide arm **28** is spaced radially inwardly from the inner wall of the barrel **30** to create a clearance space between the linear portion of the guide arms and

WO 02/072171

PCT/US02/07712

-19-

the barrel. Preferably, the minimum radial thickness of the clearance space is greater than the thickness of the wall of the cartridge 50 or the cartridge rim 51. In this way, when the cartridge 50 is advanced forwardly to disengage the retaining arms 22, advancement of the cartridge will not be impeded by the guide arms 28.

Each alignment groove 31 is substantially parallel to the longitudinal axis of the barrel 30. In Fig. 4, the groove 31 is shown extending to rearward end of the barrel. However, it may be desirable to terminate the groove forward of the rearward end of the barrel. The rearward portion of each alignment groove 31 intersects a lockout window 39 formed in the wall of the barrel 30. The lockout windows 39 are adapted to receive the forward ends of the guide arms 28, as shown in Fig. 10. In particular, as the front end of each guide arm 28 aligns with the corresponding lockout window 39 during needle retraction, the radially outward bias of the guide arm displaces the arm outwardly so that the forward end projects into the lockout window. The engagement between the guide arms 28 and lockout windows 39 prevent further axial movement of the retainer 22. As a result, the retracted elements are limited from further displacement in the forward or rearward direction.

Preferably, the injection device 10 includes a mechanism to limit tampering or removal of the cartridge 50 from the barrel socket 34. Referring now to Fig. 11, the present embodiment includes an annular lip 35 that projects radially inwardly from the inside wall of the socket 34 in barrel 30. The lip 35 is adapted to seat against the beaded rim 51 on the cartridge 50 so that the cartridge can not be easily pulled out of the rear of the barrel 30. As a result, access to the retracted elements, and the contaminated needle in particular, is limited.

Referring now to Figs. 4-10, the operation of the injection device

WO 02/072171

PCT/US02/07712

-20-

10 will be described. Prior to use, the needle 12 is disposed in an extended position so that the distal end 16 of the needle projects forwardly from the barrel 30, as shown in Fig. 4. Preferably, the device 10 is shipped with the cartridge 50 already mounted in barrel 30 so that the barbed connector 25 is engaged in the first recess 82a. Alternatively, the cartridge 50 may be shipped separately from the barrel 30, so that the cartridge must be attached to the barrel prior to use.

With the cartridge 50 and barrel 30 assembled, the device 10 is held vertically so that the distal end 16 of needle 12 points upwardwardly. The user holds the device 10 by placing the user's thumb in a supporting position beneath the thumb pad 42 of plunger 40. In addition, the user places a finger over each finger grip 36 to control the operation of the device 10. With the user's fingers anchored over the finger grips 36, the user applies a slight squeezing pressure on the thumb pad 42, much like a conventional syringe. The squeezing pressure displaces the cartridge 50 forwardly relative to the barrel so that the barbed connector 25 on the needle retainer 20 engages the second recess 82b in front seal 80 and the needle 12 pierces the wall 86. As the front seal 80 is pierced, entrapped air in the forward chamber 56 is vented through needle 12.

Continued advancement of the plunger 40 drives the seal 70 toward the piercing element 64 until the piercing element pierces the mid seal, thereby providing fluid communication between the forward and rearward chambers 52, 56. At this point, the first component 54 may be advanced into the forward chamber 56. Pressure is applied on the thumb pad 42 until the first component 54 is completely expelled from the rearward chamber 52 into the forward chamber 56 and the forward end of the plunger meets the rearward end of the mid seal 70. The user then shakes the injector device 10 to mix the first and second components 54, 58 inside the forward chamber 56.

WO 02/072171

PCT/US02/07712

-21-

During mixing, the locking clip **100** prevents the cartridge **50** from being advanced forwardly into the needle retainer **20**. This constraint on the cartridge **50** limits the potential for inadvertent discharge of the medication **59** from the needle **12** and premature needle retraction. Once the medication **59** is adequately mixed, the user removes the locking clip **100** from the barrel **30** so that the cartridge **50** can be advanced forwardly within the barrel. At this point, initial pressure applied to the thumb pad **42** advances the cartridge and vents excess air out of the second chamber **56**.

The needle is then inserted into a patient and the plunger **40** is depressed to axially advance the cartridge **50** relative to the barrel **30**, thereby injecting the medication **59** from the cartridge into the patient. At the end of the injection stroke, the beaded rim **51** on the cartridge **50** engages the retaining arms **22**, thereby displacing the retaining tabs **24** radially inwardly to disengage the needle retainer **20** into the unlocked position. Although the needle retainer **22** is in the unlocked position, the needle **12** does not retract until the user releases pressure from the thumb pad **42**. In this way, the user can retain pressure on the thumb pad **42** until after the needle is withdrawn from the patient. The user can then release pressure from the thumb pad **42** so that the needle is propelled rearwardly by the spring **26**. Alternatively, the user can release pressure from the thumb pad **42** while the needle **12** is still inserted in the patient. Once the thumb pad **42** is released, the spring **26** propels the needle **12** rearwardly so that the contaminated distal tip **16** of the needle is enclosed within the barrel **30**.

Referring now to Figs. 12-16 in general, and to Figs. 12-13 specifically, a second embodiment of a pre-filled safety diluent injector is shown. The injector device **110** includes elements that are substantially similar to the elements described above in connection with the first embodiment 10, illustrated in Figs. 1-11. These elements include: a double-ended needle **112**, a generally cylindrical barrel **130**, a compression spring

WO 02/072171

PCT/US02/07712

-22-

126, a needle retainer 120 releasably retaining the needle against the bias of the spring, a locking clip 200. The needle 112 has a sharpened proximal tip 114 and a sharpened distal tip 116. The spring 126 circumscribes the needle 112 and is compressed against the interior of the barrel 130 at the barrel's forward end. The rearward end of the spring 126 bears against the interior of the needle retainer 120 to bias the needle 112 and needle retainer in the rearward direction.

In contrast to the previous embodiment, the second embodiment utilizes a cartridge 150 having a selectively sealable by-pass fluid passage 160 to separate the two medicinal components, rather than a mid wall and a pierceable seal as described above with the first embodiment. Prior to use, a mid seal 170 within the cartridge 150 separates the two medicinal components 154, 158. Prior to use, the mid seal 170 is displaced forwardly adjacent the by-pass passage 160, which provides a fluid passage, allowing the two medicinal components 154, 158 to be mixed. The mixed components can then be injected into the patient.

Referring to Figs. 12, 13, the detail of the Cartridge 150 will be described in greater detail. The cartridge is a generally cylindrical container. The forward end of the cartridge is sealed by the pierceable forward seal 180. The rearward end of the cartridge is sealed by a piston 143 that forms a fluid-tight seal with the interior wall of the cartridge. Intermediate the forward seal 180 and the piston 143, a mid seal 170 forms a fluid-tight seal with the interior wall of the cartridge, separating the cartridge into two chambers, a forward chamber 156 for receiving a first component 158, and a rearward chamber 152 for receiving a second component 154.

The cartridge 150 includes a bubble-like fluid passage 160 that protrudes outwardly from the side of the cartridge. The fluid passage 160 forms an area in which the diameter of the cartridge is greater than the

WO 02/072171

PCT/US02/07712

-23-

diameter of the mid seal. The fluid passage 160 is an axially elongated channel having a length that is greater than the axial length of the mid seal 170, and preferably, is shorter than the combined length of the mid seal and the piston 143.

5

Although the fluid passage 160 is illustrated as a bubble-like protrusion, the fluid passage may be formed in other configurations. For instance, the fluid passage may be a recess or axial groove formed in the interior wall of the cartridge 150, so that the fluid passage does not protrude from the exterior surface of the cartridge. Similarly, the fluid passage may be an annular recess formed in the interior wall of the cartridge.

10

Referring to Fig. 12, the device 110 is illustrated in a "storage" position. In this position, the mid seal 170 prevents the two medicinal components from mixing. Therefore, the sealed cartridge 150 can be stored for an extended period, if desired, without compromising the efficacy of the medicinal components. In the stored position, the mid seal 170 is disposed rearwardly of the fluid passage 160 so a fluid-tight seal is formed between the mid seal and the interior wall of the cartridge, around the entire circumference of the mid seal.

15

20

During storage of the injection device 110, the medication is divided into two separate components stored in the cartridge 150, as shown in Figs. 12-13. Specifically, the first component 154 of the medicine is stored in the first chamber 152 and the second component 158 of the medicine is stored in the second chamber 156. As discussed further below, preferably, when the cartridge is being filled during manufacture, a quantity of air remains within the second chamber 156.

25

30

A plunger 140 is slidably disposed in the rearward end of the cartridge 150. The plunger 140 is comprised of a plastic molded plunger rod

WO 02/072171

PCT/US02/07712

-24-

141 and an elastomeric piston 143. The piston 143 forms a fluid-tight seal with the inner wall of the cartridge, and is slidably displaceable within the cartridge. The plunger rod 141 can be connected to the plunger seal 143 in a number of ways. In the present embodiment, the plunger rod 141 includes
5 external screw threads that are configured to engage internal threads inside the plunger seal 143, whereby the plunger rod and seal can be screwed together.

Referring now to Fig. 14, the transfer of the first medicine
10 component 154 into the second chamber 156 shall be described. The mid seal 170 is advanced axially until it registers with the fluid passage 160. The fluid passage 160 then provides a by-pass passage so that the component in the rearward chamber can be injected into the forward chamber. Since the forward chamber preferably includes a quantity of air (or other compressible
15 fluid), the material in the forward chamber can be compressed to allow the mid seal to be advanced into registry with the fluid passage 160. Alternatively, the forward chamber may include a vent for venting the air from the forward chamber when the fluid is transferred from the rearward chamber into the forward chamber. If a vent is included, preferably the vent is sealable
20 to prevent leakage of the mixed components during injection.

Specifically, to mix the two components in the cartridge, the
plunger 140 is axially advanced into the cartridge 150, to compress the first
25 component 154 against the rearward end of the mid seal 170 in the first chamber 152. As back pressure on the mid seal 170 overcomes the frictional resistance between the mid seal and the cartridge 150, the mid seal is displaced forwardly in the cartridge. Once the mid seal 170 is displaced into alignment with the fluid passage 160, a passage is created between the mid seal and the inside wall of the fluid passage, as shown in Fig. 14.

30

The fluid passage 160 is sufficiently large to allow the first

WO 02/072171

PCT/US02/07712

-25-

substance **154** to flow around the mid seal and into the second chamber **156** where it is mixed with the second substance **158**. Once the first component is completely transferred to the second chamber **156**, the plunger seal **143** is advanced until it abuts the mid seal **170**, as shown in Fig. 15. The combined
5 axial length of the mid seal **170** and piston **143** is slightly longer than the length of the fluid passage **160**. Therefore, the mid seal and piston seal off the entire length of the fluid passage. This prevents the contents of the second chamber **156** from backflowing during mixing of the components.

10 After mixing of the components is completed, the locking clip **200** is removed to allow injection of the medication into the patient. Pressure is applied to the cartridge **150** to discharge the medication from the second chamber **156**. At the completion of the injection stroke, the cartridge **150** actuates the needle retainer **120**. Pressure on the cartridge **150** is then
15 released so that the needle can be retracted, as shown in Fig. 16.

Referring now to Figs. 17-23 in general, and to Fig. 17 specifically, another embodiment of a pre-filled safety diluent injector is designated generally **210**. The injector device **210** includes a double-ended
20 needle **212**, a generally cylindrical barrel **230** that houses the needle and a generally cylindrical cartridge **250**. The barrel **230** further includes a compression spring **226** and a needle retainer **220** releasably retaining the needle **212** against the bias of the spring. The needle **212** has a sharpened rearward tip **214** and a sharpened forward tip **216**. The spring **226**
25 circumscribes the needle **212** and is compressed against the interior of the barrel **230** at the barrel's forward end. The rearward end of the spring **226** bears against the interior of the needle retainer **220** to bias the needle **212** and needle retainer in the rearward direction.

30 In this embodiment, the transferring and mixing of the medication components is done in the cartridge **250** prior to attaching the

WO 02/072171

PCT/US02/07712

-26-

cartridge to the needle hub 221. Since the cartridge 250 is not connected to the needle assembly during mixing, there is no risk of inadvertently retracting the needle during the mixture of the components. As a result, the barrel does not include a locking clip, as in the other embodiments.

5

Referring now to Figs. 18-19, the cartridge 250 and barrel 230 are packaged and distributed so that the two are disassembled. The cartridge 250 is a generally cylindrical vessel that may be molded out of pharmaceutical quality glass such as borosilicate or a rigid inert plastic such as polyolefin or polyester. A cartridge cap 253 is disposed over the distal end of the cartridge 250. The cartridge 250 is configured similar to the cartridge 150 illustrated in Figs. 12 - 16, and includes a bubble-like fluid passage 260 that protrudes outwardly from the side of the cartridge. A mid seal 270 is slidably disposed in the cartridge 250 and divides the cartridge into a first chamber 252 and a second chamber 256. Each chamber of cartridge 250 is filled with a predetermined amount of a component of medication during manufacturing of the device 210. In particular, the first chamber 252 is prefilled with a first component 254 of the medication and the second chamber 256 is prefilled with a second component 258.

10
15
20

Referring now to Fig. 20, a plunger 240 is slidably disposed in the proximal end of the cartridge 250. The plunger 240 is comprised of a plastic molded plunger rod 241 and an elastomeric plunger seal 243. When the plunger 240 is axially advanced into the cartridge 250, the first component 254 is compressed against the rearward end of the mid seal 270 in the first chamber 252. As back pressure on the mid seal 270 overcomes the frictional resistance between the mid seal and the cartridge 250, the mid seal is displaced forwardly in the cartridge. Once the mid seal 270 is displaced into alignment with the fluid passage 260, a passage is created between the mid seal and the inside wall of the fluid passage to allow the first substance 254 to flow around the mid seal and into the second chamber 256 where it is mixed

25

30

WO 02/072171

PCT/US02/07712

-27-

with the second substance **258**.

5 The fluid passage **260** is sufficiently long to allow the first substance **254** to flow around the mid seal and into the second chamber **256** where it is mixed with the second substance **258**. Once the first component is completely transferred to the second chamber **256**, the plunger seal **243** is advanced until it abuts the mid seal **270**, as shown in Fig. 21. The combined axial length of the mid seal **270** and plunger seal **243** is slightly longer than the maximum length of the fluid passage **260** so that the mid seal and plunger seal close off the entire length of the fluid passage. This prevents the contents of the second chamber **256** from backflowing during mixing of the components.

15 Referring again to Fig. 18, the cartridge **250** includes an elastomeric front seal **280** in the distal end of the cartridge. The front seal **280** may be molded of a self-sealing biocompatible elastomer such as polyisoprene. The front seal **280** is generally cylindrical with a wide cylindrical rearward end **282** disposed within the cartridge and a reduced diameter forward end **284** projecting forwardly from the forward end of the cartridge.

20 The rearward end **282** has an outside diameter that is similar to the inside diameter of the cartridge **250**. In addition, the rearward end **282** has a plurality of axially-spaced circumferential ribs **286** that frictionally and sealingly engage the interior of the cartridge to provide a fluid tight seal and prevent fluid from leaking from the cartridge.

25 The forward end **284** of front seal **280** includes an external thread **288** about its circumference. The distal end **284** also contains a shallow frontal cavity **290**. A narrow bore **292** in fluid connection with the second chamber **256** extends from the proximal end of the front seal **280** and terminates within the reduced diameter distal end **284**. Fluid communication between the frontal cavity **290** and the bore **292** is obstructed by a pierceable

30

WO 02/072171

PCT/US02/07712

-28-

membrane **294**.

Referring now to Fig. 19, the barrel **230** is generally cylindrical and has a tapered nose **232** at its distal end. The nose **232** has an opening through which the needle **212** extends. In addition, the nose **232** is configured to receive a needle cover **211** that fits over the nose to prevent accidental needle sticks when the needle **212** is in an extended position. The proximal end of the barrel **230** is open, forming a cylindrical socket **234** adapted to receive the cartridge **250**. Prior to attachment with the cartridge **250**, the rearward open end of the barrel **230** is closed by a cylindrical barrel cap **233**. The barrel further includes a pair of retaining apertures **238** that cooperate with the needle retainer **220** to releasably retain the needle, and a pair of lockout windows that cooperate with locking tabs to lock the needle in the retracted position.

The needle retainer **220** includes a generally cylindrical body **221** and a pair of retaining arms **222** that extend radially forwardly from the body **221**. A generally cylindrical aperture **296** is disposed within the proximal end of the needle retainer body **221**. The inner wall of the aperture **296** includes internal screw threads **298** that are adapted to receive the external screw thread **288** of the front seal **280** in the cartridge **250**.

The cartridge cap **253** and barrel cap **233** are removed from the cartridge **250** and barrel **230**, respectively, to prepare the cartridge and barrel for assembly. The cartridge **250** is connected to the barrel **230** by inserting the forward end of the front seal through the open end of the barrel **230** and screwing the cartridge clockwise into the aperture **296**. The frontal cavity **290** in the front seal **280** is preferably coaxial with the needle **212**, such that attachment of the cartridge **250** to the barrel **230** causes the proximal needle tip **214** to enter the cavity **290** and pierce the membrane **294**, thereby connecting the second chamber of the cartridge in fluid communication with

WO 02/072171

PCT/US02/07712

-29-

the needle **212**, as shown in Fig. 17.

Referring to Fig. 17, the cartridge **250** is connected to the barrel **230**, the medication can be injected into the patient by advancing the cartridge forwardly into the barrel. The proximal end of the front seal **280** is configured to form a sliding fit with the interior of the cartridge **250** so that the cartridge slides over the front seal during advancement of the cartridge. As the cartridge **250** is advanced, the rearward end of the front seal **280** bears against the needle retainer **220**, thereby keeping the front seal stationary during advancement of the cartridge. At the same time, the mid seal **270** at the rear of the second chamber **256** is displaced toward the front seal **280**. This causes a reduction of volume in the second chamber **256**, whereby the medication is displaced into the needle to facilitate the injection. At the completion of the injection, the mid seal **270** bears against the rearward end of the front seal **280**, as shown in Fig. 22.

As in the previous embodiments, the needle **212** is retracted by actuating the needle retainer **220**. In particular, the needle **212** is retracted by disengaging the retaining arms **222** from the retaining apertures **238** in the barrel wall to allow the spring **226** to propel the needle **212** rearwardly. To actuate the needle retainer **220**, pressure is applied to the cartridge **250** to advance the cartridge over the needle retainer body **221**, as shown in Fig. 22. During advancement, the distal end of the cartridge **250** engages a cylindrical sleeve **300** that is disposed around the distal end of the needle retainer body **221**. The inside and outside diameters of the release sleeve **300** are preferably equal to the inside and outside diameters of the cartridge **250** so that the distal end of the cartridge mates with the proximal end of the sleeve. Prior to engagement with the cartridge **250**, axial movement of the release sleeve **300** along the needle retainer is limited by an internal flange **302** that slides within an annular fluid passage **223** on the needle retainer body **221**. After the cartridge **250** engages the sleeve **300** continued advancement of

WO 02/072171

PCT/US02/07712

-30-

the cartridge drives the sleeve axially forwardly into engagement with the retaining arms 222. The release sleeve 300 deflects the retaining arms radially inwardly and out of engagement with the retaining apertures 238, allowing the spring 226 to propel the needle 212 rearwardly, as shown in Fig. 23.

As described above, the third embodiment includes a threaded engagement between the front seal 280 and the needle retainer 220 rather than a barbed connection as described in the first two embodiments. Using a threaded connection can increase the overall length of the needle retainer 220, which in turn increases the distance between the distal end of the cartridge 250 and the retaining arms 222. One manner for accommodating this increased length is to increase the length of the barrel 230. However, by incorporating the release sleeve 300, the length of the barrel 230 need not be substantially increased. The release sleeve 300 compensates for the increased distance by acting as an extension of the cartridge 250. This eliminates the need to increase the overall length of the device 210. Preferably, the length of the release sleeve 300 is slightly longer than the length of the threaded engagement between the front seal 280 and the needle retainer 220.

Referring now to Figs. 24-29 in general, and to Figs. 24-25 specifically, a fourth embodiment of a pre-filled safety diluent injector is shown. The injector device 310 includes a double-ended needle 312, a generally cylindrical barrel 330 that houses the needle and a generally cylindrical cartridge assembly 350 mounted within the proximal end of the barrel. Like the previous embodiments, the barrel further includes a compression spring 326 and a needle retainer 320 releasably retaining the needle 312 against the bias of the spring. The device 310 also includes a U-shaped locking clip 400 in the barrel wall to prevent accidental discharge of medication from the device 310.

WO 02/072171

PCT/US02/07712

-31-

The cartridge assembly 350 has a two-part design that offers the advantage of using cost-efficient plastic in the assembly. The cartridge assembly 350 includes a front cylinder 351 having an open proximal end and a rear cylinder 353 having an open distal end telescopically mounted to the proximal end of the front cylinder. The front cylinder 351 contains an internal wall 360 that divides the cartridge assembly 350 into a first chamber 352 and a second chamber 356. The first chamber 352 contains a predetermined amount of a first component 354 of medication, and the second chamber 356 contains a predetermined amount of a second component 358 of medication. The proximal end of the front cylinder 351 is closed by a pierceable elastomeric front seal 380.

In many applications, the second component 358 will be a dry powdered component. Dry components do not require a glass container and can be stored in plastic containers without jeopardizing long term stability of the component. Since it is more cost-efficient to mold complex parts out of plastic than glass, it is preferable to minimize the complexity of the glass portion of the cartridge assembly 350. To this end, the front and rear cylinders 351, 353 are configured so that the first component 354 is stored entirely within the rear cylinder and the second component 356 is stored entirely within the front cylinder. In this arrangement, the front cylinder 351 comprises a more complicated structure to allow the rear cylinder to be a simple cup-shaped container. Therefore, the more complex forward cylinder can be molded out of cost-efficient plastic for those devices that store a dry second component 358 in the second chamber 356. Preferably, glass is only used, if at all, to mold the rear cylinder 353.

As stated earlier, the rear cylinder 353 is telescopically mounted on the proximal end of the front cylinder 351. The outside diameter of the rear portion of the rear seal is generally equal to the inside diameter of the rear cylinder 353 so as to frictionally engage the interior of the rear cylinder

WO 02/072171

PCT/US02/07712

-32-

and provide a fluid tight seal. The rear cylinder **353** is adapted to slide axially over the rear seal **340** in response to pressure applied to the proximal end of the rear cylinder.

5 The barrel **330** has an inside diameter large enough to accommodate the outside diameter of the rear cylinder **353**. As a result, the outside wall of the front cylinder **351** is separated from the interior wall of barrel **330** by a clearance space, as shown in Fig. 25. The front cylinder **351** is maintained in a concentric relationship with the much larger barrel **330** by a pair of opposing longitudinal ribs **355** on the outside wall of the front cylinder. 10 The longitudinal ribs are illustrated in Fig. 24.

 An elastomeric rear seal **340** is disposed between the front cylinder **351** and rear cylinder **353**. The rear seal **340** includes a reduced diameter end **342** partially disposed in the open proximal end of the front cylinder **351**. The rear seal **340** also includes a flanged end **344** disposed 15 within the rear cylinder **353**. The reduced diameter end **342** and flanged end **344** frictionally and sealingly engage the interior of the front cylinder **352** and rear cylinder **354**, respectively. This engagement provides a fluid tight seal with the interior of both cylinders, while allowing the rear seal **340** to be 20 displaced relative to either cylinder. Forward advancement of the rear seal **340** relative to the front cylinder **351** is limited by the proximal end of the front cylinder, which is configured to matingly engage the flanged portion of the rear seal.

25 As stated earlier, the front cylinder **351** contains an internal wall **360**. The internal wall **360** is adjacent the rearward open end of the cartridge, forming a socket for receiving the rear seal **340**. The internal wall **360** contains an orifice **362** mounted in the center of the wall **360**. A hollow 30 piercing member **364** is mounted in the orifice and extends rearwardly toward the rear seal **340**. In addition, it may be desirable to provide a vent opening in

WO 02/072171

PCT/US02/07712

-33-

the internal wall **360** to vent the air between the rear seal **340** and the internal wall when the rear cylinder is advanced to pierce the rear seal.

5 The distal end of the rear seal **340** is closed by a membrane **348** that is configured to be pierced by piercing member **364**. The rear seal **340** includes a hollowed mid section **346** that is connected in fluid communication with the first chamber **352** through the proximal end of the rear seal. Once the membrane **348** is pierced, a fluid passage is created through the piercing member **364** and rear seal **340**, such that the first and second chambers, **352**, **356** are connected in fluid communication. The rear seal **340** may be molded in a high elongation self-sealing biocompatible elastomer, such as polyisoprene.

15 The operation of the device **310** will now be described. A slight squeezing pressure is applied to the proximal end of the rear cylinder **353** to axially advance the rear cylinder over the front cylinder **351**. This causes the first component **354** to become compressed between the rear seal **340** and the closed proximal end of the rear cylinder **353**. Continued pressure on the rear cylinder **353** creates back pressure on the rear seal **340** which axially displaces the rear seal forwardly into the piercing member **364**. At this time, the membrane **348** is pierced to create a fluid passage between the first and second chambers **352**, **356**.

25 The rear cylinder **353** is advanced forwardly relative to the front cylinder **351** to expel the first component **354** from the first chamber **352** into the second chamber **356**. Once the first component **354** is completely expelled from the first chamber **352**, additional pressure on the rear cylinder **353** advances the rear cylinder forwardly relative to the front cylinder **351** until the closed proximal end of the rear cylinder abuts the proximal end of the rear seal **340**, as shown in Fig. 26. At this point, the device **310** is shaken to mix the components within the second chamber **356**. During the mixing process,

30

WO 02/072171

PCT/US02/07712

-34-

displacement of the cartridge assembly 350 is prevented by the locking clip 400, thereby minimizing the potential for accidental discharge of the medication.

5 After the components are mixed, the locking clip 400 is removed. The cartridge assembly is then displaced forwardly so that the rearward end of the needle 312 pierces the forward seal 380. The air is then vented from the forward chamber. Further pressure is applied to the cartridge assembly 350 to discharge the medication from the second chamber 356 and through the needle 312. At the completion of the injection stroke, the proximal end of the cartridge assembly 350 actuates the needle retainer 320, as shown in Fig. 27. Pressure on the cartridge assembly 350 is then released so that the needle 312 can be retracted, as shown in Figs. 28 and 29.

15 In some instances, it may be desirable to store the cartridge in its component parts. In other words, the rear cylinder 353 may be detached from the forward cylinder 351. Prior to use, the rear cylinder 353 would be attached to the forward cylinder 351 and the combined assembly would be utilized as described above. In such instances, the separate rear container 20 353 may include a separate cap to cover its forward end. Similarly, the forward cylinder 351 may include a cap to cover its rearward end. The detachable rearward cylinder 353 may permit a variety of pre-measured medicinal components to be stored and readily combined in various combinations prior to use.

25 The terms and expressions which have been employed are used as terms of description and not of limitation. There is no intention in use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof. It is recognized, however, that 30 various modifications of the embodiments described herein are possible within the scope and spirit of the invention. For instance, the embodiments

WO 02/072171

PCT/US02/07712

-35-

described above include a needle retainer having a pair of radially
displaceable arms to automatically release the needle for retraction after use.
However, the devices may be modified by utilizing different needle retainers
that may or may not automatically retract the needle after use. Accordingly,
5 the invention incorporates variations that fall within the scope of the following
claims.

CLAIMS

1. A medical device, comprising:
 - a barrel having an open proximal end and a distal end;
 - a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
 - a cartridge in fluid communication with the needle, comprising:
 - a first chamber containing a first substance;
 - a second chamber containing a second substance;
 - a fluid flow controller between the first chamber and the second chamber; and
 - a plunger slidably disposed within the cartridge;
 - a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip; and
 - a needle retainer releasably retaining the needle in the extended position;

wherein axially advancing the plunger within the first chamber advances the first substance through the fluid flow controller and into the second chamber where said first substance combines with the second substance to form a medicinal mixture, and continued advancement of the plunger and cartridge relative to the barrel after the mixture is expelled from the cartridge actuates the needle retainer to release the needle, whereupon the biasing element displaces the needle relative to the barrel to shield the first sharpened tip.
2. The medical device in claim 1 wherein the medical device further comprises a needle carrier fixed to the needle.
3. The medical device in claim 1 wherein the needle has a second sharpened tip at its rearward end.

WO 02/072171

37

PCT/US02/07712

4. The medical device in claim 1 wherein the needle is retracted upon release of pressure on the plunger.
5. The medical device in claim 1 wherein the medical device further comprises one or more stops that impede continued rearward displacement of the first sharpened needle tip beyond the proximal end of the barrel as the needle is moved to the shielded position.
6. The medical device in claim 1 wherein the plunger is comprised of a plastic molded plunger rod connected to an elastomeric seal.
7. The medical device in claim 1 wherein the plunger is displaceable relative to the cartridge while the first substance is expelled from the first chamber, and the plunger is stationary relative to the cartridge when the mixture is expelled from the second chamber.
8. The medical device in claim 1 wherein the second substance is a powdered material.
9. The medical device in claim 1 wherein the second substance is a liquid material.
10. The medical device in claim 1 wherein the volume of the second chamber is greater than the combined volume of the first substance and the second substance.
11. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a wall between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending into the first chamber; and
 - a fluid flow pathway through the piercing element;wherein axially displacing the cartridge toward the barrel displaces the plunger until the plunger is ruptured by the piercing element,

creating a passage through the plunger which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the plunger into the second chamber.

12. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a barrier between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending into the first chamber;
 - a fluid flow pathway through the piercing element; and
 - a pierceable mid seal axially displaceable within the first chamber that provides fluid communication between the first and second chambers upon being pierced by the piercing element;wherein axially displacing the plunger toward the barrel displaces the pierceable mid seal until the mid seal is ruptured by the piercing element, creating a passage through the mid seal which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the mid seal into the second chamber.

13. The medical device in claim 1 wherein the fluid flow controller comprises:
 - a mid seal between the first and second chambers that is axially displaceable within the cartridge; and
 - an elongated fluid passage in the side wall of the cartridge;wherein axially displacing the plunger toward the barrel displaces the mid seal into alignment with the fluid passage, creating a passage between said mid seal and the inside wall of the fluid passage that allows the first substance to flow around the mid seal into the second chamber.

14. The medical device in claim 1 wherein the cartridge is substantially permanently attached to the barrel.

WO 02/072171

39

PCT/US02/07712

15. The medical device in claim 1 wherein the cartridge comprises a beaded circumferential rim on the distal end of the cartridge, and the barrel contains a lip projecting radially inwardly from the inner bore of the barrel at the barrel's proximal end, said lip adapted to engage the beaded rim of the cartridge to impede removal of the cartridge from the rear of the barrel after needle retraction.
16. The medical device in claim 2 wherein the biasing element comprises a compression spring disposed between the distal end of the barrel and the needle carrier.
17. The medical device in claim 2 wherein the needle retainer comprises a pair of forward tines extending radially outwardly from the needle carrier and configured to releasably engage a pair of windows in the barrel wall.
18. The medical device in claim 2 wherein a cylindrical sleeve having generally the same outside diameter as the cartridge is disposed around the circumference of the needle carrier in general axial alignment with the cartridge, such that axial advancement of the cartridge at the end of the injection stroke displaces the sleeve toward the distal end of the barrel to actuate the needle retainer.
19. The medical device in claim 3 wherein the cartridge further comprises a front seal at the distal end of the cartridge that is configured to be pierced by the second sharpened tip to connect the needle and second chamber in fluid communication.
20. The medical device in claim 19 wherein the minimum axial force on the plunger that is required to pierce the front seal is less than or equal to the minimum axial force required to axially displace the plunger in the rear chamber.
21. The medical device in claim 19 wherein the distal end of the front seal

WO 02/072171

40

PCT/US02/07712

includes an external thread and the proximal end of the needle carrier includes a cavity adapted to receive the threaded end of the front seal.

22. A medical device, comprising:
- a barrel having an open proximal end, a distal end and an opening through the barrel wall oriented perpendicularly to the longitudinal axis of the barrel;
 - a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
 - a cartridge in fluid communication with the needle, comprising:
 - a first chamber containing a first substance;
 - a second chamber containing a second substance;
 - a fluid flow controller connecting the first chamber and the second chamber; and
 - a plunger slidably disposed within the cartridge;
 - a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip;
 - a needle retainer releasably retaining the needle in the extended position; and
 - a locking clip detachably connected to the barrel;
- wherein axially advancing the plunger within the first chamber advances the first substance through the fluid flow controller and into the second chamber where said first substance combines with the second substance to form a medicinal mixture, and removal of the locking clip from the barrel permits further advancement of the plunger and cartridge relative to the barrel to expel the mixture from the second chamber, whereafter axially advancing the cartridge disengages the needle retainer to allow the biasing element to displace the needle relative to the barrel to shield the first sharpened tip.

WO 02/072171

41

PCT/US02/07712

23. The medical device in claim 22 wherein the medical device further comprises a needle carrier fixed to the needle.
24. The medical device in claim 22 wherein the needle has a second sharpened tip at its rearward end.
25. The medical device in claim 22 wherein the needle is retracted upon release of pressure on the plunger.
26. The medical device in claim 22 wherein the cartridge comprises a beaded circumferential rim on the distal end of the cartridge, and the barrel contains a lip projecting radially inwardly from the inner bore of the barrel at the barrel's proximal end, said lip adapted to engage the beaded rim of the cartridge to impede removal of the cartridge from the rear of the barrel after needle retraction.
27. The medical device in claim 22 wherein the medical device further comprises one or more stops that impede continued rearward displacement of the first sharpened tip beyond the open proximal end of the barrel as the needle is moved to the shielded position.
28. The medical device in claim 22 wherein the plunger is comprised of a plastic molded plunger rod connected to an elastomeric seal.
29. The medical device in claim 22 wherein the plunger is displaceable relative to the cartridge while the first substance is expelled from the first chamber, and the plunger is stationary relative to the cartridge when the mixture is expelled from the second chamber.
30. The medical device in claim 22 wherein the locking clip comprises a flat U-shaped disk having a plurality of teeth along the inner edge, said clip being configured to slide through the slits in the barrel in a direction perpendicular to the longitudinal axis of the barrel and at a location between the cartridge and the needle retainer, thereby impeding

contact between the cartridge and the needle retainer.

31. The medical device in claim 22 wherein the second substance is a powdered material.
32. The medical device in claim 22 wherein the second substance is a liquid material.
33. The medical device in claim 22 wherein the volume of the second chamber is greater than the combined volume of the first substance and the second substance.
34. The medical device in claim 22 wherein the fluid flow controller comprises:
 - a barrier between the first and second chambers having an opening;
 - a hollow piercing element disposed through the opening having a sharpened end extending within the first chamber;
 - a fluid flow pathway through the piercing element; and
 - a pierceable mid seal axially displaceable within the first chamber that provides fluid communication between the first and second chambers upon being pierced by the piercing element;wherein initial axial displacement of the plunger toward the barrel displaces the pierceable mid seal into contact with the piercing element, piercing the mid seal and creating a passage through the mid seal which aligns with the fluid flow pathway in the piercing element to allow the first substance to pass through the mid seal into the second chamber.
35. The medical device in claim 22 wherein the fluid flow controller comprises:
 - a mid seal between the first and second chambers that is axially displaceable within the cartridge; and
 - an elongated fluid passage in the side wall of the cartridge between the

WO 02/072171

43

PCT/US02/07712

- mid seal and the distal end of the cartridge;
wherein axially displacing the plunger toward the barrel displaces the mid seal into alignment with the fluid passage, creating a passage between said mid seal and the inside wall of the fluid passage that allows the first substance to flow around the mid seal into the second chamber.
36. The medical device in claim 23 wherein the biasing element comprises a compression spring disposed between the distal end of the barrel and the needle carrier.
37. The medical device in claim 23 wherein the needle retainer comprises a pair of forward windows in the barrel wall and a pair of forward tines extending radially outwardly from the needle carrier and configured to releasably engage the forward windows.
38. The medical device in claim 24 wherein the cartridge further comprises a front seal at the distal end of the cartridge that is configured to be pierced by the second sharpened tip to connect the needle and second chamber in fluid communication.
39. The medical device in claim 38 wherein the minimum axial force on the plunger that is required to pierce the front seal is less than or equal to the minimum axial force required to axially displace the plunger in the rear chamber.
40. A medical device, comprising:
a barrel having an open proximal end and a distal end;
a needle having a first sharpened tip and being operable between an extended position in which the first sharpened tip projects forwardly from the barrel and a shielded position in which the first sharpened tip is shielded to prevent inadvertent contact with the first sharpened tip;
a cartridge in fluid communication with the needle, comprising:

WO 02/072171

44

PCT/US02/07712

a first chamber containing a first substance;
a second chamber containing a second substance;
a fluid flow controller between the first chamber and the second chamber; and

a biasing element imparting a force capable of displacing the needle relative to the barrel to shield the first sharpened tip; and
a needle retainer releasably retaining the needle in the extended position;

wherein the fluid flow controller is adapted to keep the first and second substances separate prior to use, and also adapted to allow mixing of the first and second substances prior to an injection, wherein after use the needle is disposed in the shielded position.

41. A method for injecting medicine, comprising the steps of:
providing an injection device having a first chamber containing a first medicinal component, a second chamber containing a second medicinal component, and a needle;
transferring the first medicinal component from the first chamber to the second chamber;
mixing the first and second components to form a medicinal mixture;
expelling the medicinal mixture from the chamber; and
retracting the needle after expelling the medicinal fluid to shield the needle against contact.

WO 02/072171

PCT/US02/07712

1/18




Figure 1

SUBSTITUTE SHEET (RULE 26)

WO 02/072171

PCT/US02/07712

2/18




Figure 2




Figure 3

SUBSTITUTE SHEET (RULE 26)

WO 02/072171

PCT/US02/07712




Figure 4




Figure 5




Figure 6




Figure 7

WO 02/072171

PCT/US02/07712

5/18




Figure 8




Figure 9

SUBSTITUTE SHEET (RULE 26)

WO 02/072171

PCT/US02/07712





Figure 10

SUBSTITUTE SHEET (RULE 26)

Figure 11



WO 02/072171

PCT/US02/07712




Figure 12




Figure 13

WO 02/072171

PCT/US02/07712

9/18






Figure 16



WO 02/072171

PCT/US02/07712




Figure 17

SUBSTITUTE SHEET (RULE 26)

WO 02/072171

PCT/US02/07712




Figure 18




Figure 19

SUBSTITUTE SHEET (RULE 26)




Figure 20






Figure 21

WO 02/072171

PCT/US02/07712



SUBSTITUTE SHEET (RULE 26)

WO 02/072171

PCT/US02/07712




Figure 24




Figure 25




Figure 26

WO 02/072171

PCT/US02/07712

17/18




Figure 27

SUBSTITUTE SHEET (RULE 26)




Figure 28




Figure 29

【国際公開パンフレット(コレクション)】

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072171 A3


- (51) International Patent Classification: A61M 37/00
- (21) International Application Number: PCT/US02/07712
- (22) International Filing Date: 13 March 2002 (13.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/275,568 13 March 2001 (13.03.2001) US
- (71) Applicant (for all designated States except US): MDC INVESTMENT HOLDINGS INC. [US/US]; Suite 200, 900 Market Street, Wilmington, DE 19801 (US).
- (81) Designated States (national): AU, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GI, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TH, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KR, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, HU, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published: with international search report

- (72) Inventors: and
- (75) Inventors/Applicants (for US only): BARKER, John [US/US]; 155 Sunset View Court, Ventura, CA 93003 (US); HALSETH, Thor [US/US]; 159 Stonebrook Street, Simi Valley, CA 93065 (US); CHALLIOL, Bernardo [US/US]; 3031 Lana Drive, Ventura, CA 93003 (US); MCWETHY, Robert [US/US]; 1543 Daffodil Avenue, Ventura, CA 93004 (US); KOVALSKI, Joseph [US/US]; 1296 Martha's Vineyard Court, Ventura, CA 93001 (US).
- (88) Date of publication of the international search report: 30 October 2003
- (15) Information about Correction: Previous Correction: see PCT Gazette No. 44/2002 of 31 October 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PRE-FILLED SAFETY DILUENT INJECTOR



(57) Abstract: A safety needle-bearing device (10, 110, 210, 310) for mixing and injecting medication from a two-chambered cartridge (50, 150, 250, 350) is provided. The device includes a needle (12, 112, 212, 312) that extends through the forward end of a barrel (30, 130, 230, 330). The two-chambered cartridge (50, 150, 250, 350) is attached to the barrel (30, 130, 230, 330) and contains components of a medication stored separately in the chambers. A plunger (40, 140, 240) in the rearward end of the cartridge can be advanced into the cartridge to combine the separate components and prepare the medication. As the cartridge (50, 150, 250, 350) is advanced forwardly into the barrel (30, 130, 230, 330), the medication is injected through the needle (12, 112, 212, 312) and into a patient. At the completion of the injection stroke, the cartridge (50, 150, 250, 350) engages a needle retainer to actuate needle retraction. The needle is subsequently retracted to shield the contaminated needle.

WO 02/072171 A3

【 国際調査報告 】

INTERNATIONAL SEARCH REPORT		International application No. PCT/US02/07112
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) :A61M 37/00 US CL :904/82, 87 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 904/82-91, 282, 244 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,637,087 A (O'NEIL et al.) 10 June 1997, see abstract and Figures 1, 4 & 5.	1-3, 5-15, 18-24, 26, 28, 29, 31-35, 38-41
X	US 5,281,198 A (HABER et al.) 25 January 1994, see abstract and Figures 3-6.	1-3, 5-15, 18-24, 26, 28, 29, 31-35, 38-41
X	US 5,531,683 A (KRIESEL et al.) 02 July 1996, see Figure 25.	40 & 41.
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may have priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" Enter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search 22 JULY 2002		Date of mailing of the international search report 25 SEP 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 506-3230		Authorized officer ANH Tuan T. NGUYEN <i>Diane Smitt</i> Telephone No. 703-808-2154

フロントページの続き

(51) Int.Cl.⁷ F I テーマコード(参考)
A 6 1 J 3/00 3 1 4 C

(81) 指定国 AP(GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), EA(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), EP(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OA(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG), AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

(72) 発明者 パーカー、ジョン
アメリカ合衆国、 9 3 0 0 3 カリフォルニア州、ベヌトラ、サンセット ビュー コート 1 5
5

(72) 発明者 ハルセス、ソー
アメリカ合衆国、 9 3 0 6 5 カリフォルニア州、シミ ヴァレー、ストーンブルック ストリー
ト 1 5 9

(72) 発明者 シャリオル、ベルナルド
アメリカ合衆国、 9 3 0 0 3 カリフォルニア州、ベヌトラ、ルナ ドライブ 3 0 3 1

(72) 発明者 マクウェティー、ロバート
アメリカ合衆国、 9 3 0 0 4 カリフォルニア州、ベヌトラ、ダフォディル アベニュー 1 5 4
3

(72) 発明者 コバルスキー、ジョセフ
アメリカ合衆国、 9 3 0 0 1 カリフォルニア州、ベヌトラ、マーサズ ビネヤード コート 1
2 9 6

F ターム(参考) 4C066 AA09 BB01 CC01 DD07 GG05 GG11 JJ07 JJ08 LL24 LL25
NN04 NN07